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Novel Psychoactive Substances (NPS) are currently a major cause of concern, in particular to 
drug analysts, health officials and in law enforcement. The dynamic nature of the clandestine 
synthesis of NPS results in many new analogues, some of them with different chemistry, in 
addition to the mixing of some NPS analogues in combination with other cutting agents 
(adulterants). This requires up-to-date robust analytical methods. All of the major classes of 
NPS were studied in this research project: Synthetic Cannabinoid agonists, cathinones, 
phenethylamines, arylcyclohexylamines and phenidates. Together this makes a total number 
of 341 different samples, plus their replicates. The first aim is to develop and implement 
spectroscopic, spectrometric and chromatographic methods for the qualitative and 
quantitative analysis of NPS, with a focus on the application of NMR spectroscopy in 
forensic chemistry. The second aim is to develop a validated quantitative NMR (q-NMR) 
analysis method to be employed for the quantification of MDMA/NPS mixtures and 
Synthetic Cannabinoids where a cross-method confirmation of 19F q-NMR analysis was 
developed together with an analytical platform for the separation and characterization of 
complex mixtures of Synthetic Cannabinoids. 
An extensive critical review of the literature relates to areas of illicit drug analysis 
and forensic chemistry with respect to major current events. Applying 1H q-NMR analysis, an 
analytical evidence-based connection is revealed for the association of MDMA and other 
NPS from different night-club venues. The current status of the purity and dose of MDMA in 
typical tablets is established using the first reported q-NMR method with cross-method 
confirmation (UHPLC). Complex mixtures of arylcyclohexylamines are discussed with 
respect to the advantages and disadvantages of each analytical technique applied. High 
accuracy NMR assignments are reported with impurity profiling of AM-694, AB-
CHMINACA and PX-1. Additionally, a method is developed for the analysis of molecules 






µg   microgram 
19F q-NMR  fluorine quantitative nuclear magnetic resonance 
19F-HOESY  fluorine heteronuclear Overhauser effect spectroscopy 
4-MBC   4-methylbenzyl cathinone 
4-MTA   4-methylthioamphetamine  
5-HT   5-hydroxytryptamine  
5-MeO-DIPT   5-methoxy-N,N-diisopropyltryptamine  
5-MeO-N-DALT 5-methoxy-N,N-diallyltryptamine  
ACMD   The Advisory Council on the Misuse of Drugs 
ADHD    Attention Deficit Hyperactivity Disorder  
AMT   -Methyl-tryptamine  
API    Active Pharmaceutical Ingredient 
ATS    amphetamine-type stimulants  
Binding Affinity  Ki 
BZP    benzodiazepines  
CB1    cannabinoid receptor 1 
CB2   cannabinoid receptor 2 
CBD   cannabidiol 
CBN   cannabinol 
CDC    Centers for Disease Control and Prevention  
CID    collision induced dissociation  
CNS    central nervous system  
COSY   correlation spectroscopy 
CZ   combustion zone  
D   diffusion coefficient  
Da    Dalton 
DCM   dichloromethane  
DEA    Drug Enforcement Agency  
DEAT    Drug Enforcement Action Team 
DEG    diethylene glycol  
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DEPT   distortionless enhancement by polarization transfer 
DMS   dimethyl sulphone  
DMT   dimethyltryptamine  
DOSY   diffusion-ordered spectroscopy 
EC50    half maximal effective concentration 
EI   electron impact 
EIC   extracted ion chromatogram  
EMCDDA  European Monitoring Centre for Drug and Drug Addiction  
EMS   Emergency Medical Services  
ESI/MS   electrospray ionization mass spectrometry 
FA    formic acid  
FDA   Food and Drug Administration 
FFRC   fentanyl and fentanyl-related compounds  
FT-IR   Fourier-transform infrared 
GC/IRMS  gas chromatography isotope ratio mass spectrometry 
GC-CI/MS  gas chromatography-chemical ionization mass spectrometry  
GC-MS   gas chromatography-mass spectrometry 
GHB   -hydroxybutyric acid  
H2BC   heteronuclear 2-bond correlation 
HCP    Health Care Professionals  
HMBC   heteronuclear multiple bond correlation 
HMG   Her Majesty’s Government  
HMP   Her Majesty’s Prison 
HSQC   heteronuclear single quantum coherence 
Hz   Hertz 
IPA   isopropyl alcohol 
IR   infra-red  
IS   internal standard  
JWH   John W. Huffman 
LC/MS   liquid chromatography mass spectrometry  
LLOD   lower limit of detection 
m/z    mass-to-charge ratio  
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MA    maleic acid 
MDMA  3,4-Methylenedioxymethamphetamine 
MDP2P  3,4-methylenedioxyphenyl-2-propanone 
MDT   mandatory drug tests  
mM   millimolar  
MPA    methiopropamine  
MS    multiple sclerosis  
MXE   methoxetamine  
MXP   methoxphenidine  
NIDA   National Institute of Drug Abuse  
nM   nanomolar 
NMDA   N-methyl-D-aspartate 
N-methyl-TFA   N-methyltrifluoroacetamide  
NMR    nuclear magnetic resonance 
NOESY  nuclear Overhauser spectroscopy 
NPS   novel psychoactive substances  
O1P    centre point of channel 
PCP   1-(1-phenylcyclohexyl) piperidine  
PFGSTE  pulse field gradient stimulated spin echo  
PG   propylene glycol  
PMA   4-methoxyamphetamine  
PMMA   4-methoxymethamphetamine  
ppm   part per million  
PSYCHE  pure shift yielded by chirp excitation  
PTSI   p-toluenesulfonyl isocyanate 
QC   quality control  
q-NMR   quantitative nuclear magnetic resonance 
RCT   randomized controlled trials  
RP   reverse phase  
RSD   relative standard deviation  
RSPH   Royal Society for Public Health  
S/N    signal-to-noise  
SCA   synthetic cannabinoid agonist  
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SDAT   senile dementia of the Alzheimer type 
SWGDRUG  Scientific Working Group for the analysis of seized drugs  
T1    longitudinal relaxation time  
TCF   2,2,2-trichloroethyl chloroformate  
TFMPP   N-[3-(trifluoromethyl)phenyl]piperazine  
THC   Δ9-tetrahydrocannabinol  
THC-COOH  tetrahydrocannabinol carboxylic acid  
TIC   total ion current chromatogram 
TOCSY  total correlation spectroscopy 
UHPLC  ultra high-performance liquid chromatography 
VWD   variable wavelength detector  
WADA   World Anti-Doping Association  
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Chapter 1. General introduction and literature review 
 
1.1 Aims and objectives 
The aims of this thesis include a robust pharmaceutical analysis of illicit drugs and of their 
cutting agents. The topic of “a robust analysis of drugs”, which was already important when 
these studies were designed, continues to gain in importance. Therefore, a perhaps larger than 
is typical number of press cuttings and WWW sites have been included to help set the scene 
with respect to Novel Psychoactive Substances (NPS). This topic is introduced with a review 
of the refereed literature also incorporating Press and Media reports. 
The objectives chosen in order to achieve these aims include:  a section on the 
challenges facing the integrity in drug testing with examples of how things go wrong even 
with cutting-edge analytical instruments and techniques available. The opioid crisis, currently 
sweeping across the USA in the form of illicit synthetic opioids of enhanced potency, is 
introduced as the number of reported deaths is staggeringly high. Then cannabis issues in the 
UK are introduced, from a perspective of harm reduction compared to legal drugs (alcohol 
and nicotine in tobacco) causing much more harm, and how the legal restrictions placed on 
cannabis have resulted in the now flourishing market in Synthetic Cannabinoid Agonists 
(SCA), followed by the growing problem of drugs in UK prisons with an emphasis on NPS 
use, especially SCA. Cocaine distribution is addressed, and then the controversy surrounding 
drug testing with a focus on phenethylamine and cathinone assays at music festivals. 
Quantitative analytical research on phenethylamines and cathinones and their 
impurities using samples obtained from different night-clubs in the South West of England is 
presented in Chapter 2. In Chapter 3, arylcyclohexylamines, methylphenidate analogues and 
other NPS and their associated cutting agents are analysed. In Chapters 4 and 5, the analysis 
of SCAs is reported using cross-method detection and quantification of fluorinated analogues 
by 19F q-NMR spectroscopy. A SCA smoking model has been developed. Such NPS samples 
were provided by the Drug Enforcement Action Team (DEAT) following seizures, including 
in a UK prison, Bristol. The thesis is then brought together in a general conclusions section. 
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1.2 General introduction 
The research presented in this thesis is on the pharmaceutical analysis of drugs which are 
abused and their cutting agents. Apart from the abuse of prescription drugs, these compounds 
are known collectively as Novel Psychoactive Substances (NPS). This research spans before, 
during, and after the implementation of The Psychoactive Substance Act 2016 which came 
into effect on the 26th of May 2016. This act rendered illegal all substances that are sold by 
“head shops” and marketed as “legal highs”, plant feeders, herbal incense or bath salts. It 
includes substances sold presently or any substance that might be introduced in the future.1 It 
makes it an offence to produce, supply, offer to supply, possess with intent to supply, possess 
on custodial premises, import or export psychoactive substances; that is, any substance 
intended for human consumption that is capable of producing a psychoactive effect, 
excluding legitimate substances, such as food, alcohol, tobacco, nicotine, caffeine, and 
medical products from the scope of the offence, as well as controlled drugs, which continue 
to be regulated by The Misuse of Drugs Act 1971. The maximum sentence is 7 years 
imprisonment. 
The Act defines psychoactive substances as “any substance that produces a 
psychoactive effect by stimulating or depressing the person’s central nervous system (CNS), 
thus causing an alteration in the mental or emotional state of the individual”, excluding from 
that alcohol, tobacco, and caffeine. This, in itself, is controversial as a number of people have 
criticized the law as it will drive the sale of NPS underground and may result in an increase in 
deaths from those substances,2 similar to the experience found in Ireland when they banned 
NPS in 2010. Others believe that the Criminal Justice Act (Ireland Psychoactive Substance 
Act) of 2010 resulted in a significant reduction in the number of headshops and, as a result, a 
decline in the number of users.3 Other UK researchers showed that the drop in the number of 
online headshops or vendors selling NPS on the visible web was counteracted by an increase 
in the number of NPS vendors selling in the UK on the dark web (cryptomarket).4 Another 
area of controversy is the fact that some of the exempted drugs, such as alcohol and tobacco, 
kill more people annually than all the deaths from NPS combined.5 
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The driving force behind The Psychoactive Substance Act 2016 is the continuous 
proliferation of NPS. These are synthetic compounds that could be based on mainstream 
drugs, e.g. MDMA (ecstasy), amphetamine, heroin, producing psychoactive effects by acting 
on their corresponding CNS receptors. They are not regulated by the 1961 or 1971 United 
Nations Acts, thus circumventing legislation. They are marketed as bath salts, legal highs, 
and research chemicals.6,7 Most of them are analogues of classical drugs with functional 
group modification on different positions and bioisosteric replacement of functional groups 
that potentially result in different biological and pharmacological properties. 
According to the European Monitoring Centre for Drug and Drug Addiction 
(EMCDDA) more than 3.1 tons of NPS were seized in 2014 across Europe. The majority of 
these seizures consist of synthetic cathinones and SCAs, totalling approximately 46,730 
seizures in 2013, with 101 previously unreported NPS seized in 2014 resulting in a total of 
620 NPS currently being monitored.8,9 Between the years 2008-2013, there was a seven-fold 
increase in the number of seizures of NPS. The high volume of seizures of cathinones and 
SCAs could possibly be as a result of the high demand as 8% of the youths in Europe have 
experienced NPS in their lifetime according to the European Commission Eurobarometer 
survey among youths.10,11 Alarmingly, this differs from the staggering 65.8% of people 
attending the club scenes in the UK who say they have had experience with NPS.12  
So it would appear that these are very popular among certain demographics who 
attend night-clubs. This trend is corroborated by our analytical findings of different types of 
NPS from night-club amnesty bins and police seizures. The major categories of NPS are: 
SCAs, cathinones, phenethylamines, tryptamines, benzodiazepines (BZP), 
arylcyclohexylamines, and other categories with a small number of compounds such as 
phenidate-type analogues, ring-substituted aminoindans and benzofuran derivatives. The 
fundamental difference between synthetic drugs and natural product drugs such as cocaine 
and heroin, is that the former are not geographically confined to a particular area that require 
cultivation at a particular season. All that they require for manufacture are precursors and 
moderate technical expertise in synthetic chemistry. 
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The first category of NPS to gain popularity was the phenethylamines family that 
acted as a stimulant. Popularised by Shulgin’s book PIHKAL, where he synthesised a large 
number of derivatives, some of them are MDMA derivatives with qualitative assessment of 
each analogue on himself,13 followed by the tryptamines14 experimenting on different 
tryptamine analogues. Cathinones and SCAs were introduced illicitly in Europe at 2005 and 
2008 respectively.15-17 The use of classical drugs, such as cocaine and MDMA, is still rising 
in popularity, even with increased number of seizures worldwide. 
Drug analysts must adapt to the challenge of a fast-changing climate of drug 
synthesis, with hundreds of analogues produced annually by clandestine chemists. Forensic 
and pharmaceutical analysis must be robust. Important parameters and criteria such as 
sampling, analytical technique of choice, qualitative and quantitative analysis, and validation 
of the methods must be addressed. The Scientific Working Group for the analysis of seized 
drugs (SWGDRUG) categorized analytical techniques into three categories (Table 1) to 
achieve the minimal requirements for the forensic analysis of seized drugs, taking into 
account the diminishing discriminative power of the technique that is due to the sample or the 
analytical technique employed. An example of this is the use of Infra-Red (IR) spectroscopic 
detection of samples of complex mixtures, or the use of an LC/MS method that only results in 
the identification of the molecular ion without the fragmentation pattern that provides 
structural elucidation data. In the case of using a category A (Table 1) technique, e.g. NMR 
spectroscopy, at least one other technique from any other category must be used. While in the 
case of the absence of any category A technique, three different validated methods must be 
used.18 It is true that the legal drugs that were abused were pure; with illegality came impurity 
(cutting). Not only is the scale of the drugs abused increasing, as measured by the tonnage of 
seizures, but the number and chemical variety of drug analogues are also increasing. 






Table 1. Categories of analytical techniques used by the SWGDRUG. 
Category A Category B Category C 
Infrared Spectroscopy Capillary 
Electrophoresis 
Colour Tests 






Raman Spectroscopy Liquid Chromatography Melting Point 
X-Ray Diffractometry Microcrystalline Tests Ultraviolet Spectroscopy 
 
 
Figure 1. Core structure of cathinones and possible functional group modification,  
and some examples of currently abused synthetic cathinones. 
 
Cathinones are a major group of NPS with 1.1 tons seized in 2013, a close second to 
SCAs (1.6 tons), and first in the number of newly reported drugs by the EMCDDA.8 The 
members of the cathinones family are analogues of the natural product cathinone (Figure 1). 
It is found in the fresh leaves of Catha edulis, khat, a popular plant in East Africa and parts of 
the Arabian peninsula such as Yemen. The stimulant effect of khat is noticeable after 
chewing the leaves.19 Initially, the stimulant effects were attributed to cathine (d-
norpseudoephedrine), the first compound to be extracted from the leaves in 1930,20 but later 
this was shown to be too weak to take credit for the entire stimulating effect resulting from 
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chewing khat leaves, and in 1975 the strong stimulant cathinone (Figure 1) was extracted 
from fresh leaves as it decomposes in stored leaves.21  
The synthesis of cathinone analogues occurred a year prior to the isolation of cathine 
from khat. Methcathinone and mephedrone were synthesized at 1928 and 1929 respectively. 
They were initially tested and marketed as antidepressants in the USSR and as CNS 
stimulants in the USA.16,22,23 The abuse potential of cathinones, e.g. methcathinone, was first 
reported in the mid-1970s in USSR, and in the USA in the 1990s.24 Mephedrone was first 
described in Europe in 2009.25 Since then, the drug has gained in popularity among users as 
an alternative to mainstream illicit drugs, e.g. MDMA and methamphetamine. In 2010, a 
cross-sectional survey of the dance-scene drug use of 2295 participants revealed that 
mephedrone ranked as number six after tobacco, alcohol, cannabis, cocaine, and MDMA.26 
However, after the UK mephedrone ban in April 2010, the purity of mephedrone suffered, as 
seen in the analysis of mephedrone in South Wales amnesty bins between the 2011-2013. 
Analysis by GC-MS and FT-IR showed that the purity of mephedrone declined as time 
progressed supporting the conclusion that the decline in purity began with the ban of 
mephedrone.27  
Chemically, the cathinones are similar to phenethylamines, but with the addition of a 
ketone at the β-position. Methylation at R1 and R3 results in methcathinone (Figure 1), while 
N,N-dimethylation at R1 and R2 results in metamfepramone. Additionally, aromatic position-
4 methylation results in the formation of mephedrone. The bioisosteric replacement of the 
aromatic methyl of mephedrone with F results in the formation of flephedrone; methylation 
of R3, aromatic 4, and extending R1 into an ethyl group gives 4-methylethcathione (4-MEC). 
MDMA structural similarities have been introduced, where R4 is methylenedioxy, to 
introduce methylone, butylone, ethylone (Figure 1), and others each with their own 
distinctive additional functional group modification.28-30  
Phenethylamines are a group closely associated with cathinones, in fact 
methylenedioxy cathinones are based on the MDMA (methylenedioxy methamphetamine) 
structure (Figure 2), but the resulting cathinones pharmacologically remained as stimulants 
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and are not empathogenic or entactogenic (compounds that promote emotional openness), 
partially due to lower inhibition of serotonin (5-HT) monoamine reuptake inhibitors.31 
MDMA, though legally classified as a class A drug,32 is chemically classified as a 
phenethylamine. Although first synthesized by Merck in 1912 for therapeutic use, no 
published data were reported by the company.33 Furthermore, the first illicit analytical 
detection of recreational use was in Chicago IL, USA, in 1972.34  
 
Figure 2. Abused phenethylamines and piperazines. 
 
The purity of supplied MDMA has fluctuated over the last 23 years.35 A European 
study found that 1997 recorded the lowest purity for MDMA, then purity started rising over 
1998-2004, peaking at 2004 and then dropping again.35 One of the reasons for this drop in 
purity after 2004 is the seizure of 29,100 litres of safrole and isosafrole (Figure 3), the 
precursors used for piperonal synthesis, which is used for MDMA production as reported by 
the World Drug Report.36 A further crackdown on methylenedioxy precursors may also 
explain the decrease in MDMA purity post-2008 when the authorities in Cambodia 
confiscated 5.7 tons of safrole in one seizure in 2008; a total of 33 tons were seized in that 
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year alone.37 Since then, illicit MDMA manufacturing switched to another precursor, 3,4-
methylenedioxyphenyl-2-propanone, also known as the MDP2P or piperonyl methyl ketone 
(PMK) method. When law enforcement started focusing on this precursor, the technique of 
precursor of precursor was used to synthesize MDP2P from ethyl 3-[3´,4´-
(methylenedioxy)phenyl]-2-methylglycidate (Figure 3).38  
 
Figure 3. Natural MDMA precursors and a synthetic scheme for PMK.38 
 
The 2016 EMCDDA report established that MDMA use is increasing.39 MDMA’s 
resurgence in European countries, measured by wastewater analysis, revealed that Belgian 
and Dutch cities have among the highest levels. In the UK, the downward trend of MDMA 
detection from 2011-2012 has now changed into statistically significant figures in the 
detection of MDMA seen in cities, e.g. Bristol and London (Figure 4). Additionally, this rise 
in the figures of MDMA detection in wastewater could be attributed to a number of factors 
such as availability, purity or increased demand. Additionally, Health Care Professionals 
(HCP), and Emergency Medical Services (EMS) need to be aware of the trends in cutting 
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agents, especially cutting with other psychomimetic drugs (e.g. cocaine) or NPS (cathinones 
and tryptamines) in order to be better equipped to handle overdose and toxicity cases.  
After Shulgin’s publication of the PIHKAL book revealing numerous MDMA 
analogues such as 2C-B and 2C-I (Figure 2),13 there was then further development into drugs 
with no precedent in the scientific literature, e.g. 4-methylthioamphetamine (4-MTA), 4-
methoxyamphetamine (PMA), and 4-methoxymethamphetamine (PMMA), all of which are 
now implicated in toxicities and fatalities.40 The piperazine category of NPS is also 
associated with phenethylamines and cathinones. It was originally developed as a de-
worming agent, but the stimulating effects (somehow) noted resulted in their use as anti-
depressants, acting as agonists on serotonin receptors and inhibitors of the serotonin 
monoamine reuptake transporters.41 The piperazine group makes 2% of the total NPS seized, 
in Europe in 2013.8 A study of the UK club scene reported that 26% of people attending 
night-clubs had used 1-benzylpiperazine (BZP).42 Other analogues have been identified such 
as TFMPP and mCPP (Figure 2). 
 
 





Figure 5. NPS of the arylcyclohexylamine, tryptamine, and methylphenidate classes. 
 
Additional NPS classes include arylcyclohexylamines and tryptamines which make 
up 8% and 1% respectively of the amount of NPS seized, in 2013, in Europe.8 Another NPS 
class is based on methylphenidate. Members of the arylcyclohexylamines includes 1-(1-
phenylcyclohexyl) piperidine (PCP), 2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone 
(ketamine), 2-(ethylamino)-2-(3-methoxyphenyl)-cyclohexanone (methoxetamine, MXE) and 
many others (Figure 5). The arylcyclohexylamines class exerts its dissociative sedative effect 
by acting on the N-methyl-D-aspartate (NMDA) L-glutamate sub-type receptors with variable 
efficacy and cross binding to other CNS receptors such as dopamine and also opioid 
receptors.43,44 PCP was synthesized in 1956 at Parke-Davis, and marketed for its use in 
anaesthesia,45 but it was later withdrawn by the FDA due to its reoccurring side-effects such 




Medicinal ketamine was first synthesized and used in 1962 and 1965 respectively.46 
Recreational use was reported in the early 1970s47 and, in the late 1970s, the first analytical 
detection in street samples was reported.48 Soon after, reports of side-effects among ketamine 
abusers started to surface. Chu et al., in Hong Kong, published the first findings of ketamine-
induced bladder and urinary tract dysfunction,49 which became a common side-effect and 
complication among ketamine abusers. Due to the dissociative effects, ketamine has been 
greatly side-tracked from its intended medicinal and veterinary tranquilizer uses and 
introduced into clubs and dance parties, thus joining MDMA and -hydroxybutyric acid 
(GHB).50 Ketamine started gaining popularity among clubbers in the early 2000s, and as a 
result it was classified initially by The Misuse of Drug Act 1971 as class C and later 
upgraded to class B, following many reports of abuse and harm.32  
Methoxetamine (2-(ethylamino)-2-(3-methoxyphenyl)-cyclohexanone, MXE), is an 
analogue of ketamine where the aromatic chlorine at position 2 is substituted with a methoxy 
at position 3, and the N-methyl extended into an ethyl. Internet chatter about MXE started 
appearing on the drug forum Bluelight in 2006, as chatroom members started to discuss its 
chemical structure and possible pharmacological effects. This was followed by its synthesis 
and administration by a member of the Drug Forum, which increased its popularity. Online 
research chemical companies showed interest and started manufacturing MXE giving free 50 
mg samples, which resulted in even more online chatter among Bluelight members. This was 
followed by the Vice online magazine interview with a ketamine chemist which shed more 
light on the drug.51,52 The analytical profile data of MXE in seized exhibits were provided by 
the DEA laboratories in the USA. GC/MS, IR, 1H and 13C NMR spectroscopic data became 
available.53 MXE was initially promoted as a bladder friendly alternative to ketamine, but 
later, evidence of urinary tract toxicity started to emerge.54 According to the EMCDDA MXE 
risk assessment report,55 120 intoxications were reported in member states, and of those 55 
had analytical/toxicological data for the presence of MXE. Furthermore, 20 deaths due to 
MXE were reported by member states, in eight of these cases, MXE was the sole NPS 
detected; 15 of those deaths occurred in the UK. 
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Members of the tryptamine class are indole based NPS. They are similar chemically 
to the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) and differ only in the absence 
of hydroxy at the 5-aromatic position (Figure 5), thus acting as agonists on the 5-HT2A 
receptors, producing hallucinogenic effects.56 Natural product tryptamines were used by the 
ancient Aztec civilization. The leaves of the South American plant Psychotria viridis contain 
dimethyltryptamine (DMT). Ayahuasca is a tea brew made from Banisteriopsis caapi and 
Psychotria virdis containing a significant amount of DMT (approximately 24 mg/100 mL).57 
Psilocybin extracted from magic mushroom (Psilocybe spp) is another example of natural 
product containing tryptamines.57 -Methyl-tryptamine (AMT) was used as a potential 
antidepressant in the USA and the Soviet Union in the 1960s, but the psychoactive effects 
experienced by users limited its clinical use.57  
Later on in 1997, Shulgin’s work on tryptamines in his book TIHKAL resulted in an 
increased popularity of this class and many analogues started appearing, e.g. 5-methoxy-N,N-
diallyltryptamine (5-MeO-N-DALT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-
DIPT), with many modifications mostly at the aromatic position with a methoxy group, and 
diallyl groups at the nitrogen side-chain (Figure 5). Signs of toxicities included tachycardia, 
elevated blood pressure, and hyperthermia; cases of overdose started emerging. 5-MeO-DIPT 
was identified along with its metabolites in a fatality in Japan.58 AMT and 5-MeO-N-DALT 
have also been identified in fatalities with high blood and urine concentrations.58-60  
Phenidate-type NPS are all based on methylphenidate, marketed as Ritalin used for 
the treatment of Attention Deficit Hyperactivity Disorder (ADHD), acting as dopamine 
transporters reuptake inhibitors. Thus, at lower doses stimulating the CNS, enhancing 
cognition, vigilance and reducing tiredness.61,62 As with any other CNS stimulant, abuse 
potential started emerging; side effects included psychosis and increased heart rate.62  
NPS analogues of methylphenidate started emerging on the streets, driven by drug 
forums discussions and online headshops. Ethylphenidate, the ethyl ester analogue of 
methylphenidate, was first reported as a transesterification marker when alcohol is consumed 
alongside methylphenidate,63 with first detection on the streets in the UK in 2011.64 Its first 
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reported analytical detection by LC/MS/MS in fatalities appeared in 2013.64,65 Additionally, 
ethylphenidate deaths were addressed in an Eastern Scotland study of 19 cases between 2013-
2014, where post-mortem toxicological examination revealed that ethylphenidate, among 
other drugs (benzodiazepines and opiates), contributed to the deaths. In five of these cases, 
ethylphenidate was mentioned on the death certificates as contributing to the cause of death.66 
Other analogues started appearing on the streets, all of which have no medicinal use and are 
presumably intended for recreational purposes (Figure 5).67 
Cocaine is one natural alkaloid (among many) found in the leaves of the coca plant 
(Erythroxylon coca). In Europe, cocaine is still the most popular stimulant with 3.5 million 
users in 2016 in people between the ages 15-64, followed by MDMA and amphetamine. 
Cocaine ranks second in the amounts seized after cannabis, with a value of 6.3-10.2 Billion 
Euros.39,68  The purity of cocaine has been an important issue among drug analysts. 
Levamisole was first approved by the FDA for the treatment of colon cancer in the early 
1990s, but it was withdrawn in 2000 due to several reported cases of agranulocytosis (low 
blood-count) and now is only used as an anthelmintic agent for veterinary uses. Levamisole 
has been reported as a cutting agent since 2000 by the US Drug Enforcement Agency 
(DEA).69,70 The prevalence of levamisole in cocaine bricks has increased since 2005 with up 
to 30% of cocaine samples seized found to contain this adulterant by the end of 2008,71 and 
by 2010 77% of the cocaine samples submitted for analysis in the US had levamisole in 
them.72 Levamisole-cut cocaine was first described in analytical chemistry terms in Europe, 
in 2007, by the Italian authorities using GC/MS for the analysis.73 In an analytical study 
between the years 2005-2010 of cocaine seizures in Luxembourg, the percentage of 
levamisole in cocaine ranged between 1.5-4.1%.74 The possible reasons for the addition of 
levamisole to cocaine are mostly speculative, but some believe it to be the similar physical 
appearance of levamisole to cocaine making it an ideal bulking agent and/or the actions on 
the adrenergic system such as the inhibition of monoamine oxidase-A, thus increasing 
neurotransmitter concentration in the presynaptic cleft.69, 75 There are clear and alarming 
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health implications from cutting with levamisole, especially the development of 
agranulocytosis and many incidents of necrotizing vasculitis.69,76 
SCAs, also known by their street name spice, are the largest class of NPS measured 
in the number of seizures.8 SCA are potent binders to the CB1 and CB2 receptors distributed 
throughout the CNS and immune system respectively.77 Δ9-Tetrahydrocannabinol (THC), the 
main active component of the plant Cannabis sativa L. (marijuana), is a partial agonist at CB1 
receptors, but not at CB2. Due to the possible implication of CB receptors in various diseases, 
e.g. senile dementia of the Alzheimer type (SDAT), many compounds were synthesized to 
mimic the activity of THC on CB1 receptors such as CP 47,497 synthesized by Pfizer in the 
1970s and 1980s and Hebrew University HU-210 which are both structurally similar to THC 
(Figure 6).78 In 1994, other CB1 and CB2 receptor agonists were synthesized by John W. 
Huffman with an indole core structure.79 These compounds became the first generation 
SCAs, found in herbal blends for smoking as cigarettes, to hit the streets in 2008.80  
As governments became aware of the situation and the threat level, the previously 
mentioned SCA compounds were banned, but the ban resulted in hundreds of SCA analogues 
being illicitly synthesized in clandestine laboratories, leading to a game of cat and mouse, 
where the second generation of SCA was from 2009-2012. Additional banning of these 
compounds resulted in the third generation (2013-present) of SCA. Most of these analogues 
have no precedent in the scientific literature.81  
 





1.3 Integrity in drug testing (Sochi and Randox Scandals) 
It is a sine qua non that forensic and pharmaceutical analysis must be honest. Whilst there is 
room for a wry smile, indeed it might even be ironic that the 2014 Winter Olympics in Sochi 
changed people’s lives, not least those who just failed to achieve an Olympic medal. Doping, 
the use of performance enhancing drugs, is not a new phenomenon, but has increased 
dramatically in the past 3 decades with shocking tales emerging from East Germany, and also 
the Canadian sprinter Ben Johnson doping scandal at the Seoul 1988 Olympics.82  
The Sochi anti-doping laboratory was equipped with state-of-the-art instrumentation 
to analyse banned substances, with sample reception on the first floor and the upper floors 
containing areas for peptides, non-peptide analysis and a number of mass spectrometers, 
LC/MS/MS, GC/MS/MS, GC-Isotope Ratio Mass Analysis (GC/IRMS), and many others.83 
Nevertheless, the German documentary aired on Mitteldeutscher Rundfunk (MDR) broke the 
news on possible doping and sample tampering, the allegations also implicated the anti-
doping management and high-ranking officials in a State-run doping scandal. The report 
included leaked documents and testimonies from athletes, who claimed that they were 
instructed by their coach to use performance-enhancing drugs such as oxandrolone (Anavar), 
and to keep clean urine samples for them to submit for analysis. This led the General Director 
of the World Anti-Doping Association (WADA) to initiate a full investigation.84  
The Sochi anti-doping laboratory director Dr Grigory Rodchenkov came forward and 
exposed the magnitude of the scandal. He admitted to providing Russian athletes with a 
cocktail of banned anabolic substances to enhance their performance. Additionally, he 
implicated officials who swapped tainted urine samples with clean ones prepared months in 
advance through small holes made in the laboratory walls where the urine samples were kept, 
breaking the tamper proof seals. Ultimately, 100 urine samples were switched.85 The WADA 
investigation, “the McLaren Report”86 corroborated Dr Rodchenkov’s story and came to the 
conclusion that a State-run doping system was run by Russian officials providing cover for 
athletes to use performance-enhancing drugs without being exposed. The report is based on 
eye-witness accounts, interviews, forensic analysis of samples, and documents analysis. The 
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report exposed tampering and doping facilitation by the Russians during the London 2012 
Olympics. The report also exposed the unauthorized opening of urine samples in the tamper 
proof Bereg kit bottles. As a result of the investigation, a number of Russian athletes lost their 
medals and ultimately the Russian team were removed from top of the table ranking, and the 
suspension of the Russian Olympic Committee.87,88  
Forensic drug analysts are under scrutiny most of the time. They are called upon by 
law enforcement, District Attorneys and judges to clarify, explain, and or testify in law 
courts. They are trained to the highest standards for these purposes. In the UK, drug samples 
that require forensic analysis are either analysed in house by the police or sent to private 
forensic service companies, e.g. LGC, Alere Forensics, and Randox. Nonetheless, there are 
cases where forensic services have totally failed to maintain professional standards.  
On February 19th 2017 the story broke of two Randox Testing Services analysts 
doctoring the results of toxicology samples, e.g. blood, hair, and saliva, at the Manchester 
office. It is believed that over 484 cases could be affected from different areas in the UK as 
the laboratory handled cases from across the UK with the exception of alcohol testing. The 
manipulation of the samples was of the quality control data and not by adulterating the 
samples.89 The scale of the scandal later became apparent as the laboratory handled cases for 
42 Police Force throughout the UK, including the Greater Manchester Police, with 10,000 
cases in question. That number will include cases of drink driving and violent crimes 
(murders and sexual offences). Two death cases are now being considered for appeal.90,91 
Additionally, it is believed that the retesting of 1500 samples will be required. In some cases, 
that will not be possible as the samples have not been well-maintained and some drugs may 
breakdown when stored for a long time. This will put more pressure on an already burdened 
criminal justice system.91 Many criticized the current standards of the forensic system, and 
claimed that this decline is a direct result of the closure of HMG owned Forensic Science 
Service due to losses of £2 million per month. HMG is tackling the problem by planning to 
establish new forensic science services.92 This follows the 2015 National Audit Office (NAO) 
report whose key findings included the current decline of the forensic services and the 
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inability of the current forensic regulators to enforce strict quality control measures on drug 
testing.93  
Another example of drug analysts going rogue on the same scale of the Randox 
testing scandal, occurred in Amherst, Massachusetts, USA in 2013, where an analyst was 
found guilty of stealing drugs from the drug analysis laboratory where she worked, and that 
she has been doing so for the past eight years. 8000 cases that the drug analyst has worked on 
could be thrown out of the courts. This came after another drug analyst named Annie 
Dookhan, also in the State of Massachusetts, was convicted and sentenced to 3 years in 
prison, after falsifying, not testing, and fabricating data. This resulted in over 20000 drug 
convictions being overturned.94 These are examples of how critical being a drug analyst is, 
the ethical and professional levels which the analyst should display, and how it can go wrong 
for a lot of people due to gross misconduct. 
Incidents of misconduct by drug analysts in the fields of forensics and doping result 
in mistrust and doubts in the public eye. Drug testing services should reflect an image of 
reliability, honesty, and accuracy. The impact of exonerating a drug user or a doping athlete 
as a result of false negative or doctored results can be profound on the people directly 
involved or on the public in general. The impact is even worse in the case of false drug or 
doping convictions resulting from false positives of the test results or rogue analysts 
fabricating drug results, with lives and careers on the line that could be destroyed, in addition 
to the generated mistrust of drug services which are considered a critical tool in the 
armamentarium of the justice system.  
There are no easy solutions to fully proof drug analysis services from errors 
generated in the analysis, whether they are mistakes made during the analysis (false positive 
or false negative) or deliberate data fabrication, but some precautions can help resolve or at 
least mitigate mistakes produced as a result of the misapplication of drug analysis, e.g. 
quality control (QC) of samples, method validation of the technique used. As for preventing 
misconduct, an independent external oversight body is required to ensure fairness, even 
honesty, in drug analysis.  
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1.4 The opioid crisis 
Opium is the most commonly used analgesic for mild to severe pain, and in palliative care of 
terminal-stage cancer. Historically, it is believed that the first to grow poppies and extract 
opium from the seeds were the Sumerians in 3400 B.C. From the eighth century, Arabs 
introduced it to India and China. This was followed by widespread addiction in many areas 
such as Egypt, Turkey, but more noticeably in China. Another hallmark in the history of 
opium is the isolation of the active components from the latex of the sap of poppies (Papaver 
somniferum) by the German pharmacist F. W. A. Sertürner in 1806. He named it morphine 
after the Greek god of dreams, Morpheus. Besides the main component morphine, opium 
contains codeine, thebaine, noscapine, and papaverine (Figure 7). Due to the abuse potential 
of morphine, di-O-acetylation was investigated at Bayer in 1898, heroin (diamorphine) was 
synthesized as a safer alternative; this was later found to be untrue.95 Furthermore, the first 
opium war occurred between England and the Quing Dynasty, 1839-1842, a result of the 
British East India company’s efforts to import Indian opium in to China, in order to further 
their trade expansion in Asia, but those efforts were opposed by the then Emperor of China, 
Daoguang, due to the heavy toll that opium addiction was taking on the Chinese population.96  
 
Figure 7. Compounds present in opium with the exception of semi-synthetic heroin. 
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The majority of heroin is produced in the Golden Crescent (Afghanistan, Iran, 
Pakistan) and the Golden Triangle (Myanmar, Laos and Thailand), with 90% of the world 
production of opium from Afghanistan alone. Furthermore, the Taliban ban on opium in the 
year 2000 resulted in an opium production decrease of 95% (Figure 8).97,98 
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On the 26th of October 2017, President Donald Trump declared the opioid crisis a 
national health emergency in the USA, directing funds and personnel towards reducing the 
number of opioid-related deaths, with deaths from opioids exceeding deaths from car 
accidents and guns combined.99 The number of deaths from opioids, including prescription 
(oxycodone, methadone, and hydrocodone) and non-prescription illicit opioids (heroin, 
fentanyl, and carfentanil) (Figure 9), has increased by four-fold since 1999 reaching 33,091 
deaths in 2015 (Figure 10), and in 2017, prescription and non-prescription illicit opioid 
resulted in more than 47,000 deaths.100,101  
 
 
Figure 10. NIH National Institute of Drug Abuse (NIDA) report 2017.101  
 
The problem is confounded by the fact that more than 289 million prescriptions are 
issued yearly for opioid analgesic drugs in the USA, with this trend of overprescription 
starting in the 1990s. With overprescription came an increase in the misuse of this class of 
drugs, with some demographics even using illicit heroin as a cheap and easy to obtain 
alternative compared to prescription opioids.102 Some researchers believe that one of the 
reasons for the overprescription of opioids today is the one paragraph letter published in the 
New England Journal of Medicine in 1980, stating that out of 11,882 hospitalized patients 
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that received opioid preparations, only 4 showed signs of addiction, concluding that addiction 
is rare in patients with no history of opioid addiction.103 However, the article only described 
the results in acute hospitalised patients and not patients with chronic pain who take opioid 
medications on a regular basis.104 In 2017, a bibliometric analysis of the 1980 NEJM paper 
was published, revealing that it was cited 608 times, of which 439 cited it as evidence of the 
non-addictive nature of opioids, and 439 failed to address the fact that the study was on acute 
patients in emergency settings and not patients with chronic pain.105 
According to the National Institute of Drug Abuse (NIDA) 2017 report, the sharpest 
increase in all of the drug deaths in the USA, in recent years, is attributed to the synthetic 
opioids family, e.g. fentanyl and carfentanyl (Figures 9 and 10).101  
The first wave of synthetic opioids came in the late 1970s, known as the “China 
white” fentanyl crisis after the origin of the heroin and the physical appearance of the 
samples. Two overdose cases in Orange County, CA, USA occurred. With the limited 
sensitivity of the analytical instruments at the time, the identification of the component 
responsible for the deaths was a daunting task. The low concentration in the sample received, 
and the presence of two cutting agents besides heroin complicated the analysis. Nevertheless, 
the culprit was identified using 1H NMR spectroscopy and Gas Chromatography-Chemical 
Ionization Mass Spectrometry (GC-CI/MS) fragmentation pattern to be α-methylfentanyl in 
the chloroform fraction. Its highest mass ion was at 350 m/z. 1H NMR revealed that it was the 
citrate salt, with lactose and propionic acid in the water-soluble fraction believed to be a 
cutting agent and synthesis impurity respectively.106 Toxicological examination of the 
overdose cases confirmed the presence of α-methylfentanyl in peripheral blood and the 
analytical data were a match with the analysed exhibits recovered at the scene.107  
The current wave of fentanyl and fentanyl-related compounds (FFRCs) started in 
2013, with 5000 deaths in 2014, 1100 of which occurred in Ohio.108 Ohio State Health 
Services reported that, in 2016, 11 drug overdoses occurred daily.109 In the summer of 2016, 
27 people were hospitalised in Huntington West Virginia in 4 hours as a result of a batch of 
heroin laced with a potent unknown compound. The Centers for Disease Control and 
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Prevention (CDC) confirmed later that toxicological analysis revealed the presence of 
fentanyl and also the much more potent fentanyl analogue carfentanil.110,111 Carfentanil 
(methyl 1-(2-phenylethyl)-4-(N-propanoylanilino)piperidine-4-carboxylate) which differs 
from fentanyl by the additional methyl ester at position-4 of the piperidine ring (Figure 11), 
has recently been implicated in a number of deaths in the USA. Carfentanil is 100-times more 
potent than fentanyl and 10,000-times more potent than heroin, where a dose of 20 µg could 
result in death.108 Carfentanil is believed to be implicated in the 125 deaths at the Moscow 
theatre siege (2002) after Russian forces released an aerosol gas of fentanyl derivatives onto 
the terrorists to “save” the hostages. The high number of casualties is believed to be a 
combination of deficient medical care and the presence of two fentanyl derivatives, 
carfentanil and remifentanil (Figure 11) in unknown proportions. The presence of strong 
opioids in the released gas was confirmed by urine and clothing analysis of three British 
survivors, using LC/MS/MS with transition ion monitoring mode 395 m/z to 351 m/z for 
carfentanil, and 377 m/z to 285 m/z, and 377 m/z to 116 m/z for remifentanil.112 The 
administration of multiple doses of naloxone (a potent competitive agonist at the µ opioid 
receptors) in heroin overdoses is highly indicative of a potent opioid and therefore higher 
than usual doses of naloxone were used, as seen in the Huntington West Virginia incident, 
where 6 of the 16 who received the naloxone antidote required multiple administrations.113  
Even though the UK has a more strict prescription policy when it comes to opioid 
painkiller prescriptions, reflected in the lower number of fentanyl deaths, still the trend of 
FFRCs seems to have crossed the Atlantic. Here the police reported at least 60 deaths, related 
to heroin laced with FFRCs, mostly in the Yorkshire area.114 The UK crime agency report 
stated that fentanyl and its analogues started appearing in the UK drug market in late 2016,115 
and the report emphasized the vulnerability of heroin abusers as they represented a high-risk 
group due to the fact that heroin is being cut with fentanyl or its analogues. It is also unclear 
whether the two-fold increase in the heroin-related deaths, in 2015 compared to 2012, is due 
to the high purity of heroin or fentanyl lacing. Additionally, in Europe, there has been a 
growth of fentanyl analogues such as 4-chloro-isobutylfentanyl and 4-fluoro-isobutylfentanyl 
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(Figure 11), responsible for three and four deaths respectively.115 Moreover, 95 seizures of 
another analogue of fentanyl, acryloylfentanyl (Figure 11) have been reported. The majority 
of the seizures were in Sweden and Estonia with 63 serious adverse events reported.115 
Furthermore, from a toxicological point of view, the detection of fentanyl and other 
analogues is relatively easy. Carfentanil is more difficult to test for, due to its low levels in 
blood and urine and no actual limits have been established for its detection.115 
 
Figure 11. Illicit fentanyl analogues seized in Europe with their non-systematic nomenclature 
based on fentanyl which contains a tertiary propanamide. 
 
Clandestine chemists are synthesizing analogues of fentanyl at a rate faster than they 
can be controlled by law enforcement agencies. The opioid epidemic is hitting the USA and 
has really already started spreading to Europe and other countries. Complicating the problem 
is the fact that fentanyl analogues are potent at microgram doses and found as cutting agents 
or mixing agents with mainstream drugs such as cocaine, but mostly with heroin, making it 





1.5 Cannabis in the UK 
No longer “just a bit of weed”, cannabis is now grown by the industrial-scale manufacturing 
of high concentration skunk also known as sinsemilla, bred to have a high concentration of 
THC. In August 2017, three men were charged with large-scale farming of cannabis inside a 
sold-on Ministry of Defence nuclear bunker near Salisbury. Approximately 4400 cannabis 
plants were found and the estimated amount of cannabis that could have been produced was 
£2M. The culprits diverted electricity to power the heating lamps to create ideal conditions 
for growing the cannabis plants.116 However, there was also modern slavery, and it was 
certainly not a jape for those in forced labour. 
The term cannabis stands for the extract of the plant Cannabis sativa L. in the form 
of leaves of marijuana or cannabis oil. Even though there are more than 60 compounds in the 
plant, the effects of cannabis are attributed to the compound Δ9-THC. Other components 
(Figure 12) either possess weak or no activity on the cannabinoid (CB1) receptors producing 
the psychoactive effects. 
 




The concentration of THC in marijuana has been increased (by horticulture) from 1% 
in 1973 to 9% in 2008. The main route of administration remains inhalation, some users 
resorting to vaporization to avoid potentially harmful pyrolysis products. Ingestion is less 
popular, possibly due to the irregular peak plasma concentration and delayed action of up to 
two hours.117 Large randomized controlled trials (RCT) gave positive results for the use of 
smoked marijuana in the treatment of spasticity associated with Multiple Sclerosis (MS).118 
Medically approved marijuana such as Sativex, containing THC:CBD (cannabidiol), in the 
ratio 1:1, is delivered as an oromucosal (administration through the mucosa of the mouth) 
spray of 100 µL. It is used for the treatment of moderate to severe spasticity associated with 
MS which is not responsive to conventional medications.118 It is believed that CBD 
potentiates the effects of THC and reduces the side effects associated with THC.119 Illicit 
cannabis is believed to be the leading drug in Europe in terms of the number of users with 
23.5 million users in 2016 and life-time users (at least once in their lifetime) of approximately 
87.7 million among adults aged between 15-64. This is 70 million more life-time users 
compared to those for the most popular stimulant, cocaine. In the form of marijuana and 
resin, it accounts for 70% of drug seizures, with a retail value of 9.3 billion Euros. Most of 
the seized illicit cannabis products are either grown indoors in Europe or are shipped from 
Morocco; the amounts seized annually since 2009 remain the same.39  
The legalization of marijuana has been a controversial issue for discussion 
throughout the past 50 years, even though it remains illegal in the UK and at the federal level 
in the USA. In the majority of European countries it is either illegal or decriminalised 
(reduction of penalties), with the exception of the Netherlands, where it remains illegal 
except in coffee shops i.e. for personal use. Nevertheless, restrictions were put in place to 
control the sales of cannabis in coffee shops, e.g. prohibition of the sales of cannabis to 
minors, no more than 5 grams per person is sold per day, no sales of hard drugs are permitted, 
and no advertisements.120 Recently, there has been a change in policy regarding the legal 
status of cannabis, e.g. The Canadian Cannabis Act, implemented in August 2018, which 
made cannabis legal at the federal level, thus making Canada the second country in the world 
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to legalize cannabis after Uruguay. A decision which was aimed to combat high crime rates 
resulting from the sales of illicit cannabis.121 The justification for the Canadian Act was 
different from the Uruguayan. It stemmed from the fact that a survey revealed that 
approximately half of Canadians claimed to have used cannabis even though it is illegal.121  
On August 2nd, 1977, President Carter addressed Congress and stated that penalties 
for the use of any drug should not be more harmful to an individual than the use of the drug 
itself.122 The harm caused by legal drugs, e.g. alcohol, and tobacco with respect to tar and 
nicotine, compared to cannabis is grounds for debate. Indeed, there is a clear association 
between alcohol and domestic violence.123 In a paper published in The Lancet, Professor 
David Nutt and co-workers revealed that in developing a harm-score criteria for drugs of 
abuse, alcohol scored above all other drugs tested in harm to the individual and harm to 
society, much more significantly than cannabis, ketamine, and ecstasy (Figure 13).124 These 
data add to the controversial problem of such legal drugs doing more harm than illegal drugs, 
e.g. cannabis for MS, and ketamine as a horse tranquilizer. MDMA has been found to have 
the potential to treat PTSD (as part of psycho- and other therapies). Indeed, MDMA was 
recently granted Breakthrough Status by the FDA in Phase 3 trials.125 MDMA is also being 
studied as a treatment for alcoholism by Dr Ben Sessa also at Imperial College, London.126  
 
Figure 13. Harm scores to users (blue) and to others (red) of a number of drugs of abuse.124 
[Reprinted with permission from Elsevier (The Lancet, 2010, 376, 1558-1565)] 
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1.6 Drugs in UK prisons 
In any community, drugs flourish whenever there is demand, coupled to the socio-economic 
level of the individuals in the community. In UK prisons, violence and anti-social behaviour 
as a result of drug abuse and dependence, especially mainstream illicit drugs, i.e. cocaine, 
heroin, amphetamines, have been well documented.127 A systematic review of drug and 
alcohol abuse among male and female inmates in prisons, from the USA, UK, Ireland, and 
New Zealand, revealed significant variation in the percentage of prisoners’ drug abuse. Males 
had a range between 10-48%, while females had between 30-60 % incidence of drug abuse or 
drug dependence. Furthermore, comparing the percentage of USA prisoners to the general 
population of a similar age, showed that male prisoners had a 2-10-fold increase in the 
incidence of drug dependence, while female prisoners had more than a 13-fold increase in 
drug dependence compared to the general population of a similar age.128  
In a 2010 Policy Exchange report about combating drug misuse in the UK, the 
magnitude of the drug problem among prisoners was made clear. About 35% of prisoners had 
used drugs of abuse in prisons, with 14,000 inmates using at least once a week. The leading 
drug of choice among inmates was cannabis, followed by heroin, MDMA, amphetamine, and 
cocaine. The numbers are an improvement compared to the 2006 report conducted after 
surveying six UK prisons with regard to abuse of drugs in prisons, where 60% of inmates 
used heroin, and 70% used cannabis.129 The annual report 2011-2012 of Her Majesty’s Chief 
Inspector of Prisons for England and Wales reported that 29% of prisoners have a drug 
problem prior to their arrival in prison and 6% developed a drug problem during their time in 
prison. Additionally, 24% of prisoners admitted that it was easy for them to obtain drugs in 
prisons. Furthermore, the report also addressed the trend of diverted prescription drugs such 
as buprenorphine, tramadol, and gabapentin (Figure 14) that were not on the list of drugs 
detected by the Mandatory Drug Tests (MDT) which are conducted randomly or in the case 
of suspicion of drug intoxication or possession.130 However, in the following annual report, 
the percentage of prisoners who developed a drug dependence in prison increased by 1%, 
whereas 31% stated that acquiring drugs in prison is easy. In 2013-2014 Her Majesty’s Chief 
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Inspector of Prisons for England and Wales said that the MDT positive results declined 
significantly which was not attributed to the reduction of drug use among inmates, but rather 
the inability of the MDT to detect NPS including the popular SCAs (spice), e.g. “Black 
Mamba”. Also, the report highlighted the increase in the incidence of bullying among 
prisoners, with a 38% increase in life-threatening assaults, which is believed to be primarily 
due to the increased smoking of spice.131 
 
 
Figure 14. Commonly abused prescription drugs among prisoners. 
 
Since 2014, the number of spice seizures has continued its dramatic increase in UK 
prisons from 15 seizures in 2010 to 737 in 2014.132 In 2016, there were increases of 27% and 
31% on the previous year concerning overall assaults and life-threatening assaults 
respectively.133 Even prior to the appearance of NPS including spice, that caused analytical 
difficulties to the MDT, the MDT was under fire as not being a clear representative of the 
number of drug users in prisons, as there were massive discrepancies between the number of 
drug users in prison surveys and the MDT results. Additionally, there is some criticism of the 
MDT as being degrading to the prisoners and a violation of their human rights. Further 
adding to the problem are reports of corrupt prison officers manipulating urine samples that 
are destined for MDT testing.129  
Now the UK and especially UK prisons are in the midst of a SCA (spice) crisis. The 
reports of prisoners’ intoxications and death as a result of the so-called legal highs in 2015,134 
from the Prisons and Probations Ombudsman stated that, in 2012-2014, 19 deaths were 
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attributed to the use of legal highs and in particular to SCA brands such as “spice” and 
“Black Mamba”. The report added that the prisoners were using SCAs unknowingly, by 
smoking spice-spiked cigarettes, or knowingly as a way of experimentation with new and 
alternative drugs to cannabis. According to eyewitness accounts, at least one prisoner 
collapsed after taking a cigarette from another inmate, and died later the same day. Violent 
behaviour and unrest in the prison population have also been growing. Prisoners under the 
influence of SCA are either being hospitalized or are attacking guards.135 Prison authorities 
are revealing that the unrest in prisons has a direct connection with prisoners’ consumption of 
SCA and this impact is more profound than for any other drug. Furthermore, prison guards 
and prison workers have been hospitalized on different occasions in different prisons as a 
result of accidently inhaling the fumes of the burnt herbal blends containing SCA.136 
A survey conducted in 9 prisons, on 805 inmates, revealed that a third of them had 
used SCA in the last month and between 50-100% had used spice at some point.136 The report 
also indicated that in particular, spice intake allows prisoners to alter their perception of time, 
which is one of the problems faced by prisoners in general in that they have too much time on 
their hands, and they are taking drugs due to being bored. Additionally, the report highlighted 
that the emergency calls for medical help in prisons had increased by more than 50% in 2015 
compared to 2011, with reports of 17 ambulance calls to a particular prison in just one day. 
Moreover, deaths in prisons are on the increase. Indeed, they are at their highest since official 
records began. The Prisoners’ Ombudsman revealed that the number of deaths in prisons has 
risen to 89 deaths in 2017, a possible result of the increase in the use of spice in prisons.137  
One example of the amount of SCA seized is from HMP Lindholm near Doncaster, 
from where it was reported that more than a kilo of NPS had been seized in one month among 
other contraband. Additionally, the failure of the routine urine testing among inmates was 
reported by the University of Maryland Center for Substance Abuse Research such that SCA 
appeared in 33% of the urine samples submitted for analysis. The identification was made 
possible by special testing as the routine drug analysis failed to identify them. Additionally, 4 
prisoners in a Louisiana prison became unresponsive after overdosing on spice.138 The drug 
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markets in prisons has significantly changed as evidenced by the type and amounts of drugs 
seized. SCA seizures in prisons increased by 400% in 2015 compared to 2014, over the same 
period cannabis seizures decreased by 60% compared to the previous year. It has been 
established that the driving force for this change was profit. SCA are sold in prisons at 3-4 
times the price on the street (£100 per 1 gram), coupled with the low chance of detection 
compared to mainstream drugs. Furthermore, one prisoner described the situation as “it’s all 
spice now” describing how it has taken over the popularity of heroin and even cannabis. 
Moreover, intoxications reported among inmates include agitation, stomach cramps, 
sweating, twitching, and mental and emotional alterations in behaviour. Prison guards 
reported many incidents of violence. One prison guard was stabbed in the face as a result of 
approaching a prisoner who had smoked spice and was hallucinating in the prison yard, and 
some reports describe the hallucinations as five times more frequent than with cannabis. 
SCAs are smuggled in compressed soda drinks lids, as a joint for smoking, and others use 
“Kinder egg” smuggled rectally also known as “plugging” to evade detection by prison 
guards, as there are restrictions on searching intimate areas of prisoner’s bodies.139  
Many reasons have been proposed for the spice takeover of the drug culture in 
prisons. Spice has started to become the preferred drug for prisoners. SCAs result in the 
alteration of perception and time, allowing time (apparently) to pass quicker for the users. 
Cannabis was the most popular drug among inmates, but due to its showing in the blood and 
urine analytical tests for days or weeks after consumption, because of its retention in fatty 
tissues (lipophilicity), there was a significantly increased chance of detection.140 Additionally, 
detection limits have been established in many types of users by monitoring the 
tetrahydrocannabinol carboxylic acid (THC-COOH) metabolite in urine using GC/MS, 
showing that even after a single use, the metabolite can be detected for up to three days 
while, in chronic users, the THC-COOH metabolite can be detected for up to thirty days.141 
The prisoners switched to heroin which stays in the blood, urine, and saliva for a shorter time, 
and thus is unlikely to be detected by the MDT. The inability of MDT to detect SCA, and its 
potent psychoactive effects, caused the prisoners to refer to it as the “perfect drug”.139 Also, 
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smoking spice does not give the distinctive smell that results from smoking cannabis.139 
Perrone et al. conducted a study on students in southern California applying for criminal law 
jobs that required MDT, found that 60% of students consumed spice, this included students 
trying to apply to the military or who are under correctional facilities supervision, and their 
main reason for using spice is because it did not show on the MDT even though they 
preferred cannabis. The study concluded that the drug policies of the USA, such as the 
illegalization of marijuana on a federal level, and the large scale implementation of drug tests 
is causing the increase in spice and other NPS use.140 
Many routes had been reported for the smuggling of drugs in to prisons, such as 
social visits which are believed to be the most common route, new inmates arriving into 
prisons, throwing items with weights, such as coins and car tire bolts, over the prison wall 
(throw-overs), corrupt prison officers, and more recently drones flying into prisons with 
prisoners using hooks to pull in the suspended goods. A drone carrying class B drugs, NPS 
and mobile phones was recently captured on CCTV at Wandsworth Prison.139,142 Reports 
from other countries in Europe have also shown the spread of spice in their prisons. A 
Slovenian study revealed that 54.5% of inmates aged between 18-35 had used synthetic 
drugs, with spice being the most popular. The study also reported that at least a third of the 
users had experienced side-effects.143  
For the reasons listed above and the continuous news reports from across the UK 
about spice incidents in prisons, it is unlikely that this problem will come to an end anytime 
soon. To tackle such a complex issue, a harm reduction approach is required that spreads 
awareness among prisoners of the dangers of SCA. Additionally, incorporating new 
analytical techniques into the MDT might help in the accurate detection of SCA and their 
metabolites, ultimately leading the prisoners to stop abusing this class of drugs (or choose to 







The high profile of cocaine in the media, its role in human suffering and cost to countries are 
both perceived and documented. Horrific stories of addicts, people’s lives destroyed, murder, 
and impacts on economies are all well documented in the literature.144,145 People outside 
South America became aware of cocaine with the development of industrial scale production 
methods related to the drug.  
Cocaine is a natural product alkaloid occurring in the leaves of Erythroxylum coca, 
which is endogenous to the Andes mountains in South America that span e.g. Bolivia, 
Columbia, Ecuador, and Peru (Figures 15 and 16).146 It was perceived in ancient Incan 
civilizations as a gift from their gods. Only the privileged would be allowed to inhale it and 
participate in religious ceremonies that were considered as ritualistic or for treating the ill, 
and it was either smoked or chewed.147 Peruvian mummies have been discovered with coca 
leaves in their mouths, which reveals how established is the ancient use of this plant. After 
realizing its potential, the Spanish used to supply the conquered natives with coca to boost 
their stamina and reduce their appetite while working in silver mines.147  
German chemists first isolated cocaine in the 1850s, and then an improvement of the 
extraction was made by Albert F. E. Niemann in 1859 who noted its numbing properties. 
These were exploited in 1884 when cocaine was used as a local and general anaesthetic, with 
Karl Köller claiming that discovery.148 Cocaine had been used for the making of wine such as 
the Vine Mariani which is a mixture of alcohol and coca leaves extract prepared by soaking 
coca leaves (60 g) for ten hours in wine. The resulting drinks contained less than 50.0 mg of 
cocaine in two glasses. Others made soft drinks and tonics such as the famous Coca-Cola 
drink created in May 1886 by pharmacist Dr John S. Pemberton in Atlanta, GA, USA, with 
many recipes containing different amounts of cocaine. The original 1886 recipe contained 
coca leaves with approximately 9 mg of cocaine in a glass of Coca-Cola (with caffeine from 
the Kola nut of evergreen trees in the genus Cola), until 1903, when the fresh leaves were 
substituted with used ones (cocaine rapidly deteriorates in aged coca leaves). Furthermore, 
cocaine was found in tonic drinks that could be obtained without a prescription in the USA 
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until 1916. The problems of the decomposition of the leaves during shipment was overcome 
by Parke-Davis chemists by using on-site semi-refinement of cocaine, resulting in higher 
concentrations of cocaine and a cheaper price. Sigmund Freud contributed to the increased 












ecgonine cocaine benzoylecgonine 




Figure 16. Cocaine growing and cultivation regions among major producing countries.149  
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Columbia and Peru are responsible for most of the cocaine exported to the USA. The 
extraction of cocaine is by harvesting fresh leaves that contain the highest amount of cocaine 
in the coca plant, followed by soaking in hexane until a thick paste is formed. Finally, salting 
out using hydrochloric acid and packaging of the powder, the hydrochloride salt of cocaine 
which can be administered by snorting or intravenous injection. On the other hand, the free 
base is formed by the addition of ammonia to the cocaine hydrochloride in water, followed by 
dissolving in ether and evaporation. Unlike the hydrochloride salt, the free base has a low 
melting temperature, and therefore can be smoked, but there are many safety concerns such 
as the flammability of remaining processing residues, e.g. ether, that caused many accidents 
and fatalities due to its combustion.143,150  
Crack cocaine (the free base) is converted from the hydrochloride salt by mixing it 
with aqueous baking soda and heating, resulting in decarboxylation yielding lumpy rocks, 
that give a popping or cracking sound when smoked. This free base has a low melting point 
making it suitable for smoking, but in using water in the manufacturing it is without the risks 
associated with the residual organic solvents above.143 Between the mid-1970s and mid-1980s 
the USA witnessed an explosion of cocaine on the streets. Initially, in the form of powder 
hydrochloride salt, reaching a peak of 25 million American users in 1985, followed by a 
gradual downward trend in its use. Unfortunately, the wave of crack cocaine swept across the 
USA with cheap prices of $5 per rock expanding the market for this previously upper-middle 
class drug to include minorities and marginalized groups. This expansion was coupled with 
unprecedented violence.151 All forms of cocaine possess identical pharmacology, increasing 
dopamine indirectly by acting as inhibitors of the dopamine reuptake monoamine transporter. 
Pharmacokinetically, cocaine has fast absorption and distribution, with the form of drug 
(hydrochloride, crack) and consequently the route of administration resulting in more abuse 
potential for crack cocaine as a result of its more instant effect.151,152 
United Nations drug report on cocaine (2010) revealed that there are approximately, 
16-17 million cocaine users worldwide with an estimated 470 tons shipped to North America, 
with North America and the European Union (EU) combined making up 80% of the world 
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cocaine market (Figure 17).153 The European Monitoring Centre for Drug and Drug 
Addiction (EMCDDA) reported 3.5 million European users of cocaine. The drug accounts for 
9% of seizures of all classes of drugs, equating to 69.4 tons estimated to be worth 5.7 billion 
EUR.39 In the UK, more than half of the class A drugs seized in 2015/2016 was cocaine. 
Crack cocaine seized showed an increase of 14% in 2015/2016 compared to the previous 
year.154 
 
Figure 17. Quantities of South American cocaine and shipping routes to different areas 
around the world.153  
 
 
Figure 18. Cocaine seized disguised as wooden pallets.155  
 
A big blow to organized crime came with the 2015 seizure of 1.4 tons of cocaine in 
the port city of Valencia, Spain.155 The most striking feature of this drug bust is not the sheer 
quantity of the amount in one seizure, but the way that the drugs were concealed. The cocaine 
was in the form of pallets, apparent wood pallets used for shipping and the loading of 
shipments (Figure 18). Moreover, an additional amount of cocaine, compressed and moulded 
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in the form of BBQ charcoal briquettes, was also seized in the same shipment .155 This is 
considered one of the major seizures in Europe similar in magnitude to the 23rd of April 2015 
North Sea bust of £500,000,000 worth of cocaine on board a Tanzanian registered ship by the 
British Royal Navy with the aid of local and international agencies.156 Additionally, men of 
different nationalities from Britain, Peru and Dubai were arrested in connection with the 
shipment that came from Colombia to be delivered to a charcoal factory which the authorities 
in Spain believe to be a front for the distribution of the drugs to Europe. It is also believed 
that the charcoal factory is the location where the cocaine from the pallets and compressed 
charcoal briquettes was to be extracted.157 According to the Daily Mail online, the 
involvement of 6 British men might indicate that the shipment was intended to be distributed 
in the UK and more specifically Liverpool.158  
Clearly drug manufacturers and distributers are going to great lengths to smuggle 
drugs in very sophisticated and clever ways to by-pass border check-points undetected. Even 
though this drug bust is considered a major setback to organized crime in Europe, it will 
undoubtedly cause the price of cocaine to increase and that might also influence (reduce) the 
purity of the drug, for example increasing the presence of benign cutting agents such as 
sugars or the more dangerous pharmaceutically active drugs e.g. benzocaine, ephedrine, and 
levamisole.70,71 Illicit drugs are well known for being cut with adulterants or cutting agents. 
These agents should not be confused with excipients found in pharmaceutical preparations 
that are used to bind the drug e.g. cellulose. Common cutting agents used for cocaine from 
the years 1991-1996 in the UK are:  sugars, paracetamol, caffeine, benzocaine, and procaine 
with a mean cocaine purity of 85%.159 
Recently, the Maritime Analysis and Operations Centre-Narcotics (MAOC-N) 
conducted an operation close to the coast of Portugal where £200,000,000 worth of cocaine 
weighing approximately 3.7 tons was seized aboard a tug boat. There was much media 
speculation about the destination of the shipment, but officials believe that it was destined 
either for Europe or the UAE.160 Pure crystalline cocaine and its free-base crack are 
continuing to arrive in the EU by the ton. Free samples are causing a rise in crack addiction. 
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1.8 Phenethylamines and cathinones testing at music festivals 
Drug testing at music festivals is a controversial issue nowadays. The debate includes 
politicians, music festival organizers, drug analyst experts, harm reduction specialists, police 
forces, and not least of all music festivals attendees most of whom are young people. It is 
well known that drugs are popular and trendy at music festivals and night clubs, especially at 
rave scenes. One study revealed that of young people aged between 16-29 attending dance 
scenes, one in five intended to take drugs which might increase the pleasure of the 
experience.161 By the end of 2017, organizers of six music festivals had implemented on-site 
drug testing including the Reading and Leeds music festivals. This number is expected to 
rise, though the UK biggest music festival (Glastonbury) still has a firm stance that drug use 
of any kind is illegal and that police officers on site will apprehend any person caught with 
drugs on them.162,163 The Royal Society for Public Health (RSPH) is recommending on-site 
testing. It is supported by 95% of festival attendees and will help in harm reduction of the 
growing drug problem at music festivals. One in five of the users at the Secret Garden Party 
and Kendal Calling festivals chose to dispose of their drugs after receiving the results of their 
drugs’ contents analysis.164  
The first to implement on-site testing at music festivals was in Cambridgeshire, 
where the charity responsible for the testing, the Loop, coordinated with police officials, 
offering a 10 minutes harm reduction service to festival goers to test their drugs, with the 
main concern among festival organisers and goers being high strength MDMA tablets.165 
Additionally, Loop officials stated that more than 80 substances monitored are a cause of 
concern.165  
Prior to on-site testing, drug analysts used to rely on amnesty bins situated at major 
music festivals and dance clubs for the analysis and to educate attendees in harm reduction 
awareness. Methods used by the forensic company TIC TAC rely on coupling FT-IR and 
GC/MS to create a drug database for the analysis of the disposed sample, which gave insight 
into some of the drugs used in such venues. However, some critics argued that these drugs are 
disposed of and do not represent the actual drugs of choice. Nevertheless, analyses by 
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Kenyon et al.166 revealed that cocaine is the most used drug powder and that most of the 
tablets used are MDMA tablets.166  
The main drive behind this trend of on-site testing is intoxications and deaths among 
young people in general and music festivals goers in particular. MDMA causes euphoria and 
excitation, but also potentially serious side-effects such as hyperthermia (increase in body 
temperature), rhabdomyolysis (muscle injury) and significant dehydration. The availability of 
high purity MDMA, combined with the use of the Dark Web to buy such MDMA make it 
more difficult to tackle the issue. Van Hout and Hearne167 shed some light on the use of  the 
Dark Web also known as online cryptomarkets such as Silk Road, Alphabay and Valhalla for 
the purchase of NPS and illicit drugs that can only be accessed through TOR browsers that 
conceal the identity of the purchasers. Their study explored the dynamics of two such online 
markets (Alphabay and Valhalla) in the second quarter of 2016 by searching for NPS under 
seven categories: cathinones, stimulants, opioids, cannabinoids, dissociative, hallucinogenic 
and other non-categorized drugs, revealing that the buyer is well informed regarding harm 
reduction and each vendor’s reputation. Moreover, the study revealed a rise in demand for 
GABA activating substances and the poly-drug use of NPS, along with mainstream drugs 
such as MDMA. Although, in a sample of 50,000 individuals, only 10% buy their MDMA 
from the Dark Web.168 Nevertheless, the main issue still remains as the drug buyer currently 
has no guarantee of the type, purity (adulteration) or the dose of the drug. Wood et al.169 
concluded in their retrospective study using the UK National Poison Information Service 
(NPIS) with regards to the reporting of toxicity in hospital A&E Departments, coupled with 
urine drug testing results, that poisoning from other stimulants such as amphetamine is not as 
significant as MDMA poisoning.  
The UK MDMA hospitalizations and fatalities receive significant attention in the 
main stream media. A man died and four are in critical care in Rochdale after reportedly 
taking a crystalline form of MDMA known locally, according to police sources, as “Pink 
Champagne” or “magic”.170 Two weeks prior to the Rochdale incident, in the Sheffield area, 
a 22 year old student died after taking an ecstasy tablet.171 Furthermore, a 15 year old boy 
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died and two others were hospitalized after taking ecstasy at a youth disco event in 
Plymouth.172 These are just some fatalities and hospitalizations from late May to late June 
2017. Another troubling incident is the appearance of teddy-bear shaped ecstasy tablets that 
could possibly attract younger people to experiment with them. Indeed, three 12 year old girls 
were hospitalized in Salford after taking these tablets, having been told that they were 
sweets.173 Overall, in England and Wales, deaths due to ecstasy have maintained a generally 
increasing trend, only fluctuating minimally with the exception of the years 2010 and 2011 
where, in the latter, deaths due to ecstasy dropped by 50% compared to 2009 (Figure 19).174 
One possible explanation for this drop is the 2008 seizure of enormous amounts of the 
MDMA precursors safrole and isosafrole (Figure 3).37 
 
 
Figure 19. Number of MDMA deaths in England and Wales, 1993-2016.174  
 
Even though their number is not anywhere near as high as deaths from cocaine and 
opioids, deaths from so-called legal highs including cathinones and phenethylamines have 
increased between 2004 and 2013, with a 3-fold increase in the number of deaths between 
2011 and 2013.175 A three year review over 2010-2012 of deaths and intoxications resulting 
from NPS found that the polydrug trend is common in fatalities involving NPS such as 
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mephedrone (4-methylcathinone), flephedrone, methiopropamine and many others, with 
mephedrone being the NPS most frequently found.176 In 84% of the deaths, other drugs were 
also found, in order of decreasing frequency:  alcohol, antidepressants, cocaine, 
amphetamines, opioids, benzodiazepines, and cannabis, with a worrying combination of 
stimulants such as amphetamines and cocaine which could result in serotonergic toxicity 
(serotonin syndrome) due to the monoamine transporter activities of those drugs. Another 
perhaps interesting, certainly macabre, finding of their review is that most of the deaths 
resulting from cathinones ingestion were from hanging.176  
A study examining deaths among music festivals goers, using published scientific 
literature and news reports, found that 75% of non-traumatic deaths at music festivals are due 
to drug overdose.177 A survey conducted for self-reporting NPS use on 682 attendees aged 
between 16-25 at electronic dance music festivals in New York (2015), found that 35% 
reported the use of NPS including cathinones, with methylone being the most popular 
cathinone and 2C-I the most popular phenethylamine NPS. The survey also highlighted the 
multidrug use of MDMA with other NPS and its risk factors for intoxication and possibly 
death.178 In 2013, two deaths occurred at a dance music festival in New York. This triggered 
an investigation by the US Department of Health and Mental Hygiene (DOHMH) which 
identified 22 cases of intoxication, 17 of them tested positive for MDMA and other drugs, 11 
of them tested positive for the cathinone methylone. Moreover, toxicological analysis on both 
deaths revealed MDMA in one case and MDMA plus methylone in the other.179 The 
association of MDMA and cathinones has also been documented in another toxicological 
(blood, urine and oral fluids) study in 396 individuals at dance scene festivals in the USA, 
where 75% of the participants tested positive for a drug or alcohol, and of those, 36% tested 
positive for NPS and/or MDMA. Furthermore, methylone was the most detected drug in 
blood and urine samples (n = 34), while ethylone was the most detected drug in oral fluids (n 
= 54). Also, ethylone was implicated in deaths in nine other cases.180,181  
The issue remains that other legal drugs such as tobacco and alcohol kill many more 
people than MDMA and cannabis which are illegal. Lung cancer was the leading cause of 
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death in the UK in 2014 with 98 deaths every day and 80,000 deaths that year attributed to 
smoking.182,183 It is believed that smoking (tobacco) cost the NHS £2.7 billion in 2006, while 
the revenues were £8.1 billion.184,185 Additionally, in 2015 there were 8,758 deaths related to 
alcohol with an estimated annual cost to the NHS of £3.5 billion.186,187 Moreover, the 
socioeconomic impact of alcohol is evident in the 491,000 violent crimes recorded in the year 
2015/2016 making up 40% of all violent crimes.188 Furthermore, the increase in the 
consumption of alcohol is directly proportional to the incidence of cirrhosis which ranks third 
in the premature cause of deaths in the UK, with 1 million annual admissions to hospitals as a 
result of disorders caused by alcohol.189 Professor David Nutt used various examples of legal 
activities that cause more annual harms and mortalities than MDMA, when he stated that 
horse riding caused more deaths (10 annually), more accidents (over 100 road traffic accident 
annually) and more injuries (350 annually). Additionally, Nutt criticised the media for 
eliciting fear in the public, an example of that is the reporting of all (100%) MDMA deaths 
each year compared to reporting 1 out of 250 deaths for paracetamol.190  
The debate around this issue has been divided between advocates and critics. People 
for the on-site music festivals testing see it from a harm reduction angle and that it could 
deter users, in some instances, from using. Even though some data show festival goers are 
positive and responsive toward the testing issue as stated by The Royal Society for Public 
Health (RSPH) and other research,191 other studies have shown a higher percentage (27%-
42%) of people attending music festivals choosing not to use drug testing. 192 Additionally, 
one of the reasons that some are against such testing is purely analytical. Some argue that the 
on-site testing is not equipped to identify and quantify, with a high degree of safety, the drugs 
involved. This might result in life threatening false-negative results, or inaccurate dose 
quantitation, that could be problematic, e.g. in the case of high dose MDMA tablets. 
Furthermore, some of the techniques, e.g. reagent colour testing, may fail to identify novel 
compounds. The method of chipping off part of the tablet for its identification is not good 
practice, because illicit manufacture of drug tablets may result in a non-uniform distribution 
of the active drug in the tablet, potentially affecting the analytical results. 
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HPLC and GC used on-site at festivals and clubs will require reference standards to 
be used in the drug libraries for detection. This is a problem encountered in the most 
sophisticated drug laboratories all over the world in accurate NPS analysis.192 Added to that, 
the problem of multicomponent drugs (polypharmacy) will complicate the analysis, as some 
of the peaks appearing in the chromatogram could overlap in closely related analogues of 
NPS. There is also the limitation of some analytical instrumentation such as FT-IR and near 
IR when used to investigate samples which are complex mixtures. 
Drug testing at music festivals and night-clubs is a commendable work, that is aimed 
toward protecting young people from illicit drugs including NPS. Nevertheless, many drugs 
exist in a complex mixture of different groups of illicit drugs such as MDMA, cathinones e.g. 
ethylone, methylone and/or other groups of NPS. Their detection requires accurate validated 
techniques and instruments that can reliably identify and quantify such samples that do 
currently exist in music venues. Complex mixtures require techniques such as 2D NMR 
spectroscopy for robust analysis. Trace amounts of impurities, cutting agents, and potent 
drugs that exist in µg amounts require sensitive techniques such as hyphenated-MS for 
analysis whether qualitative or quantitative. 
In the following chapters, demonstrations are given of the complexity of samples 
surrendered or seized from different dance venues and HMP Bristol. The analyses rely 
primarily on 1D/2D NMR spectroscopy and MS techniques. Identification and quantification 
of illicit drug samples and their frequency of coexistence with other NPS will be revealed. 
What is the dose of MDMA in tablets that were recently in circulation, at least in the South 
West of England? A q-NMR analysis method has been developed to answer this question. 








Chapter 2. Phenethylamines and cathinones 
 
2.1 Introduction 
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is considered to be by far the most 
popular of the phenethylamines in Europe, as demonstrated by the amount seized, 5.3 million 
tablets and 295 kg of powder in 2016.193 This popularity is the result of many factors such as 
the high purity (higher than seized amphetamine and methamphetamine) and the low price of 
only 6-11 Euros/tablet.193 Even though considered as a phenethylamine, the presence of the 
methylenedioxy group in MDMA results in altered pharmacology compared to amphetamine 
and methamphetamine.31 
Cathinones are the second most popular class by seizures among NPS (after SCAs) 
and the leading NPS available in the powdered form.193 They are based on the natural product 
S-cathinone, with many positions along the chemical structures that can be altered with 
different alkyl substituents resulting in a large number of derivatives, e.g. methylenedioxy 
substituents giving rise to analogues such as butylone, ethylone and methylone.28,194 The 
pharmacology and dose of cathinones and MDMA are of importance, especially in the 
context of analytical and forensic toxicology. Cathinones elicit their action on dopamine 
levels either by inhibiting reuptake by pre-synaptic dopamine transporters or directly by 
causing the release of dopamine. This dual effect is believed to be the reason for their strong 
action on the user/abuser. On the other hand, MDMA works primarily on serotonin receptors 
(5-HT-R), but also possesses dopamine release action.28,194 Moreover, mephedrone is a more 
potent inducer of locomotor activity in rodents than MDMA.28 Therefore, taking both types 
of drug can lead to serious consequences such as tachycardia, hypertension, hyperthermia and 
dehydration.195,196 
The association of cathinones with each other and with other NPS has been described 
by Zuba et al.197 Using LC, GC/MS and NMR, they showed that the most common 
cathinones detected were 3,4-methylenedioxypyrovalerone (MDPV) and butylone, found 
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with piperazines. Toxicological identification of post-mortem cases showed MDMA with 
methylone, and MDMA with ethylone.180,181  
Analytical techniques used for the detection and quantification of phenethylamines 
and cathinones depend primarily on chromatographic methods coupled to MS (UHPLC/MS 
and GC/MS).9 Although considered as gold standards in the pharmaceutical industry and in 
forensic analysis, each technique has its limitation and drawbacks. For example, the failure of 
the UHPLC method in detecting impurities with no chromophore that are associated with 
MDMA and cathinones will affect the outcome of the analysis. Additionally, the high 
polarity of some of the components present in the seized samples may result in poor peak 
resolution and even no retention on the UHPLC column.198 Poor ionization of some of the 
impurities will hinder the identification process using MS methods, while GC analysis will 
require derivatization to give sharp peaks in the chromatogram that are suitable for 
integration to achieve quantitative analysis. Moreover, a derivatizing agent is required to 
provide a distinctive mass ion, especially molecular ions that are at best weak due to the high 
energy collision (70 eV) of the Electron Impact (EI) in GC analysis. The main issue affecting 
chromatographic techniques is the need for an authentic reference compound for the targeted 
drug, which is either expensive or simply not available in the case of many NPS. 
NMR spectroscopic analysis provides a great opportunity for the characterization and 
quantification of complex exhibits containing multiple components of NPS and illicit drugs. 
1D (1H, 13C, DEPT) and 2D (COSY, HSQC, HMBC, H2BC, NOESY) NMR allow the 
definitive structural elucidation and assignment of the compounds in the mixture. Unlike MS 
and chromatographic techniques, NMR does not require a reference standard, a particular 
problem with NPS. NMR also does not require interaction with a chromatography column 
that could result in many drawbacks such as retention, carry-over that requires injecting a 
blank sample prior to the next analysis. Furthermore, the time-consuming preparation of 
mobile phases and chromatographic method development makes NMR a more attractive 
method.198,199 With the development of high-field NMR instruments, sensitivity is improving 
and that is reflected in quantitative NMR experiments with lower amounts of analyte. 1H 
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NMR is inherently quantitative, as the intensity of the signal being integrated is directly 
proportional to the number of protons represented by the signal, with the exception of some 
exchangeable protons (OH, NH, SH). This is only true when certain parameters are met such 
as the relaxation delay (T1) of the signal which can be measured using an inversion recovery 
pulse sequence of the signals of the analyte. Leaving 5xT1 to recover the magnetization to 
99.3% of its size will allow accurate integration for optimum quantitative results, given an 
appropriate number of scans to provide an acceptable signal-to-noise (S/N) ratio.199,200  
The first q-NMR experiment was performed by Jungnickel and Forbes,201 and also by 
Hollis 1963,202 where both research groups employed the molar ratio of the integrated protons 
for the quantitative analysis of a number of compounds including APIs, e.g. paracetamol, 
phenacetin and caffeine.199 
Another q-NMR experiment was developed and reported in 1997 by Akoka and co-
workers,203-205 known as Electronic Reference To access In vivo Concentrations (ERETIC) 
which does not rely on an Internal standard (IS) present in the solution, but instead uses an 
electronic signal of a separately calibrated real standard that is integrated into the probe 
during aquisition.200,206 QUANTAS (QUANTification by Artificial Signal),207is another q-
NMR protocol which is similar to ERETIC, but the artificial signal is integrated during 
processing and not acquisition.206 Electronic methods for NMR quantification were 
developed due to the absence of an ideal IS, as solubility and spectral overlap has always 
been an issue, especially in the quantification of large molecules such as proteins. 
Many reports on the increase of purity and overdose cases of MDMA have surfaced 
and made news headlines in some cases.35,39,170 Most of the published literature regarding 
MDMA tablet analyses rely on hyphenated chromatographic techniques,9,198,208 and no recent 
analysis of MDMA tablets in the UK has been published. Furthermore, no validated q-NMR 
method has been applied to MDMA tablets in the UK, thus warranting an investigation. 
GC-FID analysis of phenethylamines and related cathinones mostly suffer from non-
reproducible, broad and tailing peaks due to poor interaction with the stationary phase. This is 
most likely due to the compounds’ high polarity as a result of the presence of an amine in 
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their structure. Therefore, derivatization is essential, especially for consistent integration that 
will result in accurate quantitation.209,210 Additionally, depending on the derivatizing reagent 
used, the formation of distinctive molecular ions and fragments is helpful in confirming the 
identity of the target compound. This is a problem frequently encountered in NPS GC/MS 
analysis where the absence of a mass ion or only a weak mass ion peak will hamper definite 
identification of the analyte. The non-distinctive nature of other fragments, including the base 
peak, will negatively affect any definitive identification of the NPS analyte. 
In this chapter, qualitative and quantitative analysis of multicomponent MDMA with 
other NPS, such as cathinones, phenethylamines, and piperazines, will illustrate the 
complexity of the samples with definitive identification using NMR and UHPLC/MS/MS 
using a HILIC column. Additionally, a cross-method validation of q-NMR using an internal 
standard (IS) method is used to assay different MDMA tablets seized from night-club venues 
in Bristol. Validation is by UHPLC and UHPLC/MS using d5-MDMA as an IS for the latter. 
Furthermore, derivatization followed by GC/MS and ESI-MS analysis of selected cathinones 
and phenethylamines is performed using 2,2,2-trichloroethyl chloroformate. Derivatization of 
ethylone and 2C-B have not been published before. 
 
2.2 Experimental 
2.2.1 Chemicals and samples 
NMR grade solvents D2O 99.9%, CD3OD 99.8%, DMSO-d6 99.9%, and TMSP-2,2,3,3-d4 
98.0% were purchased from Cambridge Isotope Laboratories (UK, Goss Scientific). 
Methanol and water for UHPLC and UHPLC/MS analysis were Lichrosolve Honeywell 
LC/MS grade, and ethyl acetate 99.9% AcroSeal were purchased from Fisher Scientific 
(UK). ±-MDMA 1.0 mg/mL in methanol solution reference standard, ±-MDMA-d5 1.0 
mg/mL in methanol solution reference standard, N-[3-(trifluoromethyl)phenyl]piperazine 
hydrochloride (TFMPP) 99%, 1-(3-chlorophenyl)piperazine hydrochloride (m-CPP) 99%, 
maleic acid (MA) 99.94% and dimethyl sulphone (DMS) 99.96% are TraceCERT certified 
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for quantitative NMR analysis, acetanilide (99%), 2,2,2-trichloroethyl chloroformate 98%, 
and trifluoacetic acid (TFA) were purchased from Sigma-Aldrich (UK).  
In-house reference standard MDMA was prepared by converting a seized sample into 
its free base, followed by purification by flash column chromatography using a mobile phase 
of dichloromethane (DCM) and 10% methanol, followed by HCl salt formation in aqueous 
hydrochloric acid (1M, one equivalent) to obtain MDMA HCl as a white powder. 
Illicit samples (n = 195) were provided by the Drug Expert Action Team (DEAT), 
Avon and Somerset Constabulary, in sealed evidence bags containing numerous drug samples 
in different forms (capsules, crystals, powders, tablets and plant materials) in different 
packaging (small packs, magazine twists). Samples in small packs in the form of crystals and 
powders weighing between 50-250 mg were from different night-club venues in Bristol, 
while MDMA tablet weights ranged between 188-645 mg. 
 
2.2.2 Sample preparation 
For qualitative analysis, depending on the purity and complexity of the samples, between 10-
30 mg were weighed using a Sartorius BP221S balance in a 1.5 mL Eppendorf tube, followed 
by dissolving the samples in either D2O or CD3OD. Samples were then vortexed until all 
contents were dissolved or centrifuged and the supernatant was transferred to a 5 mm NMR 
tube. For LC/ESI-MS analysis, a stock solution (1.0 mg/mL) of seized materials was 
prepared, followed by 100-fold dilution into a MS vial. For quantitative analysis, crystals and 
powders were weighed using a Sartorius analytical balance MC 5 followed by extraction with 
D2O containing IS maleic acid (2.0 mg/mL) and 0.5% of TMSP-2,2,3,3-d4 (1.0 mL) for NMR 
spectroscopic analysis.  
For MDMA quantitative analysis, tablets of different sizes and shapes were 
photographed for documentation, followed by manual pulverization using a mortar and 
pestle. 10.0 mg of powder was weighed using a Sartorius analytical balance MC 5, 
transferring into a 7.0 mL glass screw neck specimen vial (Fisher Scientific), then extraction 
with D2O (2.0 mL) containing maleic acid (1.0 mg/mL) as an NMR quantitative IS with 
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sonication for 30 minutes, filtration through a Sartorius Minisart® 0.2 µm filter followed by 
taking a final volume of 1.0 mL for NMR spectroscopic analysis. For UHPLC analysis, the 
sample was diluted 100-fold into a MS vial. Samples were quantified using a 6-point 
calibration curve 1.5, 3.1, 6.3, 12.5, 25.0, and 50.0 µg/mL prepared in UHPLC solvent. For 
UHPLC/ESI-MS quantitative tablet analysis, the sample was extracted with LC/MS grade 
water and diluted 10000-fold into a MS vial and spiked with MDMA-d5 (500 ng/mL) as an 
IS. Samples were quantified using an 8-point calibration curve from 32.25, 62.50, 125.0, 
250.0, 500.0, 1000, 2000, and 4000 ng/mL. Each concentration was spiked with IS MDMA-
d5 (10 L of 25 g/mL) to achieve a final IS concentration of 500 ng/mL. The response was 
calculated as the ratio of the area under the curve of the target compound to that of the IS. 
The derivatization protocol is based on the work developed by Frison et al.,209,210 
with some modification. Prior to the analysis, samples were identified by 1D/2D NMR and 
ESI/MS. Seized samples (2.0 mg) of MDMA, mephedrone, and ethylone, and 10 mg of 
tablets containing 2C-B were placed in 1.0 mL micro reaction-vials (Sigma-Aldrich, UK), 
100 µL of a 3:7 v/v mixture of derivatizing reagent 2,2,2-trichloroethyl chloroformate and 
ethyl acetate was added to the residue and heated to 80˚C in a reaction vial heating block for 
15 min, followed by evaporating under a gentle stream of nitrogen, and finally it was 
reconstituted in ethyl acetate (100 µL), transferred into 200 µL polypropylene vials 




NMR spectra were recorded on a Bruker AVANCE III 500 MHz spectrometer, 1H and 13C 
frequencies are 500.130 and 125.758 MHz respectively. The probe was a variable 
temperature BBFO+ with three channels, temperature was 25˚C. Chemical shifts were 
referenced to 0.00 ppm for TMSP-d4 or the HDO residual solvent peak at δ 4.76 (HDO) and 
are reported in ppm. Coupling constants (J, line-separations, absolute values) are rounded to 
the nearest 0.5 Hz and rationalised. Structural elucidation was achieved with 2D NMR 
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Correlation Spectroscopy (COSY) which shows 2-, 3- and sometimes 4-bond connection of 
protons as cross peaks. Heteronuclear Single Quantum Coherence (HSQC) shows direct 
connection between protons and their carbon, Heteronuclear 2-Bond Correlation (H2BC) 
which is an exclusive 2-bond experiment between protons and their neighbouring carbons, 
Heteronuclear Multiple Bond Correlation (HMBC) which shows 2-, 3- and rarely 4-bond 
couplings between protons and their neighbouring carbons, 15N HMBC NMR which shows 
the two- and three-bond coupling of the 15N to protons, NOESY (proton-proton through space 
interaction). NMR spectra were processed using Bruker TopSpin 3.5 and Mestralab Mnova 
11.2. For quantitative 1H NMR (q-NMR) analysis, the zg pulse sequence was composed of 
3.18 s acquisition time, 16 scans, 50 s delay, 90° pulse angle, phase and baseline corrections 
were automatic while integration was performed manually. 
 
ESI-MS infusion  
Electrospray Ionization-Mass Spectrometry (ESI-MS) was conducted on a Bruker Daltonik 
micrOTOF in positive-ion mode on diluted samples (10 µg/mL in HPLC grade methanol). 
The mass accuracy of the [M+H]+ and [M+Na]+ ions is within 5 ppm of the required mass 
ion, unless otherwise stated. 
UHPLC and UHPLC/ESI-MS 
UHPLC calibration curve and samples quantitative analysis, was performed on a Dionex 
Ultimate 3000 UHPLC (Thermo Fisher Scientific, CA, USA) with a variable wave-length 
detector (λ = 210, 254, 280, 285 nm). Liquid chromatographic separation was performed 
using an Acquity UPLC BEH C18, 1.7 µM, 2.1 x 50 mm RP-column (Waters, Milford, MA, 
USA) with a flow rate of 0.3 mL/min, and an injection volume of 10 µL at 25°C column 
temperature. Mobile phase A consisted of water 0.1% TFA, mobile phase B was ACN 0.1% 
TFA. Gradient elution started with 1% B for 1.0 min, followed by a linear increase from 1.0 
min to 100% B at 4.0 min and maintained for 1.0 min, followed by a decrease to 1% B at 5.1 
min, where it was held for equilibration 2.9 min, total run time of 8.0 min. Data analysis used 
Bruker Data analysis 4.3, and Excel data analysis tool pack. QTOF-UHPLC-MS analysis was 
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conducted on a MaXis HD Quadrupole electrospray Time-of-Flight (ESI-QTOF) mass 
spectrometer (Bruker Daltonik GmbH, Bremen, Germany), operated in ESI positive mode. 
The QTOF was coupled to an Ultimate 3000 UHPLC (Thermo Fisher Scientific, CA, USA). 
The capillary voltage was set to 4500 V, nebulizing gas at 4 bar, drying gas at 12 L/min at 
220°C. The TOF scan range was from 75-1000 mass-to-charge ratio (m/z). Formic acid (FA) 
0.1% was used for the mobile phase instead of TFA and the same gradient and conditions as 
the UHPLC were used. For LC/MS/MS the in-source CID was set to 0.0 eV, with the 
collision energy for TOF MS acquisition at 3.0 eV. The collision energy was set to a sliding 
scale from 100 m/z at 14.0 eV, 500 m/z at 20.0 eV and 1000 m/z at 30.0 eV. For the analysis, 
the actual collision energy was between 15.0-18.0 eV. For the HILIC UHPLC-ESI/MS 
analysis, the column was a Kinetex 1.7µ 100A 100 x 2.1mm (Phenomenex, UK). Flow rate 
was 0.4 mL/min, mobile phase A consisted of 50:50 ACN:water v/v with 10 mM ammonium 
formate and 0.1% FA, while mobile phase B consisted of 95:5 ACN:water v/v with 10 mM 
ammonium formate and 0.1% FA. Gradient elution started with 100% B until 4.0 min, 
followed by a decrease to 0% B between 4.0-6.0 min and maintained until 8.0 min. followed 
by an increase to 100% B from 8.0-8.2 min, followed by an equilibration for 4.8 min with a 
total run time of 13.0 min. 
 
GC/MS 
Derivatized and non-derivatized samples were run on a Shimadzu GC-2010 GC-FID/MS 
under the following conditions:  full-scan mode 50-500 m/z, split mode ratio 1:20, with He as 
the carrier gas with a flow rate of 40.0 mL/min. BPX-5 column (30 m x 0.25 mm, 0.25 µm 
thickness) was used with the starting (0.5 min) oven temperature 50°C increased to 200°C at 
30°C/min, then to 280°C at 10°C/min, and maintained for 7.5 minutes with a total run time of 
21 min, except for ethylone where the temperature was maintained at 280°C for 21.5 min 






Excel data analysis tool pack was used for the statistical analysis, using Anova single- and 
two-factor analysis for obtaining the p values. 
 
2.3 Results and discussion 
2.3.1 Coexistence of MDMA with Novel Psychoactive Substances (NPS) 
In this study the association (formulation) of MDMA with other NPS will be presented, using 
spectroscopic and spectrometric assays. The complexity of the samples will be revealed with 
structural elucidation (1D/2D NMR and UHPLC/ESI-MS) and quantification using a fast, 
simple and accurate 1H q-NMR of each of the components without resorting to tedious 
preparation and method development assays. Analysis of 195 seized samples, obtained 
through DEAT in the years 2015-2016, revealed 174 MDMA samples and a further 21 
MDMA mixtures in different combinations (Figure 20). High dose MDMA is already a 
health concern; to find it associated with stimulant cathinones and other NPS is 
alarming.169,211 
 
Figure 20. Pie chart revealing the proportion of MDMA and its association with other NPS 
and cutting agents (in n = 195 samples) using both NMR and ESI-MS analysis. 
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Samples of MDMA/ethylone mixtures in different ratios were identified and 
quantified using a combination of 1D/2D NMR and UHPLC/ESI-MS. 18 non-coinciding 
peaks were found in the 1H NMR (see Table 2 and Figure 21).  
 
 
Table 2. 1H and 13C NMR (in D2O) assignments of one of the MDMA plus ethylone mixtures. 
 MDMA ethylone 
Position 13C 1H 13C 1H 
1 38.4 2.75 1H, dd (14.0, 7.0) 
2.89 1H, dd (14.0, 7.0) 
195.3 - 
2 56.4 3.39 1H, sextet (7.0) 57.7 4.96 1H, q (7.0) 
3 14.8 1.19 3H, d (7.0) 16.0 1.51 3H, d (7.0) 
1′ 129.4 - 126.7 - 
2′ 109.6 6.75 1H, d (1.5) 107.9 7.38 1H, d (2.0) 
3′ 147.4 - 148.4 - 
4′ 146.2 - 153.5 - 
5′ 108.6 6.79 1H, d (8.0) 108.6 6.94 1H, d (8.0) 
6′ 122.8 6.69 1H, dd (8.0, 1.5) 126.5 7.59 1H, dd (8.0, 2.0) 
7′ 101.0 5.88 2H, s 102.6 6.03 1H, d (2.0), 6.04 1H, d (2.0) (AB) 
1′′ 29.9 2.61 3H, s 41.4 3.02 1H, dq (12.5, 7.5)  
3.11 1H, dq (12.5, 7.5) 




Figure 21. 1H NMR (500MHz in D2O) of MDMA/ethylone mixture 





Figure 22. HSQC of MDMA (black lines)/ethylone (blue lines) mixture,  
the blue cross peaks indicate methylene protons, the red cross peaks indicate methyl and methine.
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Two distinctive NMR spectroscopic features were observed between the 2 
compounds in the mixture. The first is the quartet at 4.96 ppm of ethylone (-ketone MDEA) 
at the α-position (H2), and the other is the chemical shift of the signals for the 
methylenedioxy, which in MDMA occurred as a singlet at 5.88 ppm. In ethylone its chemical 
shift was further downfield at 6.04 ppm with an apparent dd splitting pattern (AB system). In 
fact the signal is two doublets with a particularly small 2J geminal value.212 This separation of 
the two methylene proton signals can be interpreted as an effect of the (somewhat distant) 
chiral centre transmitted through the benzoyl carbonyl functional group. It is not seen in the 
MDMA 1H NMR spectrum. HSQC analysis 2D dispersive powers allowed definitive 
structural assignments (Figure 22). In the LC/ESI-MS analysis of sample HN26, using a 
HILIC column allowed chromatographic base-line separation of the two components and 
molecular ion identification. Retention times for ethylone and MDMA were 4.0 min and 4.4 
min respectively. The found [M+H]+ for MDMA 194.1174 and ethylone 222.1121, for the 
required C11H16NO2 194.1175 (MDMA) and C12H16NO3 222.1124 (ethylone) (Figure 23). 





Figure 23. Sample HN26 analysis on a HILIC column (top) Base Peak Chromatogram 








Table 3. 1H and 13C NMR (in D2O) assignments of one of the MDMA/methylone mixtures. 
 MDMA methylone 
Position 13C 1H 13C 1H 
1 38.4 2.73 1H, dd (14.0, 8.0)  
2.87 1H, dd (14.0, 6.5) 
195.2 - 
2 56.4 3.39 1H, overlap with TFMPP 1′,2′ 59.3 4.91 1H, q (7.0) 
3 14.7 1.18 3H, d (6.5) 15.7 1.51 3H, d (7.0) 
1′ 129.3 - 126.6 - 
2′ 109.6 6.75 1H, d (2.0) 107.8 7.37 1H, d (2.0) 
3′ 147.4 - 148.3 - 
4′ 146.2 - 153.4 - 
5′ 108.6 6.79 1H, d (8.0) 108.5 6.94 1H, d (8.5) 
6′ 122.7 6.69 1H dd (8.0, 2.0) 126.5 7.58 1H, dd (8.5, 2.0) 
7′ 101.0 5.88 2H, s 102.5 6.03 1H, d (2.0), 6.04 1H, d (2.0), (AB) 
1′′ 29.9 2.60 3H, s 30.9 2.69 3H, s 
 
 
Table 4. 1H, 19F and 13C NMR (in D2O) assignments of TFMPP in the mixture. 
Position 13C 1H/19F 
1 149.8 - 
2 113.6, q (3JC-F 3.5) 7.29 1H, t (2.5) 
3 130.9, q (2JC-F 32.0) - 
4 118.2, q (3JC-F 3.5) 7.24 1H, dd (8.0, 2.5) 
5 130.1 7.40 1H, t (8.0) 
6 120.6 7.22 1H, dd (8.0, 2.5) 
CF3 125.1, q (1JC-F 271.5) - 
1′ 46.2 3.40-3.45 4H, overlapped with MDMA 2 
2′ 42.9 3.33-3.35 4H, overlapped with MDMA 2 
19F observe   -62.50, s 
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Five samples containing a mixture of MDMA with methylone and 
trifluoromethylphenylpiperazine (TFMPP) in different ratios, from Bristol Police amnesty 
bins, were identified and characterized using NMR spectroscopy (Tables 3 and 4, and Figure 
24) and ESI-MS. In this mixture, HSQC allowed assignment of overlapping proton signals by 
connectivity to their corresponding carbon resonances. For example, the 8 protons of 
piperazine (TFMPP) overlapped with the stereogenic centre methine sextet of MDMA at 3.39 
ppm. However, they were assigned as (1′) 3.40-3.45 ppm 4H, m, and (2′) 3.33-3.35 ppm 4H, 
m in an authentic sample of TFMPP. COSY enabled the extraction of the coupled piperazine 
protons from the cross peaks. Another diagnostic feature of methylone is the proton chemical 
shift and coupling of the methine stereogenic centre quartet at 4.91 ppm and the ketone 
carbonyl at 195.2 ppm. HSQC and DEPT allowed the assignment, with high confidence, of 
the two closely placed signals of methylone in 13C spectra of quaternary 1′ (126.6 ppm) and 6′ 
(126.5 ppm). 19F-HOESY experiment allowed the differentiation between H4 and H6 of 
aromatic protons via their through-space interactions with the trifluoro group. HMBC 
allowed the differentiation of TFMPP protons 1′ and 2′ through 1′ connection to C1 
quaternary carbon at 149.8 ppm. Distinctive 13C splitting of the carbons one, two, and three 
bonds away 1JC-F 271.5, 2JC-F 32.0, and 3JC-F 3.5 Hz were observed (Table 4, Figure 25). Due 
to the low ratio of TFMPP in the mixture, the 13C results were obtained from an authentic 
sample and compared with the mixture in the sample. NMR and MS were corroborated using 
authentic MDMA, methylone, and TFMPP.  
LC/MS/MS analysis revealed the mass ions and distinctive fragmentation pattern for 
each component in the mixture. [M+H]+ MDMA 194.1177 required for C11H16NO2 194.1175, 
methylone [M+H]+ 208.0968 required for C11H14NO3 208.0968, and [M+H]+ TFMPP 
231.1108 required for C11H14N2F3 231.1103 (Figure 26). In MDMA, loss of the methylamine 
from [M+H]+ resulted in the formation of 163.0757 ion, and the formation of 1,3-dioxole-5-yl 
methylium ion at 135.0440, while the 133.0647 resulted from the loss of O=CH2 of the 
methylenedioxy moiety, the 58.0652 fragment is the iminium ion. Methylone fragmentation 
is typical of cathinones with a methylenedioxy group.213 Loss of water (190.0863), then loss 
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of methylamine from the parent molecular ion resulting in the 177.0544 ion, while the loss of 
the methylenedioxy moiety gave rise to 160.0758 ion. On the other hand, the MS/MS trace of 
TFMPP was less informative with only one fragment resulting from the opening of the 
piperazine ring and loss of C2H5N.213-215  
 
Figure 24. 1H NMR (in D2O) of a 3-component mixture, with MA as quantitative IS, and an 
expansion of the aromatic area showing resolved protons of all components. 
 
Figure 25. 13C NMR spectra (in D2O) of an authentic sample of TFMPP showing the fluorine 




Figure 26. MS/MS fragmentation of (top) MDMA, (middle) methylone, (bottom) TFMPP. 
 
1H q-NMR of MDMA/ethylone mixtures and MDMA/methylone/TFMPP mixtures 
using maleic acid (MA) as an IS resonating at  = 6.38 ppm was performed (Table 5). MA is 
an ideal IS due to its simple resonance signal (singlet), non-overlapping peak, high purity 
(99.96%) and high solubility in D2O. An inversion recovery NMR experiment of MDMA, 
methylone and TFMPP in the mixture was performed to establish the relaxation time (T1) of 
the signals selected for quantification, to satisfy the parameter of adequate relaxation delay. 
This was found by experiment to be between 1.5-4.4 s, adopting at least 5xT1 to ensure 
complete relaxation of the signals between pulses.199,200 Additionally, no more than 10.0 mg 
of sample was used for quantitative NMR analysis in D2O as the high salt concentration 
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affected the broadness of the peaks by affecting the shimming. The reported amounts are in 










   (1) 
where (x) is the analyte and (std) is the IS, (m) is the mass in mg, (P) is the purity, (Mw) is 
the molecular weight in g/mol, (A) is the integral value of the resonance being investigated, 
and (N) is the number of protons represented by the signal.198,216  
Table 5. Replicates of 1H q-NMR analysis of 6 different mixtures of NPS with MDMA. 
Sample name Components 
identified 
mg/10 mg of sample 
± SD 
RSD % 
HN26 n = 6 MDMA 1.99 ± 0.2 6.4 
ethylone 6.54 ± 0.1 0.9 
HN31 n = 6 MDMA 5.01 ± 0.1 0.3 
ethylone 3.40 ± 0.2 5.5 
HN48 n = 3 MDMA 5.85 ± 0.1 1.2 
ethylone 2.94 ± 0.3 11.0 
HN153T n = 6 MDMA 3.22 ± 0.2 5.6 
methylone 2.31 ± 0.2 7.2 
TFMPP 2.50 ± 0.1 3.8 
HN154 n = 6 MDMA 7.42 ± 0.3 4.2 
ethylone 0.71 ± 0.1 5.1 
HN157 n = 6 MDMA 7.08 ± 0.2 2.4 
methylone 0.53 ± 0.1 8.2 
TFMPP 0.18 ± 0.1 7.5 
 
In this study, quantitative analysis of different selected samples of MDMA/NPS 
powder and crystal mixtures was achieved, with simple extraction using D2O containing MA 
(2.0 mg/mL) as an IS (Table 5). Initially the samples were identified and characterized using 
1D/2D NMR and LC-ESI/MS. Structural elucidation allowed the selection of signals for 
quantification of each component with high confidence. The amounts of MA and TMSP-d4 
were fixed throughout the analyses. The MA olefinic signal (at δ = 6.38 ppm) was used for 
quantification. It is well separated from the rest of the components in the mixture, even the 
methylenedioxy peaks of MDMA, ethylone and methylone, and was normalized to the value 
of 1.00. TMSP-d4 not only allowed the referencing of the NMR spectra to 0.00 ppm, but also 
was used to monitor the ratio of MA/TMSP in case of any impurity appearing beneath the 
MA peak, especially any cutting agents in the maleate form. 
In all the mixtures, all the signals of MDMA were available for integration with the 
exception of the chiral centre signal (2) at 3.39 ppm, where in MDMA/ethylone mixture an 
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unknown impurity resulted in a significantly higher integration value compared to the rest of 
the signals. In the MDMA/methylone/TFMPP mixtures, the same signal overlapped with the 
1′ and 2′ of TFMPP piperazine ring, whose signals were also excluded from the 
integration/quantitation analyses. Ethylone signals for integration depended on the signal to 
noise (S/N) ratio. In samples HN26, 31 and 48 all the signals were of an appropriate S/N, 
while in sample HN154, low S/N allowed only the aromatics and methylenedioxy signal (7′) 
to be integrated. The rest of the signals were too close in proximity to MDMA signals. In 
methylone spectra, each signal was used for quantitation except the 1′′ methylamine signal at 
2.69 ppm due to its close proximity with the 13C satellite signals of 1′′ and 1 of MDMA.  
The Relative Standard Deviation (RSD%) is affected by the non-uniformity of the 
original sample, and even though homogenization was carried out on the powder material 
some components comprising less than 30% of the sample, and especially less than 10% of 
the sample, resulted in more than 5% RSD.217 An example of this is the minor components of 
sample HN157, TFMPP and methylone compared to the major component MDMA (Table 5, 
Figure 27). Furthermore, the total composition of the samples is between 77.9%-87.9%. This 
is possibly due to the presence of insoluble materials, moisture in the sample, and even an 
excess of the salt to drug ratio in illicit drug samples as explained by Hays, in which salt and 
water content have influenced the purity of the samples under investigation by 1H NMR.198 
Two important parameters were taken into consideration:  the S/N ratio was more than 150, 
and the integration. The latter is believed to be the most significant parameter for error 
introduction because of it being operator dependent. Therefore, consistency in integration 





Figure 27. Spectra of 1H NMR (in D2O) between 5.70-7.80 ppm of (A) sample HN157 and  
(B) sample HN153T, revealing significant differences in the ratio of each component. 
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A fast (15 min), accurate and reproducible 1H q-NMR analysis was performed on 
many samples (n = 33) containing complex mixtures of MDMA and NPS. The extraction step 
with D2O was compatible with all the components present in their salt form due to their high 
water solubility. NMR allowed the separation of the majority of peaks, the few overlapping 
signals were excluded from the analysis. The RSD% affected the minor components (less 
than 10%) in the samples possibly due to the non-uniformity of the samples. This q-NMR 
analysis was suitable for an NPS that has no reference standard available for chromatographic 
analysis. The analysis results revealed a mixing-trend rather than cutting of MDMA with 
NPS in different ratios. Mixing is perhaps experimentation to increase the pharmacological 
effect. Cutting is dilution to increase profit. It is outside the scope of this analytical research 
to determine how such samples are marketed when 2 (or more) illicit compounds are mixed. 
MDMA is also found mixed or contaminated with its dimethyl analogue, N,N-
dimethyl-3,4-methylenedioxyamphetamine (MDDMA), reported to be found in MDMA 
samples synthesized through a nitropropene and reductive amination route.220 Due to the 
similar chemical structures, and therefore similar magnetic environments, the NMR spectra 
displayed multiple overlapping signals especially in the aromatic region and the methylene 
protons resonating at 2.73-3.10 ppm. The distinctive appearance of the stereogenic centre 
methine 3.58-3.64 ppm (Figure 28), integrals, 2D NMR (COSY and HSQC), and ESI-MS 
were all key diagnostic signals in the identification process. In addition to the 194.1194 
[M+H]+ for MDMA, the 208.1326 for the required C12H18NO2 208.1332 and its 13C 
isotopomer at 209.1364 give rise to numerous possibilities of common molecular formulae 
for associated NPS and MDMA analogues. Such compounds as 3,4-methylenedioxy-N-
methyl-butanphenamine, also known as MBDB (C12H17NO2), 3,4-MDMA methylene 
analogue (C12H17NO2) and 3,4-methylenedioxy-N-ethylamphetamine also known as MDEA 
(C12H17NO2) are shown in Figure 29. A total of 7 protons, 2 x N-CH3 plus one CH from the 
methylene overlapped with one of the MDMA methylene doublet of doublets at 2.78. 
MDDMA comprises 10% of the sample. The NMR spectra and MS acquired [M+H]+ are 




Figure 28. 1H NMR (in D2O) of sample HN165 containing MDDMA impurity with 



















Figure 29. Analogues with the same molecular formula C12H17NO2 (A) MDDMA,  
(B) MDEA, (C) MDBD, (D) MDMA methylene homologue (phenylpropylamine). 
 
4-Bromo-2,5-dimethoxyphenethylamine (2C-B) has been identified in combination 
with MDMA (83% 2C-B, 17% MDMA as molar ratios) as a ground-up orange tablet 
supplied in a small plastic packet. First synthesized by Shulgin in the mid-1970s,13 the 2C-B 
pharmacological profile is similar to that of MDMA in that it primarily inhibits 5-HT 
transporters. It also has less potency for dopamine and noradrenalin transporters. There has 
been a report of tablets sold as MDMA, but rather containing other psychoactive drugs: 
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MDA, TFMPP, 2C-B, caffeine.222 This supports the argument that people have probably 
consumed 2C-B unknowingly. 
 
Figure 30. 1NMR (in D2O) of 2C-B and MDMA mixture with TMSP 0.00 ppm, 
(top right) expansion of the HMBC spectra showing key HMBC connectivities, 
(top left) expansion of NOESY spectra revealing key NOE cross-peak connectivities. 
 
NMR analysis (Figure 30) (500 MHz in D2O) showed:  (C1) 13C δ = 27.9 1H δ = 2.98, 
2H, t 7.0 Hz, (C2) 13C δ = 39.4, 1H δ = 3.23, 2H, t 7.0 Hz, (C1′) 13C δ = 125.4, (C2′) 13C δ = 
152.2, (C3′) 13C δ = 116.6, 1H δ = 7.33, 1H, s, (C4′) 13C δ = 109.7, (C5′) 13C δ = 149.4, (C6′) 
13C δ = 115.7, 1H δ = 7.04, 1H, s, (2′-OCH3) 13C δ = 56.2, 1H δ = 3.83, 3H, s, (5′-OCH3) 13C δ 
= 57.0, 1H δ = 3.88, 3H, s. The analysis revealed two p-aromatic proton singlets and two 
methoxy signals at 3.83 and 3.88 ppm. These two aromatic singlets confirmed that this is the 
2,4,5-trisubstitution pattern of the phenylethylamine. Accurate assignment of all the 1H and 
13C signals was established via HMBC and 2D Nuclear Overhauser Effect Spectroscopy 
(NOESY) (Figure 30), where the protons at position 1 had an HMBC connection to the 
aromatic carbons C1′, C2′ and C6′, and NOESY connectivity to the aromatic proton at 6′. 
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Other key NOE connectivities are 2′-OCH3 to H3′ and 5′-OCH3 to H6′, while other key 
HMBC connectivities include 5′-OCH3 protons to the 5′-quaternary carbon and 2′-OCH3 
protons to the 2′-quaternary carbon. Additional analytical confirmation of the presence of a 
bromine substituent and not iodine (2C-I) or chlorine (2C-C) is [M+H]+ 260.0265 for 
C10H1579BrNO2 requires 260.0286, 262.0245 for C10H1581BrNO2 requires 262.0260 (ratio 1:1 
and both within 6 ppm) (Figure 31), in addition to the [M+H]+ for MDMA 194.1173 for 
C11H16NO2 requires 194.1181. These findings are consistent with work reported by Kanai et 
al.223 
 
Figure 31. ESI-MS loop injection of the mixture showing the diagnostic 79Br:81Br isotopic 
ratio of 1:1. 
 
2C-I, the iodo analogue of the 2C family, was detected in sample HN144, a blue 
powder, in combination with 2C-B and MDMA with a molar percentage of 50% 2C-I, 41% 
2C-B and 9% MDMA. The ESI-MS analysis revealed 2C-I [M+H]+ 308.0130 for C10H15INO2 
requires 308.0147 (within 6 ppm). 2C-B [M+H]+ 260.0264 for C10H1579BrNO2 requires 
260.0286 (within 6 ppm), and [M+H]+ 262.0253 for C10H1581BrNO2 requires 262.0260 
(within 6 ppm) (ratio 1:1). The 1H NMR of 2C-I and 2C-B overlapped with the exception of 
the aromatic signals, where the presence of the iodo substituent at the para-aromatic position 
resulted in a greater chemical shift difference in the 1H spectra between the ortho- (3′) (7.49 
ppm) and the meta- (6′) (7.00 ppm) protons compared with that found in 2C-B (Figure 32). 
This difference is of diagnostic value in determining the type of substituent in the NPS 2C 








Samples from Bristol night-clubs included high purity MDMA powders and crystals. 
Nevertheless, this analysis revealed multiple components of the cathinone and 
phenethylamine families mixed with MDMA. Even the selling of NPS samples, presumably 
as MDMA (ecstasy), but with MDMA only as the cutting agent, e.g. 9% molar ratio in 50% 
2C-I and 41% 2C-B, increasing the likelihood of toxicity. 1D/2D NMR and ESI-MS/MS 
provided high confidence analytical characterization and quantification of complex mixtures. 
The use of a HILIC column which is designed for high polarity compounds, such as amino 
acids, proved useful for the analysis of these samples. Additionally, MS/MS analysis revealed 
distinctive fragments of compounds in the mixture. 1H q-NMR using the MA IS method was 
applied successfully to complex samples of MDMA cut with other NPS of closely similar 
structures. This analysis provides some insight for law enforcement agencies, drug analysts, 
emergency first responders to any overdose situation in night-club venues, and for users 

















2.3.2 A cross-method validated 1H q-NMR analysis for the quantification of seized 
MDMA (ecstasy) tablets 
3,4-Methylenedioxymethamphetamine (MDMA) is a psychoactive drug popular among 
youths especially those attending night-club venues due to its stimulating and empathogenic 
effects.224 The dose of MDMA in illicit tablets has fluctuated during the past decade, but 
currently it is at an all-time high as reported by the EMCDDA39 and in our analysis. There are 
many reports of intoxications and even some fatalities especially among young adults 
attending night-clubs and music festivals.180,181 Adverse effects have been reported with the 
use/abuse of MDMA, with most of the intoxications and fatalities attributed to hypertension, 
kidney dysfunction, rhabdomyolysis, muscle tension, hyperthermia and dehydration.195,196 
Most of the analytical methods used for the quantification of MDMA tablets are 
chromatographic techniques that may be coupled to MS.9 Even though chromatography is the 
gold standard in industrial and forensic laboratories for quantitative analysis, it suffers from 
disadvantages.198 Lengthy method development and preparation of mobile phases are time 
consuming. Furthermore, UHPLC is unable to detect impurities that have no chromophore or 
are adulterated with high polarity excipients such as glycerol and sugars. Another 
disadvantage is the poor ionization of such excipients in MS analysis. GC/MS analysis 
suffers from the absence of or only weak mass ion, and requires derivatization for 
Amphetamine-type Stimulants (ATS) in order to achieve accurate quantitative results.209 On 
the other hand, NMR requires no solvent preparation and will detect organic impurities, even 
ones not possessing a chromophore, no method development and no stationary phase 
(column) for the compounds to interact with.198,199 NMR allows a simultaneous structure 
elucidation and quantification of the targeted analyte in a relatively fast time compared to 
various different chromatographic techniques. 
In this study, 26 tablets belonging to 11 different brands of seized MDMA tablets 
were quantified using 1H q-NMR and cross-method validated using UHPLC equipped with a 
variable wavelength detector (VWD) and UHPLC/MS using MDMA-d5 as an internal 















   (2) 
where (x) is the analyte and (std) is the IS, (m) is the mass in mg, (P) is the purity, (Mw) is 
the molecular weight in g/mol, (A) is the integral value of the resonance being investigated, 
(N) is the number of protons represented by the signal, m(tablet) is the mass of the tablet in 
mg while m(sample used) is the mass of the extracted sample, e.g. ~10.00 mg.198,216  
 
Table 6. NMR and UHPLC quantitative results of seized MDMA tablets. 















a 468.77 82.80 ± 3.0 3.6 89.08 ± 0.5 0.6 
b 494.71 108.65 ± 0.9 0.8 105.26 ± 0.9 0.8 
c 486.26 93.99 ± 1.7 1.8 97.16 ± 0.8 0.8 
2 
 
a 449.57 69.76 ± 1.0 1.4 76.24 ± 0.3 0.4 
b 449.11 75.64 ± 1.1 1.5 81.54 ± 0.3 0.4 
c 443.17 72.94 ± 2.2 3.1 75.00 ± 1.1 1.5 
3 
 
a 520.37 121.13 ± 0.6 0.5 121.24 ± 0.7 0.6 
b 477.08 113.26 ± 0.4 0.3 112.66 ± 0.5 0.4 
c 501.74 94.38 ± 0.6 0.6 92.58 ± 0.8 0.9 
4 
 
a 512.73 160.55 ± 0.8 0.5 164.21 ± 0.4 0.3 
b 481.95 150.27 ± 2.4 1.6 151.92 ± 2.1 1.4 
c 496.73 160.01 ± 0.5 0.3 165.13 ± 0.5 0.3 
5 
 
a 513.82 162.88 ± 3.0 1.8 163.45 ± 0.3 0.2 
b 520.66 160.95 ± 3.6 2.2 165.10 ± 0.9 0.5 
c 514.93 166.54 ± 1.5 0.9 171.55 ± 1.4 0.8 
6 a 325.00 89.45 ± 0.2 0.2 89.08 ± 1.2 1.4 




a 211.12 85.63 ± 0.1 
 
0.1 88.36 ± 0.7 
 
0.8 
b 209.21 83.31 ± 0.3 
 
0.4 84.18 ± 0.3 
 
0.4 





a 503.50 147.70 ± 2.0 
 
1.3 151.77 ± 3.2 
 
2.1 
b 468.77 139.74 ± 1.7 
 
1.2 144.66 ± 1.4 
 
1.0 
c 476.81 155.02 ± 3.2 
 







87.13 ± 0.9 
 







85.34 ± 1.8 
 





91.57 ± 0.7 
 







For UHPLC analysis, the non-specific (in terms of analyte) UV wavelength of 210 
nm was selected to detect impurities present in tablets. Both UHPLC using UV and 
UHPLC/MS quantification were determined first by determining the % of MDMA, followed 
by calculating the MDMA content using equations 3 and 4:225  
𝐌𝐃𝐌𝐀% =
𝐜𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐬𝐚𝐦𝐩𝐥𝐞 ( 𝐠/𝐦𝐋) .𝐝𝐢𝐥𝐮𝐭𝐢𝐨𝐧 𝐟𝐚𝐜𝐭𝐨𝐫 .𝐯𝐨𝐥𝐮𝐦𝐞 𝐮𝐬𝐞𝐝 (𝐦𝐋) .𝟏𝟎𝟎%
𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐬𝐚𝐦𝐩𝐥𝐞 ( 𝐠)
   (3) 
𝐦𝐠 𝐨𝐟 𝐌𝐃𝐌𝐀 =
𝐌𝐃𝐌𝐀% .𝐰𝐞𝐢𝐠𝐡𝐭 𝐨𝐟 𝐭𝐚𝐛𝐥𝐞𝐭 𝐢𝐧 𝐦𝐠
𝟏𝟎𝟎
   (4) 
 
A single extraction, using D2O for NMR analysis and H2O for UHPLC and 
UHPLC/MS analysis, was employed. This has been deemed sufficient with 100% recovery 
according to the literature.225,226 Additionally, numerous tablets were qualitatively analysed 
for cutting agents and types of excipients using NMR. The UHPLC method gave a good 
linearity by plotting the concentration (µg/mL) against UV response (Figure 33). Using TFA 
provided a better buffering capacity for MDMA, with good peak resolution and no peak 
tailing compared to using FA with UV detection (Figure 33). 
 
 
Figure 33. (Top) calibration curve of MDMA between 1.5-50 µg/mL, R2 = 0.9996, 
(bottom) UV chromatogram MDMA RT = 5.4 min of the calibration curve concentrations. 
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For UHPLC/MS, two tablets from the red UPS brand were selected for comparative 
analysis (Table 7). The calibration curve was run in triplicate, and gave a good linearity by 
plotting the concentration (ng/mL) against response ratio of MDMA to MDMA-d5 (Figure 
34). The Extracted Ion Chromatograms (EIC) (Figures 35) and spectra (Figure 36) of the 
molecular ions of both MDMA and MDMA-d5 were used for quantification. Using a 
deuterated analogue as an IS is optimal, due to it satisfying the IS criteria by having the same 
chromatography yet with a different mass ion, no possibility of it existing in the targeted 
analyte, and possessing similar ionization in ESI-MS.227,228 Furthermore, the RSD% across all 
methods gave a good RSD% of an acceptable value lower than 5% for powdered samples as 
set out by the European Network of Forensic Science Institute,217 with the exception of one 
sample 4b using UHPLC/MS analysis. The results of the UHPLC and NMR analyses were 
comparable. Additionally, using ANOVA single factor analysis of the three methods (NMR, 
UHPLC, and UHPLC/MS), there is no significant statistical difference (p > 0.05) (Table 7). 
 
Table 7. UHPLC, NMR and UHPLC/MS quantitative results of MDMA tablet number 4. 
No UHPLC NMR UHPLC/MS 
4 Entry Weight 
mg 
MDMA dose 












a 512.73 160.55 ± 0.8 0.5 164.21 ± 0.4 0.3 161.07 ± 4.7 2.9 
b 481.95 150.27 ± 2.4 1.6 151.92 ± 2.1 1.4 153.80 ± 8.6 5.6 
 
Figure 34. Calibration curve of MDMA range between 31.25-4000 ng/mL, response was 
calculated as the ratio of the area under the curve (EIC) of MDMA to that of IS (MDMA-d5), 





Figure 35. EIC calibration curve of MDMA (black) using 500 ng/mL d5-MDMA (red) at  
(A) 4.000 µg/mL, (B) 2.000 µg/mL, (C) 1.000 µg/mL, (D) 500.0 ng/mL, (E) 250.0 ng/mL, 




Figure 36. Compound spectra of the EIC calibration curve of MDMA (194 [M+H]+) using 
500 ng/mL MDMA-d5 (199 [M+H]+) as IS at (A) 4.000 µg/mL, (B) 2.000 µg/mL, (C) 1.000 
µg/mL, (D) 500.0 ng/mL, (E) 250.0 ng/mL, (F) 125.0 ng/mL, and (G) 62.50 ng/mL. 
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MA was selected as a quantitative IS due to its high solubility in D2O, simplicity of 
the olefinic signal (singlet), non-overlapping signal at  = 6.38 ppm. Due to the hygroscopic 
nature of MA, the purity was checked against high purity DMS in D2O and acetanilide in 
DMSO-d6. TMSP-d4 was used for referencing at 0.00 ppm using a fixed concentration of 
0.5%. This allowed the use of the ratio of MA/TMSP-d4 to check for any impurities that 
might be under the MA peak, such as drugs in the maleate salt form.  
Prior to commencing the analysis, an inversion-recovery experiment was carried out 
to establish the time it takes the signals of MDMA to relax which ranged between 2-4 s. For 
MA and DMS, the relaxation times were 6.1 s and 2.9 s respectively.229 Based on these T1 
values, the relaxation delay of the pulse sequence was set to achieve at least 5xT1 for almost 
complete relaxation.199,200 
Quantitative analysis revealed variations between different brands of MDMA tablets 
and within the same brand. Most of the doses quantified are significantly more than the 
average doses of MDMA recorded up to the year 2000 (50-80 mg).230 Additionally, many 
tablets, especially tablets number 4 and 5, contain from double to more than double the dose 
of MDMA required to produce a physiological effect (70 mg or between 1-2 mg/kg).196,231   
1H q-NMR allowed not only the quantification of the dose of MDMA, but also facilitated 
both detection and quantification of any protonated impurities present in the tablets. Caffeine 
was detected and quantified in tablets 11 a and b, containing 16.72 mg and 17.93 mg 
respectively with an RSD lower than 3%. Caffeine signals N-methyl 10, N-methyl 14 and 
aromatic 8 were used for quantification,232 while N-methyl 12 was not integrated due to its 
close proximity to the methine at position 2 of MDMA (Figure 37). UHPLC using UV 
resulted in a broad peak at 4.7 min for caffeine, and the MS analysis showed a weak [M+H]+ 
at 195.0874 m/z, required for C8H11N4O2 195.0876 (Figure 37). The reason behind the poor 
UHPLC peak shape (tailing and broadening) is the pKa of caffeine at the acidic pH of the 
mobile phase, while the weak molecular ion in MS analysis is the result of the 10000-fold 
dilution of the analyte to put it in the range of the calibration curve, and not to saturate the 




Figure 37. (A) 1H NMR (in D2O) of tablet 11a showing the caffeine peaks with expansion of 
the region between 3.4-4.5 ppm, (B) UHPLC of sample 11a showing a broad peak for 
caffeine at RT= 4.7 min, (C) MS trace of sample 11a showing MDMA molecular ion and 
caffeine low intensity molecular ion at 195.0874. 
Conclusions 
In this study, a cross-method validation of 1H q-NMR to analyse seized MDMA tablets is 
described. 1H q-NMR proved its versatility in the identification and quantification of MDMA 
as well as cutting agents, with less sample handling (no serial dilution) and better precision 
(RSD%) compared to chromatographic and MS-based techniques. NMR analysis provided a 
fast, reproducible quantification without the use of a reference standard of the analyte under 
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investigation. MA is a suitable NMR quantitative internal standard due to its high solubility, 
simplicity of the peak and non-overlapping signal. Identification of tablets containing more 
than double the dose of MDMA is a cause of concern to the public. It is of value to law 
enforcement officials and health workers. Comparative analysis with chromatographic and 
MS-based methods further corroborated the results of 1H q-NMR. When certain parameters 
are carefully optimized and considered such as the relaxation delay, number of scans, and 
S/N, NMR possesses the accuracy and reliability in the quantitative analysis of MDMA in 
seized tablets with results comparable to other gold standard techniques, e.g. GC and LC.  
 
2.3.3 GC/MS and ESI-MS analytical studies of selected derivatized phenethylamines 
and cathinones  
In this study, selected phenethylamines (MDMA and 2C-B) and cathinones (ethylone and 
mephedrone) were analysed non-derivatized and derivatized using 2,2,2-trichloroethyl 
chloroformate (TCF) to produce the carbamate derivative of the drugs selected, resulting in 
altered volatility and decreased polarity, thus enhancing the interaction of the compounds 
with the non-polar stationary phase (BPX-5 low polarity column). Differences in the mass 
ions detected, retention time and peak resolution are discussed. Additionally, isotopic 
analytical data on two drugs (ethylone and 2C-B) are provided for the first time.  
Simultaneous derivatization of a seized sample containing mephedrone and 2C-B 
was successful, non-derivatized mephedrone RT = 10.1 min on a BPX-5 column using the 
temperature ramp described (Experimental). On the other hand, the carbamate derivative of 
mephedrone has an RT = 16.5 min (Figure 38), as a result of the alteration of polarity and 
volatility.209 The Electron Impact (EI) MS spectrum of non-derivatized mephedrone suffered 
from an absent or a weak molecular ion at 177-178 m/z, with 119 m/z and 58 m/z (base peak) 
resulting from the 4-methylbenzoyl cation, and formation of the iminium ion found in N-
methylated phenethylamines respectively. This iminium ion is typical of phenethylamines, 




Figure 38. GC Total Ion Chromatogram (TIC) of non-derivatized mephedrone 10.1 min, 
TCF-derivatized 2C-B 13.3 min, and TCF- derivatized mephedrone 16.5 min. 
 
The mephedrone carbamate derivative resulted in a distinctive mass ion formed due 
to the isotopic ratio distribution of three chlorine atoms in the derivative, displaying: 
27:27:9:1, seen for the mass ions in low abundancy at 351:353:355:357, while the loss of 1 
chlorine results in the formation of the 316:318:320 weak ions (Figure 39). The base-peak 
cluster at 232:234:236:238 is the result of the 2,2,2-trichloroethyl N-ethyl-N-methyl 
carbamate fragment ion. The mephedrone derivative was also infused into the ESI-MS to 
obtain HR-MS on the molecular ion (Figure 40), giving [M+H]+ 352.0278 required for 
C14H17NO335Cl3 352.0268, 354.0247 required for C14H17NO335Cl2 37Cl 354.0240, 356.0214 
required for C14H17NO335Cl 37Cl2 356.0214, 358.0185 required for C14H17NO337Cl3 358.0192. 
The fragmentation pattern fits the distinctive pattern ratio of an analyte containing three 
chlorine isotopes.234  
Non-derivatized 2C-B resulted in a broad peak at 13.1 min, a difference of 0.2 min 
from the 2C-B TCF derivative (13.3 min), which was surprising given the structural 
alteration that has a significant impact on the polarity of Amphetamine-type Stimulants 
(ATS), and comparing it to mephedrone, where the derivative differed in RT by 6.4 min 
(Figure 38). Nevertheless, Kanai et al. reported only small changes in RT with 2C-B of 1.3 




Figure 39. (A) EI-MS of mephedrone carbamate derivative showing its fragmentation pattern 
with expansion of mass ion at 353 m/z and fragment at 316 m/z,  
(B) EI-MS of non-derivatized mephedrone showing base-peak fragment at 58 m/z. 
 
 
Figure 40. ESI-MS of mephedrone carbamate derivative showing the [M+H]+ with a ratio of 




For non-derivatized 2C-B, the molecular ion at 259/261 m/z was identified, as well 
as loss of part of ethylamine at 230/232 and the loss of the entire ethylamine moiety (-44) at 
215/217 (Figure 41). The rest of the fragments are less distinctive as they lack the 4-bromo 
substituent such as 121, 105 and 77, which are common in phenethylamine analogues.235  
 
Figure 41. EI-MS of non-derivatized 2C-B. 
 
Additionally, due to the broad peak and low intensity mass ion detected for 2C-B, 
further corroboration is required especially from a spectrometric point of view. 2C-B TCF 
derivative gave a distinctive isotopic pattern of one bromine and three chlorine isotopes with 
multiple isotopic clusters (Figure 42). Molecular ions at 433:435:437:439:441 are the result 
of the combination of three chlorine atoms and 1 bromine atom, giving rise to the complex 
isotopic pattern in the ratio of 27:54:36:10:1, explained using the following calculations: 
For 2 Cl atoms 3:1 a:b 
(3a + 1b)2 = 9a2 + 3ab + 3ab + 1b2 
= 9a2 + 6ab + 1b2  
For 3 Cl atoms (3:1  a:b) 
(3a + 1b) (9a2 + 6ab + b2) = 27a3 + 18a2b + 3ab2 + 9a2b + 6ab2 + 1b3 
= 27 a3 + 27 a2b + 9ab2 + 1b3 
For an added 1 Br (1:1  a:b) 79Br:81Br ratio 1:1 





Figure 42. EI-MS of carbamate derivative of 2C-B showing the region of the spectrum 
between 50-500 m/z, the proposed fragmentation pathway, and expansions of isotopic 
fragments and clusters showing the isotopic ratio of distribution of the molecular ion at  
433 m/z and the fragment at 399 m/z. 
 
The cluster fragments at 399:401:403:405 are the result of loss of one chlorine from 
the molecular ion (Figure 42), while the 354:356:358:360 cluster is the result of 4-bromo 
substituent loss giving the isotopic ratio of 3 chlorines (Figure 42). Additional fragmentations 
can be observed in Figure 42, especially the base peak (100% abundancy) resulting from the 
loss of the entire 2,2,2-trichloroethyl carbamate part. All of these complex isotopic signatures 
give a definitive identification to the compound with valuable structural elucidation 
information. The analysis could not be compared to the literature as none exists, nevertheless 
it is in line with the work of Frison et al. on a similar compound (bk-2C-B).210  
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Accurate mass was acquired using ESI-MS for all the isotopic fragments of the 
molecular ion starting with 433.9301 (51% abundancy) required for C13H16NO479Br35Cl3 
433.9322, 435.9285 (100% abundancy) required for C13H16NO481Br35Cl3 435.9302, and 
required for C13H16NO479Br35Cl237Cl 435.9293, 437.9258 required for C13H16NO481Br35Cl2 
37Cl 437.9272, and required for C13H16NO479Br35Cl37Cl2 437.9263, 439.9258 required for 
C13H16NO481Br35Cl37Cl2 439.9243, and required for C13H16NO479Br37Cl3 439.9234, found 
441.9198 required for C13H16NO481Br37Cl3 441.9213. 
The RT of non-derivatized MDMA was 10.6 min. The EI spectrum gave a very weak 
mass ion at 193, as well as a very weak signal (163) for the loss of methylamine (Figure 43). 
This is different from the ESI-MS/MS results (Figure 26), where a strong [M+H]+ at 194 m/z 
and a base peak for the loss of methylamine (163 m/z) were observed. Of the other fragments 
shown in the EI spectrum, the only prominent signal is the base peak at 58 for the iminium 
ion, which is common among phenethylamines and cathinones.236 However, the TCF 
derivative of MDMA resulted in a RT = 18.5 min, a significant increase in RT compared to 
the non-derivatized MDMA (Figure 43). This is a result of the increase of molecular weight, 
and alteration of polarity and volatility, due to the formation of the carbamate derivative.237  
In the EI spectrum 50-500 m/z scan, the MDMA TCF-carbamate derivative resulted 
in an intense mass ion at 367 m/z, showing the clear isotopic distribution of substitution with 
three chlorine atoms (Figure 43C). A low intensity fragment from the loss of one chlorine is 
visible at 332 m/z, and a base peak at 232 m/z which is the result of the loss of trichloroethyl-
(methyl)carbamate, similar to the mephedrone derivative base-peak fragment (Figure 39A). 
For an enhanced analytical specificity, the derivative was infused in the positive-ion 
mode loop-injection into ESI-MS, resulting in the detection of the [M+H]+ found at 368.0241 
required for C14H17NO435Cl3 368.0217 (within 6.5 ppm), found 370.0189 required for 
C14H17NO435Cl237Cl 370.0189, found 372.0156 required for C14H17NO435Cl37Cl2 372.0163, 
found 374.0155 required for C14H17NO437Cl3 374.0142 (Figure 43). Moreover, traces of 
ketamine and ethylone of less than 2% were confirmed by GC/MS and ESI-MS, possibly due 




Figure 43. (A) TIC of non-derivatized MDMA RT 10.6 min, and MDMA TCF-carbamate 
RT 18.5 min, (B) EI spectrum of non-derivatized MDMA showing base peak at 58 m/z, (C) 
EI spectrum of MDMA carbamate with proposed structural fragmentation showing the M+ 
isotopic cluster at 367 and base-peak cluster at 232, (D) ESI-MS loop-infusion of MDMA 
carbamate derivative showing the [M+H]+ cluster in the isotopic ratio of 27:27:9:1. 
 
Ethylone was the least polar of the seized drugs being derivatized, due to the 
presence of an N-ethyl group. This resulted in a RT = 12.5 min. Derivatization resulted in a 
significant change in polarity, with RT increasing to 21.1 min. The standard run therefore 
needed to be extended beyond 20.0 min as explained in the Experimental/Instrumentation 
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section 2.2.3. The EI-MS 50-500 m/z scan of non-derivatized ethylone gave a weak mass ion 
at 222 m/z and also a weak 149 m/z for the loss of the diethylamine radical. The base peak at 
72 m/z is the result of the formation of an iminium ion, a common base-peak in cathinones.213  
Even though the carbamate derivative of ethylone gave a weak signal for the mass 
ion at 396 m/z, the base-peak cluster (246:248:250:252) with an isotopic ratio arising from 
three chlorine atoms (27:27:9:1) corresponds to the formation of 2,2,2-trichloroethyl N,N-
diethyl carbamate fragment ion (Figure 44 top) by acyl cleavage. This differs from the 
mephedrone base-peak cluster at 232 m/z, that corresponds to 2,2,2-trichloroethyl N-ethyl-N-
methyl carbamate fragment ion. The 246 m/z base peak was distinctive enough to provide 
some evidence that the TIC peak at 21.1 min belongs to the ethylone carbamate derivative. 
Moreover, infusion of the derivative into ESI-MS positive-mode loop injection resulted in the 
detection of the molecular ion providing HR-MS molecular ion identification: found [M+H]+ 
396.0176 required for C15H17NO535Cl3 396.0168, found 398.0134 required for 
C15H17NO535Cl237Cl 398.0139, found 400.0114 required for C15H17NO535Cl37Cl2 400.0107, 
found 402.0059 required for C15H17NO537Cl3 402.0078 (Figure 44). 
 
 
Figure 44. (Top) EI-MS base peak cluster arising from ethylone carbamate derivative, 
(bottom) ESI-MS infusion in the positive-ion mode of ethylone carbamate derivative showing 




In this Chapter, an analytical description of the association of phenethylamines, in particular 
MDMA, with other NPS using 1D/2D NMR and MS is given. 2D NMR was crucial in the 
identification and structural-elucidation process due to its 2D dispersive advantages, while 
LC-ESI/MS/MS allowed observation of the molecular ion, as well as distinctive 
fragmentation patterns of drugs even in mixtures. The use of a HILIC column, which was 
developed to analyse polar components such as amino acids, proved useful for the analysis of 
phenethylamines and cathinones. 1H q-NMR using MA as the IS allowed the quantification 
of multicomponent drug samples (in powders) without resorting to chromatographic methods 
that require a reference standard and lengthy preparation steps. 
1H q-NMR for the analysis of seized ecstasy tablets allowed fast, robust, precise 
analysis of a variety of MDMA tablets, using MA as the IS. Furthermore, this method 
allowed simultaneous quantification as well as detection of organic impurities/cutting agents 
present in the tablets that were not detected by UHPLC/MS, such as caffeine. Moreover, the 
finding of MDMA tablets containing double the typical dose is alarming and a cause of 
concern with respect to potential harm. 
Chromatographic and mass spectrometric analytical studies of phenethylamines and 
cathinones allowed the examination of the altered polarity and increase in molecular weight 
of the compounds after converting them into their carbamate derivatives, and the impact on 
chromatographic behaviour. Moreover, the incorporation of three chlorine atoms resulted in a 
highly specific molecular ion observed in the ESI-MS, as well as distinctive fragmentation 
patterns in the EI-MS with complex yet discernible isotopic clusters. Finally, MDMA is the 
most popular drug from night-club seizures. It was found in high purity. However, examples 
of mixing of MDMA with other pharmacologically more potent NPS were observed, thus 
possibly increasing the likelihood of toxicity or even death to users. This is a challenge to law 
enforcement, emergency room medical personnel, and drug analysts. 
In the next chapter, a more spectroscopically complex NPS class and further complex 
mixtures are analysed, revealing how challenging analytical studies of street samples can be. 
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Chapter 3. Analytical characterization of seized arylcyclohexylamines and phenidates  
 
3.1 Introduction  
The arylcyclohexylamine family of NPS is based on the chemical structures of 1-(1-
phenylcyclohexyl)piperidine (PCP) and ketamine (Figure 45) which exert their effects 
through NMDA L-Glutamate receptors, but their NPS analogues have other CNS receptor 
cross-reactivities whilst retaining their dissociative properties similar to ketamine.43,44,238 This 
group, along with tryptamines, makes up only 8% and 2% respectively of total NPS seized in 
2013.8 Nevertheless, there are many arylcyclohexylamine-associated reports of dependence, 
intoxications and deaths.239-241 The first two such UK analytical detections were reported in 
2012 in six individuals reporting mainly signs of tachycardia, hypertension and cerebral 
toxicity.239,240 GC/MS confirmed the detection of 2-(3-methoxyphenyl)-2-
(ethylamino)cyclohexanone (MXE) in all these six intoxication cases, while one case also 
had two other NPS both belonging to the benzofuran family.239 Furthermore, with respect to 
deaths in the UK due to MXE, toxicological reports stated that MXE was solely responsible 
in 90% of cases.241 MXE is promoted through internet vendors as a research chemical. 
 
 
Figure 45. Classic arylcyclohexylamines and their NPS research chemicals. 
 
The synthesis of MXE has been described by Hays et al.53 in a four-step reaction 
scheme starting with a cyclopentyl Grignard reaction with 3-methoxybenzonitrile to form 3-
methoxyphenyl cyclopentyl ketone, followed by α-bromination, reacting the product with 
ethylamine to form a Schiff base, and finally heating the tertiary alcohol imine for thermal 




Figure 46. Synthetic scheme of MXE. 
 
Methoxphenidine (MXP) (Figure 45) is an NPS classified in the family of 
arylcyclohexylamine dissociative drugs (Figure 45). Analogues of MXP circulating among 
internet vendors include regioisomers such as 3-MXP and 4-MXP, based on the position of 
the methoxy group on the aromatic ring. Analytical characterization of MXP has been 
described by McLaughlin et al.242 Furthermore, intoxications and deaths associated with 
MXP have been reported.242 Ketamine is usually not adulterated, but night-clubs’ amnesty bin 
analysis revealed that ketamine is being cut with caffeine.166 Nevertheless, no description of 
the mixing of arylcyclohexylamines with each other or with other cutting agents has been 
reported, thus warranting an analytical study on such street samples. 
Phenidate-type NPS are based on the ADHD drug methylphenidate (Ritalin), with 
many analogues based on the methylphenidate structure. The most common analogue is 
ethylphenidate, with online drug forums chatter contributing to the increased popularity of 
this drug.64 Both methylphenidate and ethylphenidate are psychostimulants, mainly acting 
through the potent inhibition of dopamine and (nor)adrenalin reuptake.61 The first analytical 
characterization of ethylphenidate was reported by Casale and Hays in 2011,243 using 
GC/MS, FT-IR and NMR of both the free base and the hydrochloride salt in CDCl3. The first 
analytical post-mortem detection in Europe was reported by Krueger et al. in 2014,65 using 
LC/MS/MS and GC/MS. The authors believe that the levels of ethylphenidate were not in the 
lethal range, but they contributed to death which was caused by the intake of other drugs. 
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However, in 2015 Parks et al.66 reported that in Eastern Scotland there were 19 cases where 
post-mortem toxicological examination revealed that ethylphenidate among other drugs 
(benzodiazepines and opiates) contributed to death; in 5 of them, ethylphenidate was 
mentioned on the death certificates as contributing to the cause of death. Identification of 
street samples of ethylphenidate are lacking in the literature, especially in the context of the 
analysis of mixtures of multiple components. This is an avenue worth exploring. 
In this chapter, analytical studies of Bristol night-club amnesty bins and police 
seizures from different locations in the South West of England of arylcyclohexylamines and 
phenidate-based NPS are demonstrated. Furthermore, some of the samples are found to be 
complex four- and five-component mixtures of NPS, other illicit drugs, active pharmaceutical 
ingredients (APIs) as cutting agents, and impurities. Analysis utilized 1D/2D NMR 
spectroscopy and LC-ESI/MS/MS. LC/MS on a C-18 column is used for the analysis of 
arylcyclohexylamines and phenidate-based multi-component complex samples.  
 
3.2 Experimental 
3.2.1 Chemicals and samples 
NMR grade solvents D2O 99.9%, CDCl3 99.8%, and TMSP-2,2,3,3-D4 98.0% were 
purchased from Cambridge Isotope Laboratories (Goss Scientific, UK). Methanol and water 
for UHPLC and UHPLC/MS analysis were Lichrosolve Honeywell LC/MS grade purchased 
from Fisher Scientific (UK). Maleic acid (MA) 99.94% is TraceCERT certified for 
quantitative NMR analysis purchased from Sigma-Aldrich (UK). Methoxetamine (MXE) 
hydrochloride 98.3% and 5-methoxy-N,N-diallyltryptamine (5-MeO-N-DALT) 99.5% were 
purchased from LGC (Teddington, UK).  
Samples (collected in 2015-2016) in the form of creamy coloured powders, crystals, 
orange coloured tablet fragments, and magazine twists and wraps, weighing between 50-150 
mg, were obtained from the Drug Expert Action Team (DEAT) of the Avon and Somerset 




3.2.2 Sample preparation 
For qualitative analysis, depending on the purity and complexity of the samples, between 10-
50 mg were weighed using a Sartorius BP221S balance in 1.5 mL Eppendorf tubes, followed 
by dissolving the samples in D2O, CD3OD or CDCl3. Samples were vortexed or centrifuged 
and the supernatant was transferred in to a 5 mm NMR tube. For NMR quantitative analysis, 
samples (11.0 mg) were weighed using a Sartorius analytical balance MC5 extracted with 
D2O containing IS MA (3.0 mg/mL). For LC/ESI-MS analysis, a stock solution (1.0 mg/mL) 
of seized materials was prepared, followed by 100-fold dilution into a MS vial. Conversion of 
the MXE and ketamine salt samples into their respective free-bases was achieved using drops 
of concentrated aqueous ammonia, followed by extraction with CHCl3, drying (MgSO4) and 
then concentration under vacuum.  
 
3.2.3 Instrumentation  
NMR spectroscopy  
NMR spectra were recorded as detailed in chapter 2, section 2.2.3 instrumentation.  
 
ESI-MS infusion  
Electrospray Ionization-Mass Spectrometry (ESI-MS) was conducted as detailed in chapter 2, 
section 2.2.3 instrumentation.  
 
UHPLC/ESI-MS 
Liquid chromatography was performed using an Acquity UPLC BEH C18, 1.7 µM, 2.1 x 50 
mm RP-column (Waters, Milford, MA, USA) with an a injection volume of 10 µL at 25°C. 
Mobile phase A consisted of water 0.1% formic acid v/v, and mobile phase B consisted of 
acetonitrile 0.1% formic acid v/v. Two methods were used for the UHPLC separation of 
components. Gradient 1 flow rate 0.3 mL/min, elution started with 1% B for 1.0 min, 
followed by a linear increase from 1.0 min to 100% B at 8.0 min and maintained for 2.0 min, 
followed by a decrease to 1% B at from 10.0 to 10.1 min, where it was held for equilibration 
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for 2.9 min, total run time 13.0 min. Gradient 2 flow rate 0.4 mL/min, elution started with 1% 
B for 2.0 min, followed by a linear increase from 2.0 to 100% B at 5.0 and maintained for 3 
min, followed by decrease to 1% B at 8.1 where it was held for equilibration for 3.9 min, total 
run time 12.0 min. Mass spectra were obtained using ESI-MS micrOTOF from Bruker 
Daltonik with positive-ion mode on diluted samples (10 µg/mL in HPLC grade methanol 
from a stock solution of 5 mg/mL). The mass accuracy of [M+H]+ and [M+Na]+ is within 5 
ppm of the required mass, unless otherwise stated. The QTOF-UHPLC LC-MS analysis was 
conducted using a MaXis HD electrospray Quadrupole Time-of-Flight (ESI-QTOF) mass 
spectrometer (Bruker Daltonik GmbH, Bremen, Germany), operated in ESI positive-ion 
mode. The QTOF was coupled to an Ultimate 3000 UHPLC (Thermo Fisher Scientific, CA, 
USA). The capillary voltage was set to 4500 V, nebulizing gas at 4 bar, drying gas at 12 
L/min at 220°C. The TOF scan range was from 75-1000 mass-to-charge ratio (m/z). For 
LC/MS/MS capabilities, the in-source CID was set to 0.0 eV, with the collision energy for 
TOF MS acquisition at 3.0 eV. The collision energy was set on a sliding scale from 100 m/z 
at 14.0 eV, 500 m/z at 20.0 eV, and 1000 m/z at 30.0 eV. For the analytes the actual collision 
energy was between 15.0-18.0 eV. The MS instrument was calibrated using a range of 
sodium formate clusters introduced by 10 µL loop-injection prior to the chromatographic run. 
The mass calibrant solution consisted of 3 parts of 1 M aqueous NaOH to 97 parts of 50:50 
water:isopropanol with 0.2% formic acid (v/v) and was used to calibrate the instrument 
within 1 ppm mass error standard deviation. Ions were detected as [M+H]+ ion with a mass-
to-charge (m/z) ratio within 5 ppm, respectively. Data processing was performed using the 
Data Analysis software version 4.3 (Bruker Daltonik GmbH, Bremen, Germany). 
 
3.3 Results and discussion 
3.3.1 Analytical studies of seized arylcyclohexylamine complex mixtures 
A total of 26 samples were found containing ketamine or MXE, in addition to samples 




Table 8. Arylcyclohexylamine samples identified using NMR and ESI-MS. 










Figure 47. Magazine twists containing combinations of different 
cutting agents and NPS associated with ketamine or MXE. 
 
NMR analysis of sample HN76 revealed ketamine and the cutting agent creatine, 
deduced from 2 proton singlets at 3.02 and 3.92, and 13C NMR data for 4 carbons, 2 of them 
quaternaries. HSQC revealed the singlet at 3.02 ppm is a methyl group with corresponding 
carbon at 36.9 and the 3.92 singlet is a methylene corresponding to its carbon at 53.8 ppm 
with no correlation in COSY, but the HMBC revealed methylene carbon coupling to the 
methyl and vice versa. Moreover, the sample was converted into the free base to obtain a 
better resolution in the aromatic region compared to the salt in D2O showing a multiplet of 3 
protons and a distorted doublet of doublets (Table 9 and Figures 48 and 49). Hays et al.53 
published the first analytical characterization of ketamine. However, there the signals at 1′ 
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and 2′ were transposed. They have been re-assigned in this study, using HMBC (in D2O) that 
showed connection of 1′ carbon at 127.2 ppm to the one of H3 protons at 1.90-1.94 ppm, thus 
warranting a complete assignment of the compound with creatine impurity present. 
 
Table 9. 1H and 13C NMR ketamine assignments of sample HN76. 
Ketamine free base (in CDCl3) Ketamine salt (in D2O) 
Position 13C 1H 13C 1H 
1 208.9 - 211.4 - 
2 70.1 - 72.5 - 
3 38.6 1.73-1.74 1H, m  
2.73-2.79 1H, m 
36.0 1.90-1.94 1H, m  
3.34 1H, dd (13.5, 2.5) 
4 21.8 1.69-1.75 2H, m 21.1 1.72-1.78 1H, m, 1.86-1.90 1H, m 
5 27.9 1.78-1.85 1H, m, 1.98-2.09 1H, m 30.1 1.78-1.83 1H, m, 2.10-2.18 1H, m 
6 39.5 2.46 1H, ddd (13.5, 8.5, 5.5), 
2.49 1H, ddd (13.5, 7.5, 5.5) 
39.4 2.56-2.69 2H, m 
N-CH3 29.1 2.10 3H, s 36.9 2.42 3H, s 
1′ 133.7 - 127.2 - 
2′ 137.9 - 134.1 - 
3′ 131.2 7.36 1H, dd (8.0, 1.5) 128.4 7.59-7.64 1H, m overlapped  
4′ 128.6 7.23 1H, td (8.0, 1.5) 132.6 7.59-7.64 1H, m overlapped 
5′ 126.5 7.31 1H, td (8.0, 1.5) 131.9 7.59-7.64 1H, m overlapped 




Figure 48. (Top) 1H NMR (in D2O) of sample HN76 containing ketamine salt and creatine 
with expansion of the two creatine signals, (bottom) ketamine free-base (in CDCl3) with 
expansion of the 2.4-2.9 ppm region and expansion of the aromatic region showing the 1,2-




Figure 49. HSQC expansion (1.2-3.2 ppm and 16-44 ppm) of ketamine free-base (in CDCl3). 
 
 
Figure 50. ESI-MS loop injection in the positive-ion mode of a ketamine/creatine mixture 




ESI-MS analysis of sample HN76 detected the cutting agent creatine, found [M+Na]+ 
154.0592 required for C4H9N3O2Na 154.0586. Even though the abundancy of the mass ion 
detected was significantly low due to the poor ionization of creatine, the mass accuracy was 
within the acceptable 5 ppm error (Figure 50). Creatine impurity was easily isolated by 
separation of the water fraction against chloroform, after converting ketamine into the free 
base using drops of aqueous ammonia. Furthermore, creatine is a cheap and widely available 
supplement product in health shops, with a physical appearance that resembles a ketamine 
salt making it a suitable cutting agent. 
Analysis of sample HN209 revealed (molar ratios) ketamine (80%) with creatine 
(16%) and procaine (4%) as cutting agents (Figure 51). Procaine has been reported as a 
cutting agent in cocaine,244 but to the best of our knowledge it has not been reported before as 
a cutting agent for ketamine. The 1H and 13C NMR data in this mixture were all consistent 
with ketamine and creatine. In addition, NMR analysis of the mixture allowed the structural 
elucidation and assignment of procaine (500 MHz in D2O) (C1) 13C δ = 168.7, (C1′′) 13C δ = 
116.5, (C2′′,6′′) 13C δ = 131.9 1H δ = 7.84, 2H, d 8.5 Hz, (C3′′,5′′) 13C δ = 114.6 1H δ = 6.83, 
2H, d 8.5 Hz, (C4′′) 13C δ = 153.0, (C1′) 13C δ = 59.0 1H δ = 4.65, 2H, t 5.0 Hz, (C2′) 13C δ = 
50.4 1H δ = 3.66, 2H, t 5.0 Hz, (C1′′′) 13C δ = 48.4 1H δ = ~3.40, 4H (overlapped with 1H of 
ketamine H3), (2′′′) 13C δ = 8.3 1H δ = 1.38, 6H, t 7.5 Hz. ESI-MS analysis of the mixture 
revealed the molecular ions of ketamine with the isotopic ratio of 3:1 of 1 chlorine atom, 
found [M+H]+ 238.1033 for C13H17NO35Cl requires 238.0993 (within 17 ppm), found 
240.0957 for C13H17NO37Cl requires 240.0963, as well as procaine found 237.1605, 
C13H21N2O2 requires 237.1597. Furthermore, creatine was not detected in this mixture 
(sample HN209) by ESI-MS loop injection, possibly due to its poor ionization and low 
amount in the mixture (16%). Nevertheless, NMR allowed the detection and quantification of 







Figure 51. 1H NMR (in D2O) of ketamine salt cut with creatine and procaine (peaks assigned). 
 
MXE samples (50-100 mg) were found in folded, cut-out magazine papers, obtained 
from Bristol police seizures. NMR analysis (in D2O) of sample HNSE89 revealed the absence 
of the 1,2-disubstitution pattern of the ketamine aromatic ring in favour of the 1,3-pattern, 
together with the methoxy singlet at 3.87 ppm, and the methyl (1.17 ppm) coupling (from 
COSY analysis) to the N-methylene of the N-ethyl at 2.56 ppm and at 2.90 ppm, split 
presumably due to the chiral centre (Figure 52 and Table 10). This structural assignment was 
confirmed by MS analysis which showed the molecular ion of MXE [M+H]+ 248.1673 for 
C15H22NO2 requires 248.1645 (within 11 ppm) and [M+Na]+ of 270.1452 for C15H21NO2Na 
requires 270.1469 (within 7 ppm), and the cutting agent creatine 154.0603 incorporating Na+ 
for C4H9N3O2Na requires 154.0586 (within 11 ppm). As above in cutting ketamine, creatine 
was detected as the adulterant (41%); two singlets in the 1H NMR (in D2O) at 3.04 and 3.93 
ppm correspond to the methyl and methylene groups respectively. The 4 signals in the 13C 
NMR are assigned to the methyl (36.9) and methylene (53.8) and quaternary carbons at 157.1 
(guanidine C=N) and at 174.6 (COOH) ppm. 1H and 13C assignments of creatine in both 




Figure 52. (Bottom) 1H NMR (in D2O) of sample HNSE 89 containing MXE (59%) and 
creatine (41%) with (inset) expansions of 2.45-2.95 and the aromatic region showing the 1,3-
disubstitution pattern, (top) expansion of one of the MXE N-ethyl doublet of quartets (dq) J 





















Table 10. 1H and 13C NMR assignments of MXE salt in D2O. 
Position 13C 1H 
1 209.0 - 
2 72.0 - 
3 32.4 1.98-2.05 1H, m, 3.22 1H, ddd (14.0, 6.0, 3.0) 
4 21.1 1.78-1.83 1H, m, 1.95-1.98 1H, m 
5 27.3 1.73-1.78 1H, m, 2.06-2.09 1H, m 
6 38.9 2.52 2H, t (6.0) 
N-CH2 37.1 2.57 1H, dq (14.5, 7.5), 2.90 1H, dq (14.5, 7.5) 
N-CH2-CH3 10.6 1.17 3H, t (7.5) 
1′ 131.1 - 
2′ 114.1 6.99 1H, t (2.0) 
3′ 160.0 - 
4′ 115.9 7.19 1H, dd (8.0, 2.0) 
5′ 131.3 7.54 1H, t (8.0) 
6′ 120.8 7.05 1H, dd (8.0, 2.0) 
O-CH3 55.6 3.87 3H, s 
 
HSQC allowed the assignment of the protons in the multiplets of the cyclohexanone 
to their corresponding carbons especially at positions 3, 4, and 5 as well as the aromatic 
protons (Figure 53). The aromatic protons signals at H4′ and H6′ were assigned by the 
HMBC relationship of C3′ to H4′. Furthermore, H5′ and H2′ had HMBC connectivities to 
C3′, while H6′ had no connectivity to C3′ as expected with a para-proton. Moreover, the 
HMBC relationship of C2 to H6′ and H2′ support the proton assignments in the aromatic 
region, H4′ has no such correlation. H2′ was a triplet from two meta-couplings to H4′ and 
H6′, 4J = 2.0 Hz, but there was no additional meta-coupling between H4′ and H6′ which were 
both dd (Table 10). Unusually, the order of resonance of H4′ (7.19 ppm) and H6′ (7.05 ppm) 
is inverted in the 13C NMR data, C4′ (115.9 ppm) and C6′ (120.8 ppm). The Heteronuclear 2-
bond correlation (H2BC) experiment is an exclusive 2-bond coupling experiment that aids in 
the accurate assignment of the cyclohexanone and also the aromatic signals. This helps to 
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solve the issue of missing 2-bond connections in HMBC data. Nevertheless, for accurate 
assignment of these signals both HMBC and H2BC need to be employed. H2BC of the 
aromatic region revealed 2-bond connection of C3′-H2′, C4′-H5′ and C6′-H5′ confirming the 
carbon and proton assignments. Combining HSQC data (Figure 53) with HMBC (Figure 54) 
and H2BC allowed the unambiguous assignments around the cyclohexanone ring where H6 
has 2-bond and 3-bond connections with C5 and C4 respectively. In the H2BC experiment, 
only the cross-peak for the 2-bond connection C5-H6 showed on the diagonal. ESI-MS 
analysis revealed the molecular ion of the cutting agent creatine 154.0603 incorporating Na+ 
within 7 ppm of the required 154.0592 for C4H9N3O2Na. MXE MS resulted in the [M+H]+ of 
248.1673 requiring 248.1650 for C15H22NO2 (within 10 ppm) and [M+Na]+ of 270.1452, 
requiring C15H21NO2Na 270.1469 (within 7 ppm). Moreover, the MXE single crystal 
structure was obtained (Figure 55) with data given in Appendix 1. 
 
Figure 53. HSQC spectra of MXE/creatine mixture between 1.0-4.1 ppm and 10.0-60.0 ppm, 
red lines show creatine 1H to 13C 1-bond correlation, black lines show MXE 1H to 13C 1-bond 




















Figure 54. HMBC spectra showing key connectivities in MXE. 
 
Figure 55. X-ray structure of MXE. 
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More complex mixtures of arylcyclohexylamines and cutting agents were identified 
in a cream coloured powder wrapped in a magazine paper (samples HN163 and HN200). 
These were analysed using a combination of 1D/2D NMR, ESI-MS and UHPLC/ESI-MS. 
NMR analysis of sample HN163 revealed ketamine 58%, MXE 2%, and MXP 1%, as the 
main psychoactive compounds present, in addition to creatine 5% and dimethyl sulfone 
(DMS) 34% as molar ratios (Figure 56), which were calculated using non-overlapping signals 
at 2.89, 2.40, and 2.61 ppm for ketamine, 1.14, 3.84, 7.00, and 7.70 ppm for MXE, 3.00 and 
3.90 ppm for creatine, 6.90 and 7.40 ppm for MXP, and 3.12 for DMS, where HSQC 
revealed the singlet at 1H δ = 3.12 ppm, 13C δ = 41.6 ppm representing 2x methyls. MXP 
NMR data are consistent with the DEA SWGDRUG monograph collection.245  
UHPLC/MS analysis using gradient 1 showed RT = 5.5 min [M+H]+ for ketamine as 
the major component of the mixture 238.0997 for C13H17NO35Cl requires 238.0993, 240.0968 
for C13H17NO37Cl requires 240.0963; RT = 5.8 min MXE [M+H]+ 248.1649 for C15H22NO2 
requires 248.1645; RT = 6.9 min MXP [M+H]+ 296.2012 for C20H26NO requires 296.2008. 
As for creatine, its high polarity prevented its retention on a C18 column. Nevertheless, 
infusion of the sample into the MS using the loop-injection method allowed the detection of 
[M+Na]+ 154.0581 for C4H9N3O2Na requires 154.0586. Moreover, DMS was not detected 
using LC/MS even though it is present in 34% according to 1H NMR, a problem encountered 
for small molecules that have poor ionization and no chromophore. Furthermore, a trace 
amount of a cathinone was detected on the UHPLC/ESI-MS spectrum in a green coloured 
peak (Figure 57) at 6.3 min with [M+H]+ 254.1540 for C17H20NO requires 254.1539, 
analysed as trace amounts (< 0.1%) of methylbenzyl cathinone; the only one reported is the 
4-methylbenzyl cathinone also known as benzedrone/4-MBC.246 MS/MS analysis allowed the 
confirmation of the structure according to the proposed fragmentation (Figure 58). Even 
though MXP was detected unambiguously, complete NMR spectroscopic characterization 
was not possible due to some of the piperidine signals overlapping with cyclohexanone 





Figure 56. 1H NMR (in D2O) of sample HN163 containing ketamine, MXE, MXP, creatine 





Figure 57. UHPLC/ESI-MS of sample HN163 showing (top) EIC of the 4 active components 
with expansion showing 4-MBC (green peak RT = 6.3 min), (bottom) ESI-MS spectra of  
(A) ketamine, (B) MXE, (C) MXP, (D) 4-MBC. 
 
MS/MS analysis revealed the characteristic fragmentation pattern for each 
component in the mixture (Figures 58 and 59). Ketamine ESI-MS/MS fragmentation was 
distinctive due to the presence of a chlorine atom in all fragments giving the characteristic 3:1 
ratio two mass ions. Unlike the GC/MS analysis of ketamine that suffered from an absent or 
weak molecular ion,53 ESI-MS/MS resulted in a clear molecular ion that underwent two 
pathways of fragmentation. The first resulted from the loss of water (220.0891 m/z), and the 
second from the loss of methylamine (207.0575 m/z). 179.0624 m/z and 125.0155 m/z 
fragments result from the opening of the cyclohexanone ring and formation of 2-chlorobenzyl 
ion respectively. 4-MBC formed two fragments, 134.0970 m/z and 91.0545 m/z resulting 
from the formation of N-benzylethylamine ion and tropylium ion (C7H7+). In MXP, in 
addition to the [M+H]+ at 296.2012, fragments result from the loss of the piperidine ring at 
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211.1120 m/z (base peak) and the formation of piperidinium ion 86.0967 m/z, 193.1014 m/z 
results from the formation of a (2-phenylethylidene)cyclohexa-2,4-dien-1-ylidene)methylium 
ion, while 183.1170 m/z results from the formation of 1-(cyclohexa-2,5-dienyl)-2-phenyl-
ethan-1-ylium ion. The proposed fragmentation of MXP has a similar pattern to the parent 
compound diphenidine and as in McLaughlin et al.242 who published an in depth analysis of 
MXP analogues differing only in the methoxy position on the aromatic ring. 
 
Figure 58. MS/MS spectrum of sample HN163 showing molecular ions and assigned 


































Sample HN163 provides a good example of the various analytical advantages and 
disadvantages of NMR, UHPLC and ESI-MS. NMR allowed the assignments of all the five 
components and the calculation of their molar ratios. Creatine, which suffered from low 
ionization and poor retention on the C18 column, was unambiguously characterized in the 
NMR, as was DMS which could not be detected using UHPLC/ESI-MS, possibly due to its 
poor ionization and the absence of a chromophore. On the other hand, NMR failed to detect 
trace impurities present in the sample such as 4-MBC, which was only detected using 
UHPLC/ESI-MS and its MS/MS fragmentation is proposed. DMS has been found used in 
cutting methamphetamine analysed in the USA, thus care must be taken if considering using 
it as an IS for q-NMR.198 
Sample HN200 NMR and UHPLC/ESI-MS/MS analysis revealed similar 
components to sample HN163 analysis with the absence of DMS and the presence of MDMA 
(Figure 60). Resolved signals for each component in the mixture allowed the calculation of 
the percentage (molar ratio) of each component in the sample:  ketamine 85%, creatine 8%, 
MXE 4%, MXP 2%, and MDMA 1%. A trace amount of 4-MBC was also detected using 
UHPLC/ESI-MS/MS. The presence of MDMA in only 1% is possibly a result of cross-
contamination that may have occurred during manufacturing rather than any intentional 




Figure 60. 1H NMR stacked spectra expansion of (A) sample HN163 and (B) sample HN200 
between 2.35-3.15 ppm revealing the absence of DMS in HN200; expansions 5.5-7.4 ppm 
show the presence of MDMA aromatic (6.75-6.88 ppm) and methylenedioxy (5.94 ppm) 
peaks in HN200 which are absent in HN163. 
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MXE and ethylphenidate are frequently encountered NPS in drug analysis 
laboratories due to their popularity especially in dance scene events because of their 
stimulating and dissociative effects. Each is associated with cases of intoxications and 
fatalities.66,240,241 NMR is not usually available in forensic drug analysis laboratories, for 
technical and financial reasons, and most drug analysis laboratories rely on chromatographic 
techniques coupled to MS, whether it is soft ionization ESI-MS or CI or EI, each with its own 
set of advantages and disadvantages.9 MXE and ethylphenidate are structural isomers having 
the formula C15H21NO2, their molecular ions are indistinguishable by ESI-MS, and the EI in 
GC/MS analysis will result in no or only a weak molecular ion. However, Collision Induced 
Dissociation (CID) using ESI-MS/MS allows the detection of the molecular ions as well as 
distinctive fragmentation for each component. 
 
Figure 61. (Top) TIC and (bottom) MS spectra of a spiked sample of MXE (black) and 
ethylphenidate (red). 
 
UHPLC/MS resulted in two base-line resolved peaks at 6.8 min for MXE and 7.3 
min for ethylphenidate (Figure 61) having similar [M+H]+ found 248.1646 and 248.1648 
respectively within 5 ppm for both MXE and ethylphenidate, C15H22NO2 requiring 248.1645. 
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On the other hand, the MS/MS spectrum showed a distinctive fragmentation for both MXE 
and ethylphenidate. MXE fragmentation is similar to ketamine, with the loss of ethylamine 
instead of methylamine in ketamine, opening of the cyclohexanone ring, and the formation of 
3-methoxybenzyl cation (Figure 62). On the other hand, ethylphenidate showed more 
stability of its molecular ion fragmenting only to the piperidine cation (C5H10N+). 
Furthermore, the GC/MS spectra of both compounds show weak or even not detectable 
molecular ions,53,243 while the UHPLC/ESI-MS/MS resulted in a good intensity molecular ion 
and sufficiently distinctive fragmentation pattern to allow structural information to be 
deduced. 
 




3.3.2 Analytical characterization of complex phenidate-based NPS  
Analysis of 330 samples revealed 7 ethylphenidate-associated NPS with 2 samples of 
complex mixtures. “Charles” 4-component mixture was analysed by 1D/2D NMR 
spectroscopy and ESI-MS revealing methiopropamine (MPA), a methamphetamine thiophene 
analogue, benzocaine and mannitol as well as ethylphenidate. Quantitative 1H NMR in D2O 
on a sample (11.00 mg) was performed (n = 4) using MA (3.00 mg) as an IS revealing:  MPA 
(2.81±0.04 mg RSD = 1.46%), benzocaine (2.87±0.02 mg RSD = 0.79%), ethylphenidate 
(1.48±0.05 mg RSD = 3.23%), and mannitol (2.63±0.03 mg RSD = 1.15%) after normalizing 
the N-methyl of MPA (1′′) to 3.00, quantified using signals from each compound:  MPA (1′, 
1′′, 2′), ethylphenidate (1′′′, 6′′ax, 5′′, 4′′), benzocaine (2′, 6′, 1), and mannitol (1, 3). The 
calculated purity of the sample was 89%, small amounts of insoluble materials in addition to 
the water content of illicit samples could account for that purity value. 1D/2D NMR allowed 
the complete characterization of the 4-component sample (Tables 11 and 12, Figure 63). 
 
Table 11. 1H and 13C NMR (in D2O) assignments of ethylphenidate in the “Charles” mixture. 
Position 13C 1H 
1 172.8 - 
2 53.8 4.00 1H, d (9.0) 
1′′′ 63.0 4.18-4.28 2H, m 
2′′′ 13.0 1.19 3H, t (7.0) 
2′′ 57.9 3.83-3.84 1H, m 
3′′ 26.2 1.39-1.47 1H, m, 1.62-1.67 1H, m 
4′′ 21.3 1.39-1.47 1H, m, 1.79-1.83 1H, m 
5′′ 21.8 1.58-1.67 1H, m, 1.79-1.91 1H, m 
6′′ 45.6 3.09 1H, td (13.0, 3.5), 3.47 1H, dt (13.0, 3.5) 
1′ 133.3 - 
2′,6′ 128.6 7.34 2H, dd (5.0, 3.5) 
3′,5′ 129.5 7.45-7.51 2H, m overlapped with 4′ 




Table 12. 1H and 13C NMR (in D2O) assignments of MPA salt in the “Charles” mixture. 
Position 13C 1H 
2 137.1 - 
3 127.6 7.05 1H, dd (3.5, 1.5) 
4 127.6 7.08 1H, dd (5.5, 3.5) 
5 125.7 7.41 1H, dd (5.5, 1.5) 
1′ 32.7 3.23 1H, dd (15.0, 6.5), 3.27 1H, dd (15.0, 6.5) 
2′ 56.3 3.56 sextet (6.5) 
3′ 14.9 1.36 3H, d (6.5) 
1′′ 29.9 2.72 3H, s 
 
NMR of cutting agent benzocaine (500 MHz in D2O) (C1) 13C δ = 169.0, (C1′) 13C δ 
= 118.9, (2′,6′) 13C δ = 131.5 1H δ = 7.86, 2H, d 7.0 Hz, (C3′,5′) 13C δ = 114.7 1H δ = 6.83, 
2H, d 7.0 Hz, (C4′) 13C δ = 139.0, (C1′′) 13C δ = 61.7 1H δ = 4.33, 2H, q 7.0 Hz, (C2′′) 13C δ = 
13.5 1H δ = 1.37 3H overlapped with α-(3′)-methyl of MPA. The first analytical profile of 
MPA was published by Casale and Hays,247 the NMR of MPA HCl salt in CDCl3, but this 
research has shown that D2O resulted in more spectral information in terms of coupling. 
Additionally, D2O was the deuterated solvent of choice for the analysis of such complex 
samples containing different components of varying polarity. The CH2 (1′) of MPA occurred 
as two closely resonating doublets of doublets, overlapping and appearing as an apparent 
septet. Even though the methyl of benzocaine overlapped with the methyl of 
methiopropamine (MPA), it was possible to extract cross-peak connectivity with the CH2 
quartet at 4.33 ppm of benzocaine using COSY. Moreover, a fourth component in the mixture 
was mannitol, included as a cutting agent, with 3 carbon and 4 proton signals due to the 
symmetry of mannitol at: (1) 63.2 ppm, 3.68 ppm 2H, dd 12.0 (gem), 6.0 Hz, 3.87 ppm, 2H, 
dd, 12.0 (gem), 2.5 Hz; (2) 70.8 ppm, 3.77 ppm 2H, ddd 8.5, 6.0, 2.5 Hz; (3) 69.2 ppm, 3.81 
ppm 2H, d 8.5 Hz (Figure 63). The spectra were confirmed by coincidence with the 1H and 





Figure 63. 1H NMR (in D2O) assignments of ethylphenidate, MPA, benzocaine, and 




Not withstanding the complexity of the mixture, UHPLC/ESI-MS resulted in 
obtaining the molecular ions of all four components (Figure 64) in the “Charles” mixture. 
The different polarities and ionization of the components in the mixture was a challenge: 
ethylphenidate RT = 5.5 min, found [M+H]+ 248.1646 for C15H22NO2 requires 248.1645, 
benzocaine RT = 5.8 min, found [M+H]+ 166.0860 for C9H12NO2 requires 166.0862, MPA 
salt RT = 0.5 min found [M+H]+ 156.0843 for C8H14NS requires 156.0841. MPA salt’s high 
polarity caused it to have a retention time RT = 0.5 min, while (at RT = 0.6 min) mannitol’s 
poor ionization in the positive-ion mode using gradient 1 resulted in a low intensity mass ion. 
Additionally, the high polarity of mannitol and an absence of a chromophore makes it a poor 
candidate for UHPLC analysis on a C18 column (Figure 64 top and A). For mannitol, the 
sample was infused in a loop injection positive-ion mode and resulted in found [M+Na]+ 
205.0681 for C6H14O6Na requires 205.0682.  
 
Figure 64. (Top) TIC of “Charles” mixture showing RT of MPA, mannitol, ethylphenidate 




The second mixture (sample HN181) contained ethylphenidate, methiopropamine 
(MPA) and 5-methoxy-N,N-diallyltryptamine (5-MeO-N-DALT) (Table 13 and Figures 65 
and 66). The mixture was identified by having three different spin systems in the COSY and 
the HSQC-TOCSY experiments. The latter relates a specific proton spin system to its 
corresponding carbon signals, with the multiplets between 1.39-1.47, 1.58-1.67, 1.80-1.91 
ppm and CH2-N at 3.09 and 3.47 ppm indicating the presence of a piperidine ring as found in 
ethylphenidate. Separately, the sharp singlet at 3.90 ppm integrating for 3H is diagnostic for 
the presence of a methoxy group. Additionally, full assignments of the mixture and 
separation of overlapped peaks followed from COSY NMR. Quantification showed 
ethylphenidate and MPA both were 40% and 5-MeO-N-DALT was 20%. The NMR shifts of 
ethylphenidate (Table 11) and MPA (Table 12) are similar to those in the “Charles” mixture 
(above). Due to the low solubility of tryptamines in D2O, extraction of the mixture with 
CDCl3 resulted in distinctive spectra for 5-MeO-N-DALT, with the alkene signal of H2′′ now 
resonating at 6.16 ppm as a doublet of doublet of triplets (ddt) with 3 J values of 17.0 Hz 
trans-E-coupling, 10.0 Hz cis-Z-coupling and 7.0 Hz coupling to the two methylene protons 
(Figure 67). Furthermore, in CDCl3, H3′′ signals appeared as two doublet of doublets (dd), 
with 2 J values, the first signal has a 17.0 Hz trans-E-coupling and a 2Jgem terminal alkene of 
1.0 Hz, the second signal has a 10.0 Hz cis-Z-coupling and a 2Jgem terminal alkene of 1.0 Hz. 
Using gradient 2, UHPLC/ESI-MS/MS analysis of the mixture resulted in three base-
line resolved peaks in the EIC at 1.5, 6.9, and 7.4 min for MPA, 5-MeO-N-DALT, and 
ethylphenidate respectively, with MPA and ethylphenidate giving the same molecular ions 
and fragmentation patterns to those previously observed in the analysis of the “Charles” 
sample. 5-MeO-N-DALT was detected, found [M+H]+ 271.1808 for C17H23N2O requires 
271.1804, with an MS/MS fragmentation pathway that resulted in a base peak of the iminium 
ion formation at 110 m/z from α-position bond cleavage. Nevertheless, the small (C3) allyl 
fragment could not be observed due to the scan range being between 50-500 m/z. The 174 
m/z fragment is the result of the formation of 5-methoxyindole ethyl ion with the formula 




















Table 13. 1H and 13C NMR (in D2O) assignments of 5-MeO-N-DALT in the 3-
component mixture (sample HN181). 
position 13C 1H 
1 51.5 3.48 2H, overlapped with 6′′ ethylphenidate 
2 19.7 3.23-3.27 2H, overlapped 1′ MPA 
2′ 125.1 7.32 1H s 
3′ 113.0 - 
3a′ 131.4 - 
4′ 100.5 7.16 1H, d (2.5) 
5′ 153.0 - 
6′ 108.2 6.96 1H, dd (8.5, 2.5) 
7′ 111.9 7.48 1H, overlapped with 3x H of ethylphenidate  
7a′ 143.7 - 
O-CH3 56.1 3.90 3H, s 
1′′ 55.0 3.83 4H, d (7.0) 
2′′ 125.5 5.90 2H, ddt (17.0, 10.0, 7.0) 
3′′ 126.5 5.60 2H, d (17.0), 5.62 2H, d (10.0) 
 
 








Figure 67. 1H NMR (in CDCl3) expansion of N-allyl H2′′ of 5-MeO-N-DALT showing the 
ddt splitting pattern. 
 
5-MeO-N-DALT is based on earlier NPS, -methyl- and ethyl-tryptamines, that were 
developed in the 1960s as antidepressants, but abandoned due to their side effects.57 Later, in 
1997, they were popularized by Shulgin along with many other tryptamines.14 The number of 
tryptamine NPS has since increased dramatically, driven by the internet and sold as research 
chemicals before being banned in the 2016 NPS Act. Nevertheless, they constituted 2% of 




Figure 68. Sample HN181 (top) EIC, (middle) MS spectra of the three components in the 
mixture, (bottom) MS/MS spectrum and proposed fragmentation of 5-MeO-N-DALT. 
 
-Methyl-tryptamine was identified in seized samples using 1D/2D NMR and ESI-
MS. Its NMR analysis (Figure 69) (400 MHz in CDCl3) showed:  (C2) 13C δ = 122.5 1H δ = 
7.01, 1H, br s, (C3) 13C δ = 113.6, (C3a) 13C δ = 127.7, (C4) 13C δ = 119.0 1H δ = 7.63, 1H dd 
7.0, 1.0 Hz, (C5) 13C δ = 119.2 1H δ = 7.13, 1H td 7.0, 1.0 Hz, (C6) 13C δ = 121.8 1H δ = 7.20 
1H td 7.0, 1.0 Hz, (C7) 13C δ = 111.1 1H δ = 7.35 1H dt 7.0, 1.0 Hz, (7a) 13C δ = 136.4, (1′) 
13C δ = 36.0 1H δ = 2.68, 1H, ddd 14.0, 8.5, 1.0 Hz, 2.91 1H, ddd 14.0, 5.0, 1.0 Hz, (2′) 13C δ 
= 47.3 1H δ = 3.28-3.36, 1H, m, (3′) 13C δ = 23.7 1H δ = 1.20, 3H, d 8.0 Hz, indole amine 1H δ 
= 8.54, 1H, br s, primary amine 1H δ = 1.32, 2H, s. These NMR data are an improvement 
over published data by showing the 4-bond (1 Hz) coupling of the two methylene protons (1′) 
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possessing benzylic coupling to the indole proton on C2.249 ESI-MS showed [M+H]+ 
175.1242 for C11H15N2 requires 175.1235, and the base peak (-NH3) found 158.1005 for 
C11H12N requires 158.0969. 
 
Figure 69. 1H NMR (in CDCl3) of -methyl-tryptamine assignments, with expansion of 




Ketamine and MXE were found in pure form and in combination with other NPS and cutting 
agents. Indeed, arylcyclohexylamines were the most extensively cut category of the NPS 
analysed. Multiple adulterants have been identified ranging from simple cutting agents such 
as DMS and creatine, to the pharmacologically active dissociative agent (MXP) and a 
stimulant cathinone (4-MBC). Such complex samples are not suitable for analysis using only 
one single method. Here it has been demonstrated that there are limitations to each individual 
analytical method in tackling such complex mixtures. By NMR it was possible to calculate 
the ratios of multiple components and detect compounds with no chromophore and poor 
ionization, e.g. DMS, creatine, although NMR suffers from somewhat low sensitivity. On the 
other hand, the high sensitivity of MS allowed the detection of 4-MBC, present at a level 
below the Lower Limit of Detection (LLOD) of NMR. The poor ionization of the UHPLC 
method was overcome, in some instances, by directly infusing (the loop-injection method) the 
sample into the HR-MS, thus by-passing any column interactions. Unlike the rapid analysis 
and quantification of each component by NMR spectroscopy, UHPLC required method 
development for the separation of multi-component mixtures.  
Quantitative 1H NMR analysis (q-NMR) allowed the quantification of a complex 
ethylphenidate-based NPS mixture using MA as an IS which provided a non-overlapping 
singlet peak at  = 6.38 ppm, suitable for integration. Such a mixture of ethylphenidate, MPA 
and benzocaine was identified. It also contained a high polarity component (mannitol) that 
was impossible to quantify using a C18 column. However, mannitol was quantified by q-
NMR spectroscopy. Two tryptamine NPSs have been identified. One in a mixture (5-MeO-N-
DALT) and one as a pure sample (-methyl-tryptamine), with improved spectroscopic data 
provided for both. 
The association of psychoactive compounds requires monitoring and careful analysis. 
Such complex mixtures have not been described in the refereed literature, thus warranting an 
analytical investigation that may be helpful to drug analysts and health-care professionals 
(HCP) who are in direct contact with such samples and users/abusers. 
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Chapter 4. Chemical characterization of 2nd and 3rd generation seized Synthetic 
Cannabinoid Agonists and their impurities 
 
4.1 Introduction 
Considered one of the first plants to be used for recreational, therapeutic, and ceremonial 
purposes, cannabis use stretches back nearly 5000 years.250 Ancient Chinese civilizations 
have a well-documented record of the use of cannabis. Patients described physiological 
effects ranging from relief of pain to interacting with the spirits (getting high).251 It was 
relatively recently (1930s-1940s) when the components responsible for the effects of 
cannabis, cannabinol (CBN), cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), were 
discovered (in that order). The endogenous cannabinoid receptors CB1 and CB2 were 
discovered and isolated/cloned in the late 1980s and early 1990s.250  
The cannabinoid receptor system is of interest in many pathological conditions.252 
The cannabinoid receptors CB1 and CB2 are named after their amino acid sequences and 
tissue distribution, being the target for treatments particularly for neurological conditions 
such as Parkinson’s disease, Alzheimer’s disease, and Multiple Sclerosis (MS).78,252 THC, 
CBD, and CBN, found in Cannabis sativa L. (marijuana), are the main natural phytoproduct 
cannabinoids. In particular, THC acts on CB1 receptors as a partial agonist, producing 
psychoactive effects (EC50 = 170 nM78 and 250 nM253).  
A number of synthetic cannabinoids, that act on the same receptors as the natural 
product cannabinoids, do so with much higher potency on both receptor subtypes. They have 
been further developed, e.g. the Hebrew University compound HU-210, Pfizer compounds 
CP 47,497 and CP 59,540.252 Additionally, in the early 1990s, John W. Huffman from 
Clemson University synthesized a series of synthetic cannabinoid agonists (SCAs) with a 
core structure of naphthoylindole, most notably JWH-018 (Figure 70) which, along with CP 
47,497, constituted the first wave of illicitly synthesized SCAs that started emerging on the 
streets in 2008, with the help of internet vendors that promoted these compounds as apparent 
research chemicals, herbal incense and so called legal highs, at least before the 2016 
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Psychoactive Substance Act.79,80,254 These SCAs are still known by the street name “spice” 
due to the first brands promoted over the internet and sold on the street (spice and K2). They 
were sold in the form of herbal blends of potpourri, Damiana (Turnera diffusa), 
Marshmallow plant (Althaea officinalis) and other herbal blends soaked or sprayed with the 
SCA.  
 
Figure 70. A natural phytocannabinoid and five SCAs. 
 
Later SCAs, illicitly manufactured, retained the indole core, but with modifications to 
the head, tail and linker moieties (Figure 71) using different functional groups, resulting in 
hundreds of compounds in the second generation of SCAs, that were also based on medicinal 
chemistry compounds, some of which are based on the AM series developed by Prof. Alex 
Makriyannis at the University of Connecticut, CT, USA.255 Continuous banning of SCAs by 
Governments worldwide resulted in them being developed into compounds that possess the 
indazole core structure instead of the indole, and amino acids such as alanine and 
phenylalanine in the head components, replacing the naphthalene and substituted aromatic 




Figure 71. Regions of functional group modifications in the structure of SCAs. 
 
Synthesis of third generation indole and indazole based SCAs has been described by 
Banister et al.78,253 For indazole based SCAs, indazole-3-carboxylic acid was Fisher esterified 
using concentrated sulfuric acid to form indazole 3-carboxylates which were deprotonated 
with potassium tert-butoxide and then N-alkylated with 4-fluorobenzyl bromide or 5-fluoro-
pentyl bromide to create a 1-indazole tail with different substituents. This was followed by 
conversion into the free acid and amino acid coupling to yield the final compound (Figure 
72).253  
 
Figure 72. Synthetic scheme for indazole-based SCA 5F-ADB-PINACA. 
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The use of enantiomerically pure amino acids such as L-valine amide, L-
phenylalanine and L-tert-leucinamide will result in a final product with an S-chirality. 
Nevertheless, recent analytical chiral separation using a CHIRALPAK column revealed that 
out of 10 samples of herbal blends bought from the internet two contained 20% of the R-
enantiomer.256 Reports about the pharmacology of recently identified SCAs are scarce. In 
vivo based studies consistently confirmed that these are full agonists at the CB1 receptor and, 
unlike THC, they possess significant CB2 potencies. Examples are PB-22 and 5F-PB-22 that 
with EC50 of 5.1 and 2.8 nM respectively, are approximately 50-fold to 90-fold more potent 
than THC (EC50 = 250 nM).253 Moreover, various intoxications and fatalities have been 
reported for SCAs with toxicological post-mortem analysis revealing 3rd generation SCAs, 
e.g. 5F-ADB, MDMB-CHMICA, and 5F-PB-22.257-259 Coupling these toxicological findings 
with the fact that SCAs have been dominating the number of seizures of NPS across 
Europe,260 makes SCAs currently the most dangerous class of NPS. 
In this Chapter, four themes of SCAs in herbal blends will be considered. First is the 
analysis of herbal blends containing SCAs with impurities showing qualitative assessment of 
herbal blend package contents. This is necessary and important due to the lack of literature 
data on the impurities associated with SCAs in the herbal form. Additionally, analysis of a 
liquid form SCA for Electronic cigarettes (E-cigarettes) will reveal the type of SCA and its 
NMR profile as well as any impurities present. The second theme is the analysis of herbal 
blends seized from UK prisons. Even though there are many reports of SCAs taking over UK 
prisons in the mainstream media, no analytical findings of such have been published in the 
literature. The third study will be the first application and evaluation of 2D Diffusion Ordered 
Spectroscopy (DOSY) on different seized samples containing mixtures of SCAs in herbal 
blends. Finally, an analytical protocol will be presented for the separation and 
characterization of the contents of K2 herbal blend samples containing a six-component 
complex mixture of closely related SCAs and impurities, using NMR, UHPLC/ESI-MS/MS, 
and flash column chromatography. Such an approach has not been reported before to 




4.2.1 Chemicals and sample preparation 
All extraction solvents (methanol, chloroform, and acetonitrile) 99.9% anhydrous, were 
purchased from Fisher Scientific (UK) or ACROS Organics (UK). Deuterated solvent 
(CDCl3) was purchased from Cambridge Isotopes Laboratories (Goss Scientific, UK). DMS 
NMR internal standard was purchased from Sigma-Aldrich (UK). Herbal-blend samples were 
provided by the Drug Enforcement Action Team (DEAT), the Avon and Somerset 
Constabulary, from recent seizures (2016-2018). The samples were in the form of herbal 
blends (1.0-3.0 g) as commercially packaged brands (K2 black edition, Exodus, Loco Elite, 
Joker, Extinction), and in vials containing liquid (Kronic Juice). Prison samples were 
provided in sealed evidence bags containing herbal blends. They ranged from 10.0 mg in 
small paper twists to 9.0 g herbal blends in a nylon bag. 
Samples were weighed using a SE2F Sartorius analytical balance. Herbal blends 
were extracted with CHCl3 (2 x 20-30 mL) with sonication (30 min), centrifuged, removal of 
the supernatant extract, and the pellet (plant material) was discarded. Then the extract was 
evaporated to dryness under reduced pressure and reconstituted in CDCl3 (0.6-1.0 mL) for 





NMR spectra were recorded on a Bruker AVANCE III 500 MHz spectrometer, 1H, 13C, and 
19F frequencies are 500.130, 125.758, and 470.592 MHz respectively. The probe was a 
variable temperature BBFO+ with three channels, temperature was 25˚C. Alternatively, NMR 
spectra were recorded on a Bruker 400 MHz spectrometer, 1H and 13C frequencies are 
400.130 and 100.613 MHz respectively. Chemical shifts were referenced to 0.0 ppm for TMS 
or the residual (protio) solvent peak for chloroform (7.26) and are reported in ppm. Coupling 
constants (J, line-separations, absolute values) are rounded to the nearest 0.5 Hz. Structural 
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elucidation was achieved with 2D NMR COSY, HSQC, H2BC, HMBC, DOSY, TOCSY-
HSQC, and 15N-HMBC NMR shows the two-and three-bond coupling of the 15N to 1H. 15N-
HSQC shows protons directly attached to the nitrogen and 19F-HOESY is similar to the 
NOESY (proton-proton through-space interaction) experiment, but with the through-space 
interaction between a heteroatom (19F in this case) and 1H. DOSY NMR experiment pulse 
sequence is a bipolar gradient pulse (BPP)-longitudinal eddy current delay (LED) 2 spoil 
gradients (ledbpgp2s1d), 4 scans, acquisition time 3.0 s, delay (D1) 4.0 s with gradient 
strength (gpz6) incremented from 2% to 95%, gradient length (p30) 1500 µs, total run time 
was 19.3 min. NMR spectra were processed using Bruker TopSpin 3.5 and Mestralab Mnova 
11.2.  
 
UHPLC/ESI-MS/MS and flash column chromatography 
The QTOF-UHPLC-MS analysis was conducted using a MaXis HD Quadrupole electrospray 
ionization Time-of-Flight (ESI-QTOF) mass spectrometer (MS) (Bruker Daltonik GmbH, 
Bremen, Germany), operated in ESI positive mode. The QTOF was coupled to an Ultimate 
3000 UHPLC (Thermo Fisher Scientific, California, USA). The capillary voltage was set to 
4500 V, nebulizing gas at 4 bar, drying gas at 12 L/min at 220°C. The TOF scan range was 
from 75-1000 mass-to-charge ratio (m/z). For LC/MS/MS capabilities, the in-source CID was 
set to 0.0 eV, with the collision energy for TOF MS acquisition at 3.0 eV. The collision 
energy was set to a sliding scale from 100 m/z at 14.0 eV, 500 m/z at 20.0 eV and 1000 m/z 
at 30.0 eV. For the analytes, the actual collision energy was between 15.0–18.0 eV. Liquid 
chromatography separation was performed using an Acquity UPLC BEH C18, 1.7 µM, 2.1 x 
50 mm RP-column (Waters, Milford, USA) with a flow rate of 0.4 mL/min, and an injection 
volume of 10 µL at 40°C column temperature. Mobile phase A consisted of LC/MS grade 
water 0.1% formic acid v/v, mobile phase B consisted of acetonitrile 0.1% formic acid v/v. 
For Gradient 1 starting with 1% B for 2 min followed by a linear increase from 2.0 min to 
100% B at 5.0 min, held for 3 min, followed by return to 1% B at 8.1 min, where it was held 
for equilibration for 3.9 min, total run time of 12.0 min. For gradient 2, starting with 1% B 
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for 2 min followed by a linear increase from 2.0 min to 100% B at 10.0 min, held for 3 min 
followed by return to 1% B at 13.1 min, where it was held for equilibration for 2.9 min, total 
run time of 16.0 min. Data analysis used Bruker data analysis 4.3.  
Flash column chromatography was performed on a Teledyn Combiflash with 
RediSep normal phase columns 12.0 g (Lincoln, NE, USA) using hexane (A)/ethyl acetate 
(B) as the mobile phase. Samples were loaded using the liquid loading method, by dissolving 
the extract in CHCl3 (2.0 mL), using two gradients. Gradient 1 (flow rate 18 mL/min) started 
with 0% B for 2.3 min, followed by an increase to 18% B at 8 min, held for 0.5 min, followed 
by an increase to 37% B at 14 min, then by a linear increase to 100% B at 34 min, total run 
time of 40 min. Gradient 2 (flow rate 22 mL/min) started with 0 % B for 2 min followed by a 
linear increase to 25% B at 8 min, held for 1 min and increased to 33% B at 11 min and held 
for 1 min, followed by an increase to 38% B at 14 min and held for 2 min, followed by an 
increase to 59% B at 18 min held for 2 min followed by a linear increase to 100% B at 35 

















4.3 Results and discussion 
4.3.1 Qualitative analysis of 2016/2017 seized herbal blends 
All of the SCA seizures analysed were in herbal blend forms. Samples were received in 
marked evidence bags from DEAT in the summers of 2016 and 2017. These samples 
consisted of 61 samples of herbal blends in 7 brands such as Exodus, Extinction, Joker, K2, 
Kronic, Insane Joker and Loco elite (Figure 73). 
Mislabelling was identified in all of the brands analysed, e.g. the brands “K2”, 
“Insane Joker”, and “Exodus”. Some brands labelled one compound correctly in addition to 
incorrect ones, e.g. “Extinction” was labelled to contain both N-(adamantan-1-yl)-1-(5-
fluoropentyl)-1H-indazole-3-carboxamide (5F-AKB48) and quinolin-8-yl 1-(5-fluoropentyl)-
1H-indole-3-carboxylate (5F-PB-22), but found to contain only 5F-PB-22 in 2017 seizure 
samples and none of the compounds on the label in the 2016 seizure samples. Some brands 
such as “Kronic juice” and “LOCO elite” had no chemical compound labelling. This is 
particularly problematic for the user, where s/he cannot be certain of the SCA they are 
consuming. As each SCA has its own pharmacological profile, that could lead to serious side 
effects. This can have toxic, even fatal consequences. Furthermore, mislabelling has been 
reported by Frinculescu et al.261 following from using GC and LC/MS analysis. However, 
there has been no report on the impurities associated with SCAs. 
The carrier plant material was either Damiana (Turnera diffusa) or Marshmallow 
plant (Althaea officinalis), which were compared morphologically to purchased authentic 
herbal reference materials. The most common SCA identified (Table 14) was 5F-ADB, which 
will be discussed in detail in the following sections of this chapter. 5F-ADB was also found 
associated with other SCAs such as 5F-PB-22, MMB-2201, MDMB-CHMICA, 5F-AKB48, 
and PX-1 amide and its corresponding acid (Figure 73). In this section, chemical profiling of 
herbal blends containing SCAs seized in the South West of England was carried out using 
NMR spectroscopy and LC/ESI-MS/MS techniques. Identification of the main SCA and any 
impurities present used chromatographic and spectroscopic techniques for the separation and 































































Table 14. Results of the qualitative analysis of 2016/2017 seized herbal blend samples 
(Damiana) using NMR and ESI-MS. 
 
 
Entry Sample name/year of 
seizure 
SCAs detected 
1 HN Exod 1/2016 5F-ADB 
2 HN Exod 2/2016 5F-ADB 
3 HN Exod 3/2016 5F-ADB 
4 HN Exod 4/2016 5F-ADB 
5 HN Exod 5/2016 5F-ADB 
6 HN Exod 6/2016 5F-ADB 
7 HN Exod 7/2016 5F-ADB 
8 HN Exod 8/2016 5F-ADB 
9 HN Exod 9/2016 5F-ADB 
10 HN Exod 10/2016 5F-ADB 
11 HN Exod 11/2016 5F-ADB 
12 HN Exod 12/2016 5F-ADB 
13 HN Exod 13/2016 5F-ADB 
14 HN Exod 14/2016 5F-ADB 
15 HN Exod 15/2016 5F-ADB 
16 HN Exod 16/2016 5F-ADB 
17 HN Ext 1/2016 AB-CHMINACA 
18 HN Ext 2/2016 AB-CHMINACA 
18 HN Ext 3/2016 AB-CHMINACA 
19 HN Ext 4/2016 AB-CHMINACA 
20 HN Loc 1/2016 AM-694 
21 HN Loc 2/2016 AM-694 
22 HN Loc 3/2016 AM-694 
23 HN Loc 4/2016 AM-694 
24 HN K2/ 1/2016 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid  
25 HN K2/ 2/2016 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid 
26 HN K2/ 3/2016 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid 
27 HN K2/ 4/2016 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid   
28 HN K2/ 5/2016 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid 
29 HN K2/ 6/2016 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid 
30 HN K2/ 7/2016 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid 
31 HN K2/ 8/2016 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid 
32 HN Jok 1/2016 5F-ADB, MMB-2201 
33 HN Jok 2/2016 5F-ADB, MMB-2201 
34 HN Jok 3/2016 5F-ADB, MMB-2201 
35 HN Jok 4/2016 5F-ADB, MMB-2201 
36 HN Jok 5/2016 5F-ADB, MMB-2201 
37 HN Jok 6/2016 5F-ADB, MMB-2201 
38 HN Exod 1/2017 5F-ADB 
39 HN Exod 2/2017 5F-ADB 
40 HN Exod 3/2017 5F-ADB 
41 HN Exod 4/2017 5F-ADB 
42 HN Exod 5/2017 5F-ADB 
43 HN Exod 6/2017 5F-ADB 
44 HN Exod 7/2017 5F-ADB 
45 HN Exod 8/2017 5F-ADB 
46 HN Injok 1/2017 MDMB-CHMICA 
47 HN Injok 2/2017 MDMB-CHMICA 
48 HN Jok 1/2017 5F-ADB, MMB-2201 
49 HN Jok 2/2017 5F-ADB, MMB-2201 
50 HN Ext 1/2017 5F-PB-22 
51 HN Ext 2/2017 AB-CHMINACA 
52 HN Ext 3/2017 5F-PB-22 
53 HNK2/ 1/2017 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid 
54 HNK2/ 2/2017 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid 
56 HNK2/ 3/2017 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1 
57 HNK2/ 4/2017 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid 
58 HNK2/ 5/2017 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1, PX1 acid 
59 HNK2/ 6/2017 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1 
60 HNK2/ 7/2017 5F-ADB, 5F-PB-22, MDMB-CHMICA, 5F-AKB-48, PX1 




Table 15. NMR data of AM-694 with key connections shown in the figure. 
Position 13C 1H/19F 
1 190.4 - 
2′ 137.1 7.31 1H, s 
3′ 114.5 - 
3′a 125.7 - 
4′ 121.8 8.34 1H, d (9.0)  
5′ 122.0 7.33-7.34 1H, overlapped m 
6′ 122.7 7.34-7.35 1H, overlapped m 
7′ 109.0 7.37-7.39 1H, overlapped m 
7′a 136.1 - 
1′′ 145.3 - 
2′′ 91.6 - 
3′′ 138.5 7.92 1H, dd (7.5, 1.5)  
4′′ 129.5 7.16 1H, td (7.5, 1.5) 
5′′ 126.8 7.44 1H, td (7.5, 1.5) 
6′′ 127.0 7.39-7.40 1H, m overlapped 
1′′′ 46.1 4.13 2H, t (7.0) 
2′′′ 28.4 1.90 2H, quintet (7.0)  
3′′′ 21.7, d (3JCF 5.0) 1.42-1.48 2H, m 
4′′′ 28.8, d (2JCF 19.0) 1.69 2H, doublet of quintets (3JHF 26.0, 3JHH 6.0) 
5′′′ 82.6, d (1JCF 164.5) 4.41 2H dt (2JHF 47.5, 3JHH 6.0) 
5-F - -218.6 tt (2JHF 47.5, 3JHF 26.0) 
 
Analysis of 4 “Loco elite” herbal blend samples by NMR and LC/ESI-MS/MS 
revealed the presence of AM-694, 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl) 
methanone, a 2nd generation SCA which was developed by Makriyannis and Deng255 along 
with analogues, the AM series. AM-694 affinity (Ki) for CB1 receptors (Ki = 0.08 nM) is 500-
times that of THC (Ki = 40 nM),255 thus greatly increasing the chance for intoxication. 
Nakajima et al.262 published the first analytical characterization of synthetic AM-694 along 
with 4 other benzoyl indoles bought through the internet in Tokyo. However, their AM-694 






Figure 74. 1H NMR spectra in CDCl3 of a sample of HN Loc, containing AM-694 and 
propylene glycol, with expansions of all areas in the spectra and 19F proton coupled spectra 




Extraction of ~300 mg of herbal blend (HN Loc sample) containing AM-694 with 
CDCl3 followed by 1D/2D NMR spectroscopic analysis resulted in 20 carbon signals 
including 6 quaternary carbons, including the carbonyl at δ 190.4 ppm. 3 different spin 
systems were identified:  2 separate aromatic systems, with 9 aromatic proton signals with 
separate HSQC-TOCSY correlations consistent with the presence of 2 separate aromatic 
rings, one of which is a singlet at δ 7.31 (2′) with 15N-HMBC connection to the indole 
nitrogen. The third spin system was identified by HSQC-TOCSY as 5-fluoropentyl, with 5 
signals integrating for 10 protons (Figures 75 and 76). 15N-HMBC 2-bond connection is to 1′′′ 
downfield at δ 4.13 and the 3-bond connection is to 2′′′ at δ 1.90. The electronegative effect 
of the fluorine substituent is observed on the methylene signal at 5′′′ δ 4.41 ppm assigned as a 
doublet of triplets 2JHF 47.5 and 3JHH 6.0 Hz rather than as in Nakajima et al.262 of two triplets, 
substantiated by 19F-HOESY connection of the fluorine to the mid-point of the two triplets. 
19F-HMBC showed connection to the methylene signals 5′′′ and 4′′′. Other key correlations 
include COSY connections of H5′ to H4′, and H6′ to H7′, with NOESY contact between H1′′′ 
and H7′ of the indole. Distinctive fluorine coupling was observed at δ -218.6 (tt 2JHF 47.5, 
3JHF 27.5 Hz). Furthermore, propylene glycol (PG) was identified at 50-60% in 4 samples of 
HN Loc brand, with the methyl doublet at 1.55 ppm, 2 doublets of doublets at 3.39 and 3.62 
ppm (11.0 Hz geminal and 8.0 Hz vicinal couplings), and a methine multiplet 3.87-3.93 ppm. 
The NMR spectroscopic findings were confirmed with authentic propylene glycol which is 
believed to have been added to the herbal blends to help in the volatilization of the SCA.263 
In control experiments, both Damiana and marshmallow blank herbal materials were 
extracted under identical conditions to the above HNLoc sample. The resulting 1H NMR 
spectra showed equivalent signals at 0.88 and 1.25 ppm assigned to the long chain plant oils, 





Figure 75. Expansion of HSQC-TOCSY 2D spectra of sample HN Loc showing 1H-13C spin 
systems of three different components, (green) AM-694 5-fluoropentyl tail, (red) plant oils, 
(black) propylene glycol. 
 
Figure 76. Aromatic expansion of HSQC-TOCSY 2D spectra of sample HN Loc showing 
1H-13C spin systems of (blue) indole and (brown) iodophenyl. 
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LC/ESI-MS/MS analysis of the content of the Loco elite herbal blend showed only 
AM-694 RT 7.0 min found molecular ion 436.0576 for C20H20NOFI requires 436.0568. 
Additionally, MS/MS analysis revealed a strong molecular ion peak with loss of iodine at 309 
m/z and the loss of the indole 5-fluoropentyl moiety and the formation of the iodobenzoyl ion 
at 230 (Figure 77). The MS/MS spectrum shows significantly fewer fragments than the EI-
GC/MS trace of Nakajima et al.262 with a stronger molecular ion peak (100% abundancy). 
However, LC/MS analysis failed to detect propylene glycol due to the absence of a 
chromophore and its poor ionization. In order to confirm the NMR analysis and to adhere to 
the guidelines of the SWGDRUG requiring two methods for the confirmation of detection, 
propylene glycol was derivatized using p-toluenesulfonyl isocyanate (PTSI).  
 
Figure 77. (A) EIC of AM-694 in sample HN Loc RT 7.0 min,  
(B) CID MS/MS spectrum of AM-694. 
 
PTSI was used successfully for the derivatization of propylene glycol and diethylene 
glycol (DEG) in pharmaceutical products followed by HPLC detection at 227 nm.264 This 
literature method for derivatization was used with minor alterations. The main reason for 
choosing PTSI is the high capacity of the isocyanate moiety to undergo nucleophilic attack by 
148 
 
the primary and secondary alcohols of propylene glycol. Also, the reaction is relatively fast 
for derivatization, 10 min at only 20 ˚C (Figure 78).  
 
 
Figure 78. Derivatization products of propylene glycol showing adducts formed as detected 
by LC/ESI-MS. 
 
LC/ESI-MS analysis after derivatization resulted in the detection of multiple 
molecular ions for the propylene glycol derivatives, plus the AM-694 molecular ion. At an 
RT of 5.8 min, two propylene glycol derivatization products overlapped. The first molecular 
ion resulting from the derivatization of the primary or secondary alcohol (derivatives 1 and 
2), both having [M+H]+ 274 m/z, the found [M+H]+ 274.0733 for C11H16NO5S requiring 
274.0743, and derivative 3, which is the result of nucleophilic addition of an alcohol to the 
isocyanate moiety, followed by cyclization which occurs with loss of water, found [M+H]+ 
149 
 
256.0622 for C11H16NO5S requiring 256.0638. Moreover, [M+H]+ RT 6.5 min resulting from 
the derivatization of both the primary and secondary alcohols of propylene glycol found 
471.0876 (derivative 4) for C19H23N2O8S2 requiring 471.0890. In addition, a protonated dimer 
at 941.1652 for C38H45N8O16S4 requires 941.1707 (within 6 ppm of mass accuracy). 
Furthermore, AM-694 was detected at RT 7.0 min with the found molecular ion 436.0580 for 
C20H20NOFI requiring 436.0568, and its protonated dimer at 871.1048 for C40H39N2O2F2I2 
requiring 871.1063 (Figure 79).  
 
Figure 79. MS spectra of (A) derivatives 1 and 3, (B) derivative 4, (C) AM-694. 
 
The results of the sample derivatization were compared to the derivatization of 
authentic propylene glycol resulting in the formation of the same PTSI adducts. More in 
depth MS/MS analysis of the derivatives formed is beyond the scope of this research, as the 
aim was to detect propylene glycol by LC/ESI-MS analysis. Derivatization of sample HN 
Loc allowed the detection of four propylene glycol derivatives, thus confirming the presence 
of propylene glycol mixed with AM-694. These LC/ESI-MS results confirmed the NMR 
findings. In addition, the single crystal X-ray structure of AM-694 was obtained (Figure 80) 




Figure 80. X-ray structure of AM-694. 
 
NMR and LC/ESI-MS/MS analysis of the contents of a herbal blend package labelled 
“Extinction”, seized in 2016, showed AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-
yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide), even though the “Extinction” packet 
is labelled 5F-AKB-48 and 5F-PB-22. AB-CHMINACA and other indazoles were developed 
by Pfizer for medicinal applications.265 Langer et al.266 published the NMR of AB-
CHMINACA in CD3OD, but there are no 15N data for the compound and no mention of the 
impurities present in the sample which is one of the aims of this research, thus warranting full 
NMR assignments in CDCl3. Analysis of the crude extract revealed the excipients present 
such as propylene glycol (PG) and isopropyl alcohol (IPA). Also, the presence of plant oil 
signals between 0.8-1.3 ppm obscure the isopropyl, 3′′′, and 5′′′ peaks of AB-CHMINACA. 
Further purification is therefore required for definitive characterization by NMR. 
“Extinction” plant material (1.3 g) was extracted with CHCl3 (2 x 25 ml) with 
sonication for 30 min each time. The extract was passed through a 0.25 µm syringe filter. The 
filtrate was evaporated to dryness under reduced pressure yielding ~190 mg of a pale yellow 
residue. This was dissolved in DCM (1 mL) and loaded onto a silica column (8 g) with n-
hexane: ethyl acetate mobile phase using gradient 1. The 1H and 13C NMR analysis revealed 
28 protons and 20 carbon signals respectively (Table 16 and Figure 81), with 3 spin systems 
of indazole, N-cyclohexylmethyl, and isopropyl separated by HSQC-TOCSY NMR. Key 2D 
NOESY correlations are shown on the structure in Table 16. Spectroscopic identification of 
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PG and IPA was confirmed by comparison with the data obtained from authentic samples. 
Differentiation between the methyls of propylene glycol and isopropyl alcohol was achieved 
using COSY NMR. Moreover, different “Extinction” packages showed qualitative 
differences in the SCA present. 2 samples of “Extinction” seized in 2017 contained 5F-PB-22 
rather than AB-CHMINACA; 5F-PB-22 will be described below in section 4.3.4.  
 
Table 16. NMR data of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-
indazole-3-carboxamide (AB-CHMINACA) in CDCl3. 
 
15N-HMBC 2D analysis of AB-CHMINACA revealed all the connectivities between 
protons 2- and 3-bonds away from the nitrogen, and 15N-HSQC those directly attached to 
Position 13C/15N 1H HMBC 
1 163.0 - 2, 2′′ 
2 (NH) 80.38 7.58 1H, d (9.0) - 
1′′ 174.1 - NH2, 2, 2′′, 3′′ 
2′′ 57.8 4.67 1H, dd (9.0, 7.0) NH2, 3′′, 4′′ 
3′′ 31.0 2.391 1H, octet (7.0) 2, 2′′, 4′′ 
4′′ 18.4, 19.5 1.06 3H, d (7.0), 1.08 3H, d (7.0) 2′′, 3′′ 
(NH2) 75.4 6.18 1H, s, 6.99 1H, s - 
1′(N) 159.9 - - 
2′(N) 289.9 - - 
3′ 136.4 - 4′ 
3′a 122.7 - 4′, 5′, 7′ 
4′ 122.4 8.26 1H, d (8.0) 5′, 6′ 
5′ 122.6 7.22 1H, td (8.0, 1.5) 4′, 6′, 7′ 
6′ 126.6 7.34-7.37 1H, overlapped 7′ 5′, 7′, 4′ 
7′ 109.6 7.37-7.40 1H, overlapped 6′ 5′, 6′ 
7′a 141.4 - 4′, 7′, 1′′′ 
1′′′ 55.7 4.17 1H, d (7.0) 2′′′ 
2′′′ 38.7 1.95-2.03 1H, m 1′′′, 3′′′, 3′′′a 
3′′′ 30.9 0.94-1.04 2H, m cyclohexyl ring 
3′′′a 30.8 1.53-1.60 2H, m cyclohexyl ring 
4′′′ 25.5 1.11-1.22 2H, m overlapped cyclohexyl ring 
4′′′a 25.6 1.57-1.70 2H, m overlapped cyclohexyl ring 
5′′′ 26.2 1.11-1.22 1H, m overlapped  




nitrogen (Figure 82). CDCl3 was chosen due to the solubility of the compound in it and to 
preserve the exchangeable protons. 15N spectra were referenced to nitromethane (380 ppm). 
15N-HMBC showed 2- and 3-bond connectivities of protons 3′′ and 2′′ respectively to N2 of 
the secondary amide, methylene protons (1′′′) have 2- and 3-bond connectivities with N1′ and 
N2′ respectively of the indazole ring. 
 
Figure 81. 1H NMR (in CDCl3) of (A) a crude extract of “Extinction” herbal blend 
containing AB-CHMINACA with expansion of areas containing impurities PG and IPA, 






Figure 82. (A) 15N HBMC of AB-CHMINACA showing 2- and 3-bond connectivities of 
protons to the nitrogens, (B) 15N HSQC showing protons directly attached to the nitrogens. 
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Additionally, a weak 4-bond connection can be seen for the proton of the secondary 
amide at 7.58 ppm with the N2′ of the indazole ring. 15N-HSQC showed direct connection of 
the two protons of the primary amide at 6.18 and 6.99 ppm with their nitrogen atom and of 
the secondary amide with its nitrogen atom (N2) (Figure 82).  
LC/ESI-MS/MS analysis results are in accordance with the extensive MS/MS 
analysis reported by Langer et al.266 In the current work, an RT of 6.9 min gave [M+H]+ of 
357.2297 for C20H29N4O2 requires 357.2285. MS/MS fragmentation is described in Figure 83, 
where the most abundant fragment (312 m/z) resulted from the loss of 17 (-NH3) and then 28 
(-CO) Da from the protonated molecular ion, and the interaction of the lone pair of N2′ with 
that cation to form the tricycle. A further loss of 71 Da (-C4H9N) gave the 241 m/z ion. 
 
 
Figure 83. (Top) TIC of herbal blend sample containing AB-CHMINACA RT = 6.9 min, 






Shortly after the emergence of indole and indazole carboxamide SCAs, the 2015 
EMCDDA report267 stated that cumyl analogues (2-phenylpropan-2-yl), which just like AM-
694 are based on a patent by Bowden and Williamson,268 started to be detected as seizures 
were reported from different European countries.267 NMR characterization of 5F-cumyl-
PINACA in a E-cigarette liquid labelled “Kronic Juice” (Figure 84) has been analysed. 
 
Figure 84. E-cigarette vial containing SCA 5F-cumyl-PINACA. 
 
Direct extraction of the contents of the liquid showed the presence of propylene 
glycol and ethyl acetate among other unknown peaks that are possibly from compounds 
added as flavouring agents. Moreover, as propylene glycol is a humectant, a substantial 
amount of water is seen in the NMR spectra of the crude extract, adding to the high ratio of 
the excipients to SCA. Purification using flash column chromatography was required for a 
full characterization of 5F-cumyl-PINACA (Table 17 and Figure 85). 
Analysis of the crude extract showed the presence of propylene glycol as the main 
constituent in E-cigarettes along with other solvents, e.g. ethyl acetate, which are listed 
among many other components in E-cigarettes, e.g. nicotine, formaldehyde, limonene.269 In 
general, the NMR of 5F-cumyl-PINACA is similar to SCAs that possess a 5-fluoropentyl tail 
and an indazole or indole core structure. The most distinctive feature is the presence of the 
6H singlet at 1.87 ppm for the 2 x Me (H4) in the cumyl moiety together with the 5H for the 





Table 17. NMR (in CDCl3) data of 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-













Position 13C/15N 1H/19F 
1 161.8 - 
2 (NH) 97.9 7.36-7.40 1H, overlapped with 6′ and 7′ 
3 55.8 - 
4 29.6 1.87 6H, s 
1′′ 147.2  
2′′ 124.8 7.52 2H, dd (7.5, 2.0) 
3′′ 128.4 7.35 2H, td (7.5, 2.0)  
4′′ 126.6 7.19-7.24 1H, m overlapped with 5′ 
3′ 137.9 - 
3′a 122.8 - 
4′ 123.2 8.33 1H, dd (8.0, 2.0) 
5′ 122.4 7.19-7.24 1H, overlapped with 4′′ 
6′ 126.7 7.36-7.40 1H, overlapped 7′ and NH 
7′ 109.0 7.36-7.40 1H, overlapped with 6′ and NH 
7′a 140.9 - 
1′′′ 49.1 4.10 2H, t (7.0) 
2′′′ 29.4 2.01 2H, quintet (7.0)  
3′′′ 22.7, d (3JCF 5.0) 1.45-1.52 2H, m 
4′′′ 25.5, d (2JCF 19.0)  1.75 2H, doublet of quintets (3JHF 27.0, 3JHH 7.5)  
5′′′ 83.7, d (1JCF 165.0)  4.51 2H, dt (2JHF 47.5, 3JHH 6.0)  




Figure 85. 1H NMR spectra in CDCl3 of (A) crude extract from E-cigarette liquid showing 
excipients and impurities present in high ratio compared to the 5F-cumyl-PINACA,  
(B) purified extract showing assignments of 5F-cumyl-PINACA with expansions. 
 
19F-HMBC revealed 2- and 3-bonds coupling of the fluorine to the protons of 5′′′ and 
4′′′ respectively on the 5-fluoropentyl chain, further confirming the presence of such a 5-
fluoropentyl tail (Figure 86). Moreover, infusing 100 µL E-cigarette liquid in 900 µL of 
MeOH into the ESI-MS resulted in the detection of the protonated [M+H]+ 368.2161 for 
C22H27N3OF requiring 368.2132 (within 8 ppm) and sodiated [M+Na]+ 390.1970 for 




Figure 86. 19F-HMBC of 5F-cumyl-PINACA showing 2- and 3-bond long range coupling of 
5′′′ and 4′′′ to fluorine (where half of the 5′′′ signal is overlapped by the 1′′′ signal). 
Conclusions 
In this study, the analytical characterization of 61 herbal blend samples seized in 2016/2017 
has been reported which can give drug analysts and law enforcement agents an idea of the 
SCA market after the 2016 Psychoactive Substances Act. Moreover, analysis of the 
excipients and impurities such as propylene glycol and isopropyl alcohol in SCA herbal 
blends may help in flagging large shipments of such excipients as possibly being intended for 
illicit purposes. Although it is true that they are both common organic solvents or coolants. 
NMR characterization of AM-694 is shown with high confidence removing any existing 
spectroscopic ambiguity. Full NMR characterization of AB-CHMINACA providing 15N 
spectroscopic data which have not been published before, and also the identification of the 
impurities present in the samples are reported for the first time. Derivatization of PG present 
in SCA/plant matrices using PTSI allowed the compound previously undetectable on 
LC/ESI-MS to be detected with the formation of four adducts, confirming the NMR findings. 
Finally, analysis of an E-cigarette liquid allowed the identification of a recently introduced 




4.3.2 Analysis of prison samples  
In Chapter 1.6 a detailed review is given of how the drug culture in prisons is changing and 
that SCAs are taking over, with wide spread violence and intoxications.131-133 The Mandatory 
Drug Test (MDT) is failing to detect SCA.131 In this study, an analysis of 30 UK prison 
(HMP) samples in the herbal form is presented using NMR spectroscopy and LC/ESI-
MS/MS. The contents of the samples were examined. Samples were not packaged in 
attractive packages of brands, but found in different forms (Figure 87) from e.g. newspaper 
twists, to nylon bags, with weights (car tyre bolts or copper coins) in them for “throw overs” 
(with respect to prison walls). Whilst this Thesis was nearing completion, March 25th 2019, 
the BBC and other media reported the use of three eviscerated rats for spice and other drug 
delivery in HMP Guys Marsh, in Shaftesbury, Dorset. A Prison Officer commented that dead 
pigeons had been used previously, but using rats was new.270 
 
Figure 87. Examples of the seized samples from HMP. 
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As with the analysis of herbal blends in packaged brands, 5F-ADB was the most 
commonly seized SCA (11 samples identified), followed by cannabis (10 samples identified), 
AMB-FUBINACA (4 samples identified), 2 samples of SCA mixtures identified and 3 
samples that had the appearance of tobacco (Figure 88).  
 
Figure 88. Analysis of HMP seized (2018) drugs. 
 
Even though the sample size is not large enough (n = 30) to give a conclusive answer 
about the most common drug in HMP, these analytical findings put SCAs at the top of the 
most common drugs in this particular prison in 2018, which differs from the previous trend of 
having cannabis as the number one drug of choice among prisoners.129 Furthermore, these 
findings of SCA compared to cannabis in the ratio of 2:1 in these prison samples are in 
accordance with a recently published Government report134 of the increase in SCA in prisons. 
Nevertheless, no analytical findings have been published on the purity of SCAs in prisons.  
ESI-MS was used as the preliminary analytical tool for its speed, sensitivity, and the 
minimal sample preparation required for profiling the HMP drug samples, and for any 




Confirmation of the identification of cannabis and tobacco depends on the 
identification of the molecular ion of THC found 315.2327 m/z for C21H31O2 requires 
315.2318 and its related phytocannabinoids such as CBN found 311.2008 m/z for C21H27O2 
requires 311.2008, and of nicotine 163.1249 m/z found [M+H]+ for C10H15N2 requiring 
163.1229 (within 12 ppm) in the herbal blends (Figure 89). Furthermore, morphological 
examination of the plant material before ESI-MS analysis gave an idea of the type of herbal 
material. No SCA was found in combination with THC or nicotine.  
 
Figure 89. MS/MS spectra of a cannabis sample (HMP14) showing different 
phytocannabinoids, (A) CBN, (B) THC, and their fragments assigned,  
(C) ESI-MS of tobacco showing nicotine [M+H]+. 
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AMB-FUBINACA, an NPS inspired by the Pfizer patent of similar SCAs, e.g. AB-
FUBINACA, ADB-FUBINACA and AB-CHMINACA,265 with an indazole carboxamide 
motif (Figure 90), has been identified in prison samples. However, AMB-FUBINACA is 
among recent SCA with a substitution of a carboxamide to carbonylvalinate methyl ester, 
where the modifications are made by clandestine chemists presumably in order to evade laws 
passed (perhaps more specifically) against parent compounds. This cycle of the introduction 
of SCA, Government banning, followed by the introduction of a new SCA product has 
resulted in hundreds of SCA analogues in the clandestine drugs market. 
The para-fluorobenzyl SCA analogues are introduced to replace the SCA analogues 
possessing the 5-fluoropentyl chain, of which many have been banned.271 These para-
fluorobenzyl SCAs possess high potencies at the CB1 receptor, similar to the 5-fluoropentyl 
chain SCAs, e.g. AB-FUBINACA EC50 = 1.8 nM and ADB-FUBINACA EC50 = 1.2 nM.78,271 
 
 





Analysis of the crude herbal blend samples containing AMB-FUBINACA revealed 
no excipients such as isopropyl alcohol and propylene glycol. 2 samples (HMP 11 and 15) 
were combined and extracted with chloroform, followed by NMR spectroscopic 
characterization (Table 18), using 2 different solvents CDCl3 (Figure 91) and DMSO-d6, in 
order to compare the findings with the published work of Shevyrin et al.272 Spectroscopic 
data have also been obtained on the effect of fluorine on neighbouring protons and carbons in 
the 4-fluorobenzyl moiety. 
1H NMR, in CDCl3 and in DMSO-d6, showed a clearer definition of 3′′ assigned as a 
doublet of septets and an octet respectively rather than a multiplet.272 These multiplicities 
were due to the coupling to the isopropyl signals (7.0 Hz) and methine 2′′ (5.0 Hz) in CDCl3. 
In DMSO-d6, the octet resulted from the coupling to the isopropyl signals and methine 2′′ 
with the same coupling constant (7.0 Hz). NMR showed the inequivalence of the isopropyl 
methyls, having 2 separate 1H and 13C signals compared to compounds (e.g. 5F-ADB) (Figure 
73) with an even bulkier group such as the tert-butyl which showed equivalent methyl 
signals. This effect was interpreted by Shevyrin et al.272 as a result of the less bulkier group 
(isopropyl) having to adapt to hindered rotation in the conformation, with respect to the 
valine chiral centre. The bulkier tert-butyl group did not show this magnetic inequivalence. 
An additional NMR finding (in CDCl3) is 2′′ assigned as a doublet of doublets, due to 
coupling to the proton of the secondary amide (9.0 Hz) and also to 3′′ (5.0 Hz). Furthermore, 
differentiation between the 1H NMR signals for 5′ and 6′ of the indazole is by their HMBC 






Table 18. NMR data of methyl (2S)-2-(1-[(4-fluorophenyl)methyl]-1H-indazol-3-yl 
formamido)-3-methylbutanoate (AMB-FUBINACA) with key connectivities shown in the 
(above) figure. 
in CDCl3 
Position 13C 1H/19F 
1 162.3 - 
1′′ 171.5 - 
2′′ 55.8 4.81 1H, dd (9.0, 5.0)  
3′′ 30.6 2.32 1H, doublet of septets (5.0, 7.0)  
4′′ 17.1, 18.1 1.04 3H, d (7.0) 
1.10 3H, d (7.0) 
5′′ 51.1 3.78 3H, s 
3′ 138.2 - 
3′a 123.3 - 
4′ 121.8 8.37 1H, dd (8.0, 1.0) 
5′ 122.0 7.26 1H, overlapped with CHCl3 
6′ 127.1 7.36 1H, td (7.0, 1.0)  
7′ 109.0 7.27-7.31 1H, m 
7′a 139.7 - 
1′′′ 51.9 5.59 2H, s 
2′′′ 131.7, d (4JCF 3.0) - 
3′′′ 128.9, d (3JCF 8.0) 7.20 2H, dd (8.5, 5.0) 
4′′′ 115.8, d (2JCF 22.0) 7.00 2H, t (8.5) 
5′′′ 162.4, d (1JCF 247.0) - 
5′′′-F - -113.98 tt (3JHF 8.5, 4JHF 5.0)  
NH  7.50 1H, br d (9.0) 
 
in DMSO 
Position 13C 1H/19F 
1 161.8 - 
1′′ 171.9 - 
2′′ 57.3 4.42 1H, dd (8.0, 7.0)  
3′′ 29.7 2.26 1H, octet (7.0)  
4′′ 18.7, 19.0 0.95 3H, d (7.0) 
0.97 3H, d (7.0)  
5′′ 51.8 3.68 3H, s 
3′ 136.8 - 
3′a 122.3 - 
4′ 121.6 8.14 1H, d (8.0) 
5′ 122.7 7.29 1H, t (8.0)  
6′ 126.9 7.46 1H, t (8.0)  
7′ 110.5 7.79 1H, d (8.0) 
7′a 140.4 - 
1′′′ 51.5 5.78 2H, t (2.0) 
2′′′ 132.9, d (4JCF 3.0) - 
3′′′ 129.4, d (3JCF 8.0) 7.34 2H, ddt (8.5, 5.5, 2.0) 
4′′′ 115.4, d (2JCF 21.5) 7.17 2H, t (8.5) 
5′′′ 162.5, d (1JCF 244.0) - 
5′′′-F  -115.18 tt (3JHF 8.5, 4JHF 5.5) 





Figure 91. 1H NMR spectra in CDCl3 of a crude extract of a herbal blend containing AMB-
FUBINACA, with expansions of proton 3′′ showing the splitting pattern of a doublet of 
septets, and the aromatic region. * Denotes plant oil lipid-chain signals. 
 
The effect of the fluorine substituent on the aromatic ring (4-fluorobenzyl) is clear in 
both 1H and 13C NMR data (Table 18). Aromatic 19F to 13C nuclei couplings (in CDCl3) have 
been observed at position 2′′′ of 4-bond coupling (3.0 Hz) and to 5′′′ of a large 1-bond 
coupling (247.0 Hz). The 3-bond fluorine coupling to 4′′′ protons of 8.5 Hz resulted in a 
triplet at 7.00 ppm due to a similar coupling of 8.5 Hz from 3′′′. The effect of the fluorine on 
13C of 4′′′ resulted in a 2-bond C-F coupling of 22.0 Hz. For 3′′′, the H-F 4-bond coupling 
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constant was 5.0 Hz and the C-F 3-bond coupling constant was 8.0 Hz (Figure 92). Similar 
aromatic fluorine coupling values have been reported for the cathinone flephedrone, which is 
an analogue of mephedrone with a para-fluorine substituent instead of the para-methyl 
group. In flephedrone, 3JHF and 4JHF coupling constants were 8.4 and 5.2 Hz respectively, and 
in 13C the 1JCF, 2JCF, 3JCF, and 4JCF were 255, 22, 10 and 3 Hz respectively.30  
 
 
Figure 92. 13C NMR spectra in CDCl3 showing the fluorine coupling effects on different 13C 
nuclei in the fluorobenzyl moiety of AMB-FUBINACA. 
 
1H coupling effects of the fluorine substituent have also been studied using 1H-19F 
decoupled NMR and pure shift NMR. The 1H-19F decoupled spectrum is a normal proton 
acquisition NMR, but with no fluorine coupling to the protons. For the pure shift NMR 
experiment, a Pure Shift Yielded by Chirp Excitation (PSYCHE) was used.273 Pure shift 
experiments are generally used to simplify 1H NMR spectra, that contain many multiplets, via 




Figure 93. NMR stacked spectra of AMB-FUBINACA in DMSO-d6  
(A) 1H NMR, (B) 19F decoupled 1H spectra, (C) PSYCHE pure shift spectra. 
 
ortho-Coupling constant (J) of protons to fluorine in an aromatic system is typically 
8.0 Hz as described by Williams and Fleming (6-11 Hz),274 which can be seen in the coupling 
pattern of proton 4′′′, an apparent triplet of J = 8.5 Hz as a result of ortho-coupling to 3′′′ and 
also to F with an equal coupling constant. 3′′′ necessarily has this ortho-coupling (8.5 Hz) to 
4′′′ with a 5.5 Hz 4-bond coupling to fluorine as can be seen in Figure 93A. Moreover, in the 
19F-decoupled 1H NMR spectra (Figure 93B), where the fluorine coupling is removed, 
protons signals 3′′′ and 4′′′ both become non first-order signals with side bands resulting from 
the many energy levels in the AABB system.274 The O2P (centre point of fluorine channel) 
must be well defined with the exact chemical shift of the fluorine atom (-113.98 ppm) to 
achieve optimum fluorine decoupling, and thus a simplification in the spectra. Pure shift 
NMR (in DMSO-d6) resulted in removing all the H-H coupling leaving the fluorine coupling 
of 8.5 Hz for 4′′′ and 5.5 Hz for 3′′′ (Figure 93C). 
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Analysis of a prison sample (HMP15) containing a mixture of AMB-FUBINACA 
and 5F-ADB, using LC/ESI-MS/MS, resulted in base-line separation in the chromatogram 
using gradient 2, with molecular ion confirmation and a distinctive fragmentation pattern for 
each SCA in the mixture (Figure 94).  
 
Figure 94. LC/ESI-MS/MS analysis of a mixture of a herbal blend containing AMB-
FUBINACA and 5F-ADB showing (A) EIC with AMB-FUBINACA RT 9.6 min (green) and 
5F-ADB 9.8 min (blue), (B) HRMS showing both molecular ions, proposed MS/MS 
fragmentation pattern assignments for (C) AMB-FUBINACA and (D) 5F-ADB. 
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LC/ESI/MS analysis resulted in AMB-FUBINACA RT 9.6 min found [M+H]+ 
384.1719 for C21H23N3O3F requiring 384.1717, and 5F-ADB RT 9.8 min found [M+H]+ 
378.2187 for C20H29N3O3F requiring 378.2187 (Figure 94 A and B). Collision Induced 
Dissociation (CID) using MS/MS resulted in a similar initial fragmentation pattern starting 
with the loss of methoxy from the [M+H]+ and the subsequent loss of CO resulting in a base 
peak of 324.1508 for AMB-FUBINACA and 318.1969 for 5F-ADB (Figure 94 C and D). 
Both base peaks are the result of the interaction of the cation with indazole N2′ lone pair for 
the cyclization.272 Another characteristic fragment in indazole based SCAs is the 
indazoleacylium ion,266,272 with a 5-fluoropentyl tail at 233.1077 for 5F-ADB, and 253.0770 
for AMB-FUBINACA with its 4-fluorobenzyl moiety. The latter also has the distinctive 
fluorotropylium ion C7H6F+.272 Pharmacological data are not available for 5F-ADB and 
AMB-FUBINACA, but similar analogues are found to have a binding affinity for CB1 Ki = 
0.78 nM for AB-CHMINACA (THC Ki = 40 nM) and EC50 between 0.24-1.8 nM for 5F-
ADB-PINACA and AB-FUBINACA (THC EC50 = 170 nM).78,275  
In this study, analysis of prison herbal blend samples revealed that SCAs are popular 
in this particular prison, with mixtures of potent SCA such as AMB-FUBINACA and 5F-
ADB giving a high chance of intoxication even extending to the possibility of a lethal 
outcome. ESI-MS was used as the primary analytical tool for the fast qualitative analysis of 
prison samples. Full NMR characterization of AMB-FUBINACA has been presented above 
together with a detailed spectroscopic study of the effect of the fluorine of the 4-fluorobenzyl 
moiety on the 13C and 1H nuclei, the latter using a combination of a 19F-decoupled 1H 
experiment and pure shift NMR. LC/ESI-MS/MS characterization of a mixture of AMB-
FUBINACA and 5F-ADB resulted in base-line resolution, molecular ion confirmation, and 
CID fragmentation assignment for both components. This is the first analytical study of the 
drug situation in an HMP that provides scientific data related to the growing trend of SCA 





4.3.3 2D DOSY NMR analysis of SCA mixtures in seized herbal blends  
As seen in the previous two sections of this chapter, SCA in herbal blends exist in complex 
mixtures with multiple components such as other SCA, together with excipients such as 
propylene glycol and isopropyl alcohol, and matrix components from the carrier plant 
material. This results in complex spectra that require detailed analysis. DOSY NMR 
experiments rely on the diffusion rate to separate each component in the mixture, diffusion 
coefficient D = log(m2/s). Each D value depends on several compound specific, solvent, and 
instrumentation parameters such as molecular weight, shape, charge, viscosity and probe 
temperature.276 In a typical DOSY experiment, the 2D experiment is preceded by several 
consecutive Pulse Field Gradient (PFG) Stimulated Spin Echo (STE) 1D experiments, 
followed by dispersion into the 2nd dimension where the horizontal axis shows the 1H spectra 
and the vertical axis reveals the values of the diffusion coefficient. Ideally, this will result in 
all the chemical shift cross peaks of the same compound aligning, and the value of D is thus 
obtained.276  
The first DOSY pulse sequence application was in 1965.277 Ever since, there has been 
an expansion of the original pulse sequence into numerous DOSY experiments. The range of 
applications has widened now including the interactions of API and excipients and the 
analysis of counterfeit tablets.278,279 Another application of 2D DOSY NMR on illicit drug 
samples was by Balayssac et al. in 2014,280 who described the analytical separation of heroin 
and its adulterants/contaminants (caffeine, noscapine, acetylmorphine). 
In this analysis, four seized brands containing SCAs were investigated using 2D 
DOSY NMR. Prior to the 2D DOSY experiments, the samples were profiled using 1D/2D 
NMR and LC/ESI-MS/MS. All the samples, HN Loc3, HN EXT2, HN EXT3, HN JOK5, 
were subjected to the same extraction conditions, where herbal blends (50.0 mg) were 
extracted with CHCl3 (2 x 2.0 mL) with sonication, followed by filtration into a 25.0 mL 
round-bottom flask where the filtrate was evaporated. The residue was redissolved in CDCl3 
(1.0 mL) and transferred into an NMR tube for analysis. 2D DOSY NMR analysis of sample 





Figure 95. (Top) 2D DOSY NMR of HN Loc3 showing the alignment of the three 
components in the mixture, (bottom) extracted slices of 2D DOSY of the three components; 
(A) plant oils, (B) AM-694, (C) propylene glycol showing excellent separation by D. 
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2D DOSY revealed clear high-resolution separation of the 4 components in the 
sample, AM-694, propylene glycol, plant fatty acids, and the residual chloroform peak. Plant 
fatty acids signals at 0.88 and 1.25 ppm are the result of the extraction of the carrier material 
Damiana (Turnera diffusa) with CHCl3. Propylene glycol has been added to the herbal blend 
during illicit manufacture to act as a vehicle in the delivery of SCA, where it is hygroscopic 
and lipophilic and helps in producing thicker smoke.263 The diffusion coefficient is inversely 
proportional to the molecular weight of the compound, solvents with small molecular weights 
resulted in high diffusion coefficients. Propylene glycol resulted in a diffusion coefficient D 
value of -8.82 log(m2/s) with all peaks aligned. Similar alignment was observed for all the 
peaks of the SCA present in the sample AM-694 D -9.06 log(m2/s), and the lowest D value of 
-9.17 log(m2/s) is for the plant oil lipid-chain signals These are presumably C16 and C18 
chain and therefore the heaviest molecules. Furthermore, analysis of 4 additional samples of 
the same brand (HN Loc1, 2, 4 and 5) revealed a similar composition.  
DOSY analysis of sample HN EXT2 and HN EXT3 resulted in a similar outcome in 
terms of separation, but the type of SCA was different in each of the packages. In HN EXT2, 
AB-CHMINACA was present, D value -9.14 log(m2/s), on the other hand in sample HN 
EXT3, 5F-PB-22 was detected, D value of -9.23 log(m2/s). 2D DOSY confirmed the 1D/2D 
NMR (1H, 13C, HSQC, HMBC) qualitative differences between packs of the same brand 
(Extinction), where the 2016 seized samples contained AB-CHMINACA. However, the 2017 
seizures contained 5F-PB-22. Sample HN JOK5 was analysed by 2D DOSY. Preliminary 
1D/2D NMR analysis revealed the presence of 5F-ADB, and its indole isopropyl analogue 
MMB-2201. 2D-DOSY revealed the 2 components along with propylene glycol and plant 
oils (Figure 96 A). The two SCAs are only 15 g/mol apart, making the cross peaks separation 
in the 2 D-DOSY spectra less obvious compared to the previous samples. However, 
expansion of the area between 0.6-4.0 ppm showed different alignments of the signals which 
can be seen in the methyl ester signals of both compounds, with tert-butyl for 5F-ADB, and 
with isopropyl in the case of MMB-2201 which has a slightly higher D value -9.09 log(m2/s) 





Figure 96. (A) 2D DOSY NMR of sample HN Jok5 showing alignment of the 4 components, 
(B) expansion of 2D DOSY showing the alignment of the cross peak of a methyl ester (at 
3.75 ppm) with the tert-butyl of 5F-ADB, and of a different methyl ester (at 3.81 ppm) with 
the isopropyl of MMB-2201. 
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2D-DOSY allowed the separation of the composition of different herbal blends 
containing SCAs, based on their diffusion coefficient. Samples HN Loc3, Ext2 and Ext3 
showed good separation for all the components present, AM-694, AB-CHMINACA, and 5F-
PB-22 respectively and the excipient present (propylene glycol), and extraction by-products 
(plant oils). However, sample HN JOK5 containing similar SCAs, 5F-ADB and MMB-2201, 
cannot be definitively separated due to their close molecular weights 377.5 and 362.5 Da 
respectively, and due to their similar shape. Similar findings were reported by Balayssac et 
al.280 where heroin and noscapine could not be separated by 2D-DOSY. Even so, the herbal 
blend samples were characterized by 1D/2D NMR (1H, 13C, HSQC, HMBC), additional 
corroboration and enhanced resolution were achieved by dispersing the signal into the second 
dimension in the 2D-DOSY experiment (Figures 95 and 96). Taken together, this resulted in 
the improved profiling of impurities in these complex mixtures.  
 
4.3.4 Chemical characterization and separation of the contents of K2 herbal blends 
complex samples 
Ever since the first samples of herbal blend containing SCA hit the streets in the form of 
dubious brands such as “K2” and “spice” in 2008,80 the K2 and spice brand names have 
become the definition of the SCA category used by manufacturers, users, law enforcement 
agencies and drug analysts. The first generation SCA found in the earlier “K2” brand (CP 
47,497 and JWH-018) are no longer found. Rather, they have been replaced with 2nd and 3rd 
generation indoles and indazoles with different tail and head-component modifications. 
Herbal blend samples with more than one SCA present are not unheard of. Reports of the 
JWH (John W. Huffman) and AM (Alexander Makriyannis) series of 3-component mixtures 
were reported in 2012 following analysis by chromatography and MS (Figure 97).281 Logan et 
al.282 analysed the contents of herbal blends seized in the USA using GC and LC/MS and 
found that the “K2” blend contained different analogues of the JWH series in 3-component 




Figure 97. JWH and AM series SCA that were in “K2” samples between 2008-2013. 
 
Nowadays, both the 1st and 2nd generation SCAs have been replaced with 
carboxamide indoles and indazoles, and recently a methyl ester was found to replace the 
primary amide. The current analogues of the 2nd and 3rd generations are in most cases 
fluorinated. The presence of multiple amides in their structures makes them more polar than 
the JWH or the AM series, thus requiring alternative methods for separation and analytical 
characterization. Separation of analogues of the CP and JWH series of SCAs was performed 
by Reverse Phase (RP) flash column chromatography.283 In this study, an analytical platform 
for the detection, separation and characterization of closely related 3rd generation SCAs in 
six-component mixtures is described. These “K2” samples include a possible reaction 
impurity (Figure 98). Analysis used combination of UHPLC/ESI-MS/MS, flash column 
chromatography, and 2D NMR spectroscopy. 
The contents of herbal blend K2 analysed by LC/TOF-ESI-MS revealed six base-line 
resolved peaks on the chromatogram (Figure 99). Five of them are SCA and one, 2 PX1 acid, 
is a possible reaction precursor for the synthesis of the amide 1 (Figure 98). All mass ions 
detected in the TOF are within 2.0 ppm mass accuracy (Table 19). Additionally, the 13C 
isotopomer of 6 (385.2481) is within 2.3 ppm of 5 [M+H]+ of 385.2490 resulting in a repeating 
overlapping peak at 7.5 min in the EIC, due to the software not being able to differentiate 
between them. The presence of hydrophobic components, e.g. cyclohexylmethyl in 5 and 
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adamantyl in 6, caused them to be retained longer on the column compared to the other 



































PX-1 PX-1 acid 5F-PB-22
5F-ADB MDMB-CHMICA 5F-AKB48
1 2 3
4 5 6  
 
Figure 98. (Top) SCAs found in K2 herbal blend, (bottom) K2 herbal blend package 





Figure 99. (Top) EIC of K2 mixture analysis separating the six components 1-6, compound 1 
RT 6.4 min, 2 RT 6.6 min, 3 RT 6.8 min, 4 RT 7.0 min, 5 RT 7.3 min, 6 RT 7.5 min, 
(bottom) ESI-MS spectrum showing molecular ions in the form of [M+H]+, protonated and 





Table 19. LC/ESI-MS data of compounds 1-6 in “K2” herbal blend. 






1 C23H26FN3O2 6.4 396.2080 396.2081 -0.25 
2 C23H25FN2O3 6.6 397.1920 397.1922 -0.50 
3 C23H21FN2O2 6.8 377.1664 377.1659 1.32 
4 C20H28FN3O3 7.0 378.2193 378.2187 1.58 
5 C23H32N2O3 7.3 385.2490 385.2485 1.29 
6 C23H30FN3O 7.5 384.2452 384.2445 1.82 
 
Furthermore, the 50-1000 m/z scan range allowed the detection of: sodiated dimer of 
1 [2M+Na]+ at 813.3902 for C46H52F2N6O4Na requires 813.3910, protonated dimer of 2 
[2M+H]+ at 793.3764 for C46H51F2N4O6 requires 793.3771, protonated dimer [2M+H]+ of 3 at 
753.3264 for C46H43F2N4O4 requires 753.3246, sodiated dimer of 4 [2M+Na]+ at 777.4141 for 
C40H56F2N6O6Na requires 777.4121, protonated dimer of 5 [2M+H]+ at 769.4919 for 
C46H65N4O6 requires 769.4898, and sodiated dimer of 6 [2M+Na]+ at 789.4658 for 
C46H60F2N6O6Na requires 789.4638 (Figure 99).  
LC/MS/MS showed a unique fragmentation pattern for each component in the 
mixture providing valuable structural information. Amide 1 and its corresponding carboxylic 
acid 2 exhibited similar fragmentation patterns. In amide 1, the 379 m/z fragment results from 
the loss of ammonia (-17 Da) from the molecular ion, and in carboxylic acid 2, the 379 m/z 
fragment results from the loss of water (-18 Da). The 144 m/z fragment is the formation of an 
indoleacylium ion (Figure 100 A, B). In compound 3, the loss of the 8-quinolinyl ester from 
5F-PB-22 provided a diagnostic MS signature (fragment at 144 m/z). Additionally, all 
terminally fluorinated pentyl indoles (1, 2, and 3) formed 232 m/z base-peak fragments that 
correspond to the indoleacylium ion with the 5-fluoropentyl side chain resulting from C-N 
cleavage at the secondary amide in 1 and 2, and acyl cleavage at the 8-quinolinyl ester in 3 






Figure 100. MS/MS proposed fragmentation and assignments of (A) amide 1, (B) acid 2, (C) 
ester 3. 
 
A characteristic base-peak fragment for compounds 4 and 6 is 233 m/z 
indazoleacylium ion with 5-fluoropentyl side chain, which helps to differentiate fluorinated 
SCA with 3-carbonyindazole from the indoles (Figure 101 A and C). Moreover, compound 4 
318 m/z fragment is the result of the lone pair of N2′ of the indazole interacting with the 
formed cation, as seen in AMB-FUBINACA (Figure 94) and AB-CHMINACA (Figure 83). 
Compound 5 resulted in the formation of the most prominent ion at 240.1387 resulting from 
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the indoleacylium ion with a cyclohexylmethyl substituent (Figure 101 B). Compound 6 
MS/MS profile showed a distinctive adamantyl loss at 135.1157 m/z (Figure 101 C). MS/MS 
data for compounds 3,272,284 4,272 5,266 6,266 were corroborated by comparison with their 
respective literature. No ESI-MS/MS data are reported in the literature for compounds 1 and 
2, although compound 1 has some GC/MS data in a SWGDRUG monograph.285 
 
Figure 101. MS/MS proposed fragmentation and assignments of (A) indazole-ester 4,  





Figure 102. 1H NMR in CDCl3 stacked spectra of “K2”:   




1D/2D NMR of the crude extract (Figure 102A), resulted in complex 1H NMR 
spectra, especially in the area of the spectra between 0.9-2.0 ppm and 4.0-4.5 due to the 
presence of the 5-fluoropentyl in 4 of the compounds in the mixture. The 19F proton-coupled 
NMR spectrum revealed overlapping signals between -218 and -220 ppm, and inverse gated 
decoupled spectra revealed three signals in the range of the fluoropentyl signal. Nevertheless, 
candidate signals for integration in the 1H NMR were identified for each compound, and used 
to calculate the molar ratio of each component in the herbal blend in one sample. These were 
for compound 1 using methylene protons at position 3′′ 11%, compound 3 using the quinoline 
signal 2′′ 6%, compound 4 using chiral centre signal 2′′ 23%, for compound 5 using the 
indole 4′ signal and chiral centre signal at 2′′ 7%, for compound 6 the indazole 4′ signal 9%. 
Moreover, the major component was propylene glycol 44%, possibly added as a vehicle for 
the vaporization of the SCA. However, compound 2 could not be detected by NMR as it was 
most likely in a concentration lower than the Lower Limit of Detection (LLOD) of the 500 
MHz NMR instrument. Some of the analysed “K2” packages contained no propylene glycol.  
Flash column chromatography was employed for the separation of each of the 
detectable components using hexane/ethyl acetate as the mobile phase. Gradient 1 allowed 
the separation of components, except compounds 4 and 5. Compound 1 was separated in 
small amounts (~5.0 mg). Another sample was subjected to the same extraction procedure 
followed by flash column chromatography using gradient 2 (flow rate 22 mL/min), which 
allowed the separation of compounds 4 and 5, 1H NMR spectra are shown in Figure 102. 
Flash column chromatography has been previously applied to the isolation of SCA from 
herbal materials,283 but no separation of a closely related complex mixture has been reported. 
For PX1 (acid and amide), no assignment data have been found in the literature from detailed 
searches using Web of Science and Scifinder, only a SWGDRUG monograph with no 
spectroscopic assignments.285 PX1 (compound 1) proton 5′′ had NOE contact with 3′′ 
methylene protons and 2′′ methine of the phenylalanine amide moiety. Furthermore, 2′′ had 
NOE contact with the two protons of the primary amide, and 5′′ carbon resulted in a 3-bond 




Table 20 NMR data of compounds 1 and 3 in CDCl3. 
PX-1 1 5F-PB-22 3 
Position 13C 1H/19F 13C 1H/19F 
1 165.1 - 163.1 - 
2′ 131.6 7.67 1H, s 135.7 8.16-8.18 1H, s overlapped 
with 4′′ 
3′ 110.1 - 106.0 - 
3′a 125.4 - 127.4 - 
4′ 120.3 7.78 1H, dd (7.5, 1.0) 122.1 8.24 1H, dd (7.5, 2.0)  
5′ 121.6 7.21 1H, td (7.5, 1.0) 123.0 7.21-7.28 1H, m 
6′ 122.7 7.23-7.30 1H, m overlapped 122.2 7.21-7.28 1H, m 
7′ 110.2 7.35 1H, overlapped 109.9 7.35 1H, d (8.0)  
7′a 136.5 - 136.7 - 
1′′ 173.6 - - - 
2′′ 54.0 4.97 1H, d (7.5) 150.3 8.88 1H, dd (4.5, 1.5)  
3′′ 38.2 3.19 1H, dd (14.0, 7.5) 
3.34 1H, dd (14.0, 6.5) 
121.6 7.38 1H, dd (8.0, 4.5)  
4′′ 136.8 - 136.3 8.16-8.18 1H, m overlapped 
with 2′ 
4′′a - - 129.6 - 
5′′ 129.5 7.31-7.35 1H, m overlapped 125.5 7.70 1H, d (8.0)  
6′′ 128.8 7.31-7.35 1H, m overlapped 126.5 7.54 1H, t (8.0)  
7′′ 127.1 7.23-7.30 1H, m overlapped 122.3 7.59 1H, d (8.0)  
8′′ - - 147.5 - 
8′′a - - 140.2 - 
1′′′ 46.6 4.13 2H, t (7.0) 47.1 4.18 2H, t (7.0)  
2′′′ 29.6 1.90 2H, quintet (7.0) 29.8, d (4JCF 2.7)  1.94 2H, quintet (7.0)  
3′′′ 22.7, d (3JCF (6.5) 1.39-1.47 2H, m 22.8, d (3JCF 5.0)  1.43-1.5 2H, m 
4′′′ 29.8, d (2JCF 24.0) 1.70 2H, d quintets (26.0, 
6.0) 
30.0, d (2JCF 20.0)  1.70 2H, d quintets (27.0, 
6.0)  
5′′′ 83.5, d (1JCF 165.5) 4.41 2H, dt (47.0, 6.0) 83.6, d (1JCF 164.5)  4.39 2H, dt (47.5, 6.0)  
F (5′′′) - -218.54, tt (2JHF 47.0, 3JHF 
26.0)  
- -218.54, tt (2JHF 47.5, 3JHF 
27.0)  
NH - 6.56 1H, d (7.5) - - 






Similar spectroscopic findings to other SCAs with a 5-fluoropentyl moiety are seen 
in compound 1, such as the 5′′′ methylene at 4.41 ppm with a large 2-bond alkyl fluoride 
coupling 2JHF of 44.5 Hz and 3-bond coupling 3JHF to 4′′′ of 26.0 Hz, 1′′′ methylene triplet at 
4.13 ppm, in addition to methylenes of 2′′′, 3′′′ and 4′′′ (Figure 103). For compound 3, 
assignment of the 5-fluoropentyl tail is similar to that in compound 1 and other fluoroalkyl 
analogues. 
 
Figure 103. 1H NMR (in CDCl3) of compound 1 assignments with expansions of (top) 3.2-
5.0 ppm, (bottom) 7.2-7.8 ppm aromatic region. 
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The presence of the 8-quinolinyl aromatic system resulted in a complex aromatic 
region. Proton 2′′ of the quinoline ring at 8.88 ppm was the most downfield signal due to the 
electronegativity of the N heteroatom. There were also smaller ortho- and meta-coupling 
constants 4.5, 1.5 Hz respectively. Moreover, overlapping protons of indole (2′) and 
quinoline (4′′) resulted in a multiplet at 8.16-8.18. A multiplet at 7.21-7.28 is the result of 
indole protons 5′ and 6′ overlapping (Table 20 and Figure 104). Furthermore, HMBC 
connectivity of C2′′ at 150.3 ppm to 3′′ and 4′′, and 2D NOESY contact of 1′′′ to indole 
protons (2′) and (7′) helped in assigning multiplets, thus obtaining an unambiguous 
confirmation of the structure.284 
 
 
Figure 104. 1H NMR of compound 3 aromatic region expansion with assigned protons. 
 
Confirmation of the proposed structures of compounds 4 and 5 was established using 
1D/2D NMR and comparison with the literature (Table 21).266,272,286 Both compounds belong 
to the recent methoxycarbonyl alkyl analogues that replaced the carboxamide. Compounds 4 
and 5 both possess a tert-butyl group giving a 9H proton singlet ~1.0 ppm, and the chiral 




Table 21. NMR data of compounds 4 and 5 in CDCl3. 
5F-ADB 4 MDMB-CHMICA 5 
Position 13C 1H/19F 13C 1H/19F 
1 162.3 - 164.8 - 
1′′ 172.2 - 172.7 - 
2′′ 59.5 4.73 1H, d (9.5) 59.7 4.78 1H, d (9.0) 
3′′ 35.0 - 35.1 - 
4′′ 26.7 1.08 9H, s 26.8 1.10 9H, s 
5′′ 51.8 3.75 3H, s 51.8 3.78 3H, s 
2′ - - 132.7 7.72 1H, s 
3′ 136.8 - 110.3 - 
3′a 122.9 - 125.2 - 
4′ 122.8 8.34 1H, d (8.0) 119.9 7.97-8.00 1H, m 
5′ 122.6 7.24-7.26 1H, m 
overlapped with CHCl3 
122.4 7.26-7.29 1H, overlapped with 6′ 
6′ 126.8 7.39-7.40 1H, m 
overlapped with 7′ 
121.6 7.26-7.29 1H, overlapped with 5′ 
7′ 109.1 7.39-7.40 1H, m 
overlapped with 6′ 
110.7 7.36-7.40 1H, m 
7′a 140.8 - 137.0 - 
1′′′ 49.2 4.40 2H, t (7.0) 53.8 3.94 2H, d (7.0) 
2′′′ 29.3 2.00 2H, quintet (7.0) 38.5 1.85 1H, ttt (11.5, 7.0, 3.5) 
3′′′ 22.7, d (3JCF 5.5) 1.43-1.49 2H, m 30.97, 30.99 0.94-1.03 2H, m, 1.58-1.67 2H, m 
4′′′ 29.9, d (2JCF 19.5) 1.76 2H, d quintet 
(26.5, 6.0) 
25.6 1.12-1.21 2H, m, 1.59-1.71 2H, m 
5′′′ 83.7, d (1JCF 165.0) 4.42 2H, dt (2JHF 47.0, 
3JHH 6.0) 
26.2 1.12-1.21 1H, m, 1.58-1.67 1H, m 
5′′′-F - -218.6 tt (2JHF 47.0, 3JHF 
26.5) 
- - 
NH - 7.54 1H, d (9.5) - 6.56 1H, d (9.0) 
 
Indazole 4 has a 4 proton aromatic system (Figure 105), on the other hand 5 has the 5 
proton aromatic system of the mono-substituted indole. In the 13C spectra, differentiation 
between indazole and indole analogues can easily be achieved by comparison of the 3′ carbon 
chemical shift, where in 4 the electron withdrawing effect of the second nitrogen in the 
indazole ring on 3′ causes it to resonate at 136.8 ppm compared to 110.3 ppm in indole 5, a 





Figure 105. Compound 4 1H expansion of (top) the spectrum between 1.4-2.0 ppm,  
(bottom) aromatic region between 7.2-8.4 ppm with assigned protons. 
 
Indazole 4 is substituted with the N-5-fluoropentyl moiety similar to other SCA 
analogues. In indole 5, the fluoroalkyl moiety has been replaced with a cyclohexylmethyl, 
which resulted in multiple multiplets of methylene protons between 0.95-1.73 ppm, and the 
methine signal for 2′′′ (Figure 106), which Shevyrin et al.272 assigned as a multiplet on a 400 
MHz spectrometer in a similar compound (MDMB-CHMINACA). In this study, 2′′′ of indole 
5 appears as a triplet of triplet of triplets, resulting from 3 different JHH coupling. Coupling of 
2′′′ to 1′′′ methylene resulted in a typical averaged 3J = 7.0 Hz, with 3Jax,ax to 3′′′ of 11.5 Hz 
(large), and also 3Jax,eq to 3′′′ of 3.5 Hz (small) (Figure 106), thus fixing the 1′′′ substituent in 
the equatorial position as 2′′′ methine must be axial. 13C signals of the two methylene 3′′′ 
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appear at slightly different chemical shifts 30.97 and 30.99 ppm, a possible effect of the 
distant chiral centre on the rotation of the cyclohexylmethyl moiety. The data are confirmed 
by comparison to the work of Langer et al.266  
 
Figure 106. Compound 5 1H NMR expansion of (top) 0.9-1.9 ppm showing multiplets 
assignments, (bottom) expansion of exquisitely resolved 2′′′ at 1.85 of ttt. 
 
Compound 6 5F-AKB48 is the indazole 5-fluoropentyl analogue, of indole STS-135. 
They can be easily differentiated using TOF-ESI-MS and NMR. The NMR assignments of 
the indazole ring are similar to those of compound 4, and the 5-fluoropentyl tail has similar 
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assignments to that moiety found in compounds 1, 3, and 4. The presence of the N-adamantyl 
substituent in the head component resulted in 3 multiplets in the aliphatic region with 15 
protons (Table 22), with 6H of 4′′ overlapping with 4′′′ of the 5-fluoropentyl tail. 19F NMR 
revealed the fluorine chemical shift at -218.5 ppm with the triplet of triplets coupling 
constants of 46.5 Hz (2JHF) and 25.5 Hz (3JHF), similar to that observed in SCAs substituted 
with a 5-fluoropentyl chain. The assignments are confirmed by comparison with the literature 
for compound 6.287 
 
 
Table 22. NMR data of compound 6 in CDCl3. 
Position 13C 1H/19F 
1 162.0 - 
1′′ 51.8 - 
2′′ 41.9 2.12-2.15 6H, m 
3′′ 29.6 2.07 3H, br s 
4′′ 36.5 1.61-1.72 6H overlapped with 4′′′ 
3′ 138.2 - 
3′a 140.3 - 
4′ 123.2 8.31 1H, d (8.0) 
5′ 122.4 7.15-7.26 1H, overlapped with CHCl3 
6′ 126.6 7.30-7.32 1H, overlapped with 7′ 
7′ 109.0 7.30-7.32 1H, overlapped with 6′ 
7′a 140.8 - 
1′′′ 49.0 4.29-4.33 2H, overlapped with 5′′′ 
2′′′ 29.4 1.92 2H, quintet (7.0) 
3′′′ 22.7, d (3JCF 5.0) 1.36-1.42 2H, m 
4′′′ 29.9, d (2JCF 19.5) 1.61-1.72 2H, overlapped with 4′′ 
5′′′ 83.7, d (1JCF 165.0) 4.29-4.33 2H, overlapped with 1′′′ 
5′′′-F - -218.56 tt (2JHF 46.5, 3JHF 25.5) 





Many of the six separated components have been implicated in deaths or 
intoxications in toxicological reports.257,258 Compound 3 was found in post-mortem 
toxicological samples in 4 deaths in the USA in 2013, compound 4 was implicated in 10 
deaths in Japan in 2014.259,288 Compound 5 and its metabolites were found in a post-mortem 
case in Germany in 2018.289  
In this study, an analytical platform composed of LC/TOF-ESI-MS/MS, flash column 
chromatography and 1D/2D NMR spectroscopy is presented for the separation and 
characterization of complex mixtures of 5 closely related SCAs. The changing contents of 
“K2” are now a recent 3rd generation SCA with higher potency than the previous JWH and 
AM series compounds that used to be associated with “K2” and “spice” herbal blends. The 
NMR assignments and LC-ESI-MS/MS for PX-1 (compound 1) are presented for the first 
time. Identification of PX-1 acid (compound 2) impurity, a possible starting material or by-
product of the amide 1 synthesis is also described. Additional NMR spectroscopic data for 
compounds 3-5 have been obtained, and a flash column chromatography method has been 
developed for the separation of these 5 closely related 3rd generation SCAs. 
 
4.4 Conclusions 
A combination of NMR spectroscopy and LC/TOF-ESI-MS/MS is a powerful 
approach for the profiling of unknown herbal blend samples containing 2nd and 3rd generation 
SCAs. Applying these analytical techniques allowed the characterization of the SCAs and the 
impurities in the samples (propylene glycol, isopropyl alcohol, and ethyl acetate). Analysis of 
the packaged brands revealed that 5F-ADB is the most common SCA present and it is found 
together with different types of SCAs. Qualitative differences have been demonstrated 
between brands seized in different years e.g. Extinction contained AB-CHMINACA in 2016 
seizures, in 2017 it contained 5F-PB-22. This is an indication of how the illicit market in 
SCA is dynamic. Mislabelling or no labelling of packaged SCAs is seen in some of the 
brands. This is of importance to the drug user, as each type has different potency and this 
could have dangerous consequences. NMR characterization is described for AM-694 with 
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successful derivatization of the propylene glycol, found in the samples with AM-694, 
followed by detection via LC-ESI/MS analysis. For AB-CHMINACA, NMR characterization 
with additional 15N-NMR data are provided for the first time.  
Analytical characterization of HMP SCA samples revealed that SCAs are more 
popular than cannabis with combinations of potent SCAs such as 5F-ADB and AMB-
FUBINACA in some samples, that could explain the reports of intoxications in prisons in the 
UK. 2D DOSY NMR spectroscopy is a powerful analytical technique in separating complex 
mixtures according to their diffusion coefficient (D). This has been successfully applied to 
samples containing SCAs and impurities resulting in excellent separations where there are 
sufficient differences in molecular weight between the analytes. 
An analytical platform is provided that consists of LC/TOF-ESI-MS/MS, flash 
column chromatography and NMR for the separation of a closely related complex mixture of 
3rd generation SCAs. UHPLC/TOF-ESI/MS analysis allowed base-line resolution of all six 
components in under 8 min, and molecular ions confirmation, with identification of a 
possible PX-1 impurity (compound 2) with MS/MS analysis confirming the proposed 
structure. Flash column chromatography using 2 gradients allowed the separation and 
purification of SCAs in the mixture on a practical scale (mg). Final confirmation of the 
identity of each component, with the exception of compound 2, was achieved by 1D/2D 
NMR with PX-1 NMR assignments for the first time. The contents of “K2” herbal blends 
keep on changing, where five years ago they were made up of 1st and 2nd generation SCAs 
(JWH and AM series), this analysis now shows the presence of multiple SCAs of the 3rd 
generation with higher potencies than the previous generations. Therefore, these qualitative 
and quantitative SCA analyses provide scientific evidence in support of what is being 
observed in city centres and in HMP, namely zombification and epidemics of spice abuse, the 
latter leading to dangerous combinations of intoxication and violence. Some of these 3rd 
generation SCAs have already been implicated in various deaths.259,288,289 
In the following chapter, analytical areas rarely tackled of SCAs such as quantitative 
analysis of SCAs in herbal blends and combustion analysis are explored. 
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Chapter 5. Quantitative and combustion analysis of Synthetic Cannabinoid Agonists 
 
5.1 Introduction 
Synthetic Cannabinoid Agonists (SCAs), also known by their street name as spice, are potent 
binders to the CB1 and CB2 receptors distributed throughout the central nervous system 
(CNS) and immune system respectively, producing psychoactive effects similar to, and in 
most cases more potent than, the mainstream drugs they are trying to mimic, e.g. Δ9–
tetrahydrocannabinol (THC).78 Unlike Δ9-THC, a partial agonist with low affinity at the 
Cannabinoid receptor 1 (CB1), SCAs are full agonists with high affinity binding to CB1 and 
moreover they also possess CB2 receptor affinity.78 These pharmacological characteristics 
result in drug users/abusers having severe psychiatric episodes, not present with traditional 
cannabis smoking. These effects are described as the “cannabinoids tetrad” which are 
hypothermia, analgesia, catalepsy, and locomotor activities, leading to symptoms ranging 
from excited delirium to kidney damage.290  
According to the European Monitoring Centre for Drug and Drug Addiction 
(EMCDDA), SCAs represent the largest class of NPS, with estimated seizures weighing more 
than 2.3 tonnes in 2015.291 In 2008, the first generation of synthetic cannabinoids hit the 
streets,80 such as the Pfizer compound, CP 47,497 and John W. Huffman JWH-018 (Figure 
107), which were designed and developed as medicinal chemistry compounds, intended to 
exploit the pathological implications of the CB receptors in many diseases, but side-tracked 
to the illicit clandestine designer-drugs market.79,253 The following generations of SCA were 
based initially on JWH-018, but later evolved into a variation of indazoles (5F-ADB), with 
fluoroalkyls and quinoline (5F-PB22), and amides (PX-1) integrated into their structures, 
replacing the naphthoylindole and N-pentyl tail of JWH-018.262,286 This continuous change in 
substituents makes them into a moving target posing many analytical challenges.  
The Korean National Forensic services reported that from 2008-2010, most of the 
SCA seized were first generation non-fluorinated compounds,292 e.g. JWH-018, CP 47,497, 
and UR-144 (Figure 107). In 2012, fluorinated analogues started emerging such as XLR-11, a 
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fluoropentyl analogue of UR-144, and by 2013 approximately 90% of SCAs seized were 
fluorinated.292 It is believed that the growing trend in the bioisosteric fluorine introduction 
into SCA was inspired by a Makriyannis patent,255 where he demonstrated a much higher 
potency of AM-2201 compared to non-fluorinated analogues, e.g. JWH-018. Initially, AM-
2201 was identified in herbal blends, and it escalated into many SCA with no precedent in the 
scientific literature, e.g. 5F-ADB-PINACA, 5F-AB-PICA, and 5F-PB-22.253 Furthermore, 
besides the enhanced potency of fluorinated analogues, the addition of a fluorine substituent 
was intended to circumvent legal restrictions imposed on previous classes of SCA.253,271  
 
Figure 107. 1st, 2nd, and 3rd generation SCAs. 
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Proton Nuclear Magnetic Resonance (1H-NMR) is inherently quantitative, as the 
integrated functional group signals are directly proportional to the number of spins generated 
by the signals in question. Nevertheless, NMR is only quantitative if the appropriate 
acquisition and processing parameters are determined by experiment and then implemented. 
Early applications of quantitative NMR (q-NMR) required considerably large amounts of 
sample and IS because they were low-field instruments. The development of high-field NMR 
spectrometers allowed for improved sensitivity meaning that impurities could be quantified at 
less than 0.1%, demonstrating that NMR is comparable with chromatographic methods for 
quantitative analysis.200,218 NMR has more advantages than other analytical approaches such 
as those that are chromatography based. NMR does not require the use of a high purity 
reference standard for the construction of the required calibration curve. Such a standard is 
expensive and most of the time unavailable, especially for newer, more recently identified 
SCAs.198 NMR also has the advantage of less sample preparation being required. No serial 
dilution is required to run the sample and no mobile phase has to be prepared. Additionally, 
there is no interaction with a column which requires blank samples to be run in order to avoid 
carry-over that could affect the analysis. Furthermore, NMR is not subject to problems from 
small compounds and impurities with no chromophore or a different UV response which pose 
challenges to chromatographic and UV methods.198,199  
Quantitative analysis of SCA in herbal blends has been reported using different 
analytical techniques, mostly chromatography and MS-based.9 GC/MS showed qualitative 
and quantitative variations among SCA in herbal-blend brands in 2014.261 1H q-NMR reports 
on SCA quantitation are scarce. Techniques have been reported on purchased herbal blends 
containing SCA using MA as an internal standard.293 Dunn et al.294 evaluated the extraction 
efficiency of the major solvents e.g. chloroform, acetone, acetonitrile and methanol, using 1H 
q-NMR with 1,3,5-trimethoxybenzene as an internal standard and GC/MS on seized herbal 





The 19F nucleus is an attractive target for q-NMR spectroscopy, mainly due to the 
sensitivity of the nucleus (88% of 1H) and its natural abundancy of 100%.295 Additionally, the 
wide range of chemical shift (500 ppm) and the absence of fluorinated impurities will reduce 
the chance of overlapping signals and less background noise.296 19F q-NMR has been applied 
to analyse Active Pharmaceutical Ingredients (API).297 Nevertheless, for quantitative results 
more parameters have to be addressed compared to 1H q-NMR,296 e.g. equal excitation for the 
signals across the entire spectral width must be achieved, otherwise the integration values 
will suffer which in turn affects the analytical results. This is achieved by setting the centre 
point of the spectrum (O1P) midway between the signal of the internal standard and the 
compound, 90˚ pulse angle followed by sufficient relaxation (relaxation delay) 5xT1 to 
recover the magnetization to 99.3% of its size. This parameter is also applicable to 1H q-
NMR, decoupling the 1H signals during 19F acquisition will result in NOE enhancement 
which can be overcome by inverse gated decoupling 19F NMR.296 
The main area of SCA analysis involves the characterization and quantification using 
GC-and LC-hyphenated techniques of seized powders or often herbal blends containing 
SCAs and toxicological samples, the latter relies on MS techniques. Analytical methods that 
can be applied to a crude sample are of great value to drug analysts, but due to the fact that 
SCAs in herbal blends are mostly smoked, analytical studies of combustion are required.298 
Simulation of smoking is challenging for a number of reasons, mainly the temperature and 
the flow rate. Temperature in cigarette smoking can routinely reach 700 °C and even goes up 
900 °C at some hot spots.299 Potentially toxic pyrolysis compounds are released from herbal 
materials when temperatures exceed 200 °C which is the case in cigarette smoking. Such 
toxic compounds include toluene, benzene and naphthalene.300 The presence of several 
nitrogen atoms in the majority of SCAs could potentially result in a number of chemically 
variable combustion products due to the thermal lability of C-N bonds. For an accurate 
simulation of the smoking process, a flow rate of 30 L/min needs to be maintained.301 
The first SCA pyrolysis analysis was performed on UR-144, an indole tetramethyl-
cyclopropyl using LC/MS/MS.302 Raso and Bell303 performed GC/MS analysis, revealing 
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pyrolysis products of first generation (JWH-018, JWH-073) and second generation (AM-694) 
SCA using an in-house built pyrolysis device comprised of a quartz tube inserted into a 
round-bottom flask, where the sample is combusted using a blow torch, revealing common 
and distinctive fragments for each type of SCA, e.g. naphthalene for the JWH family and 
cinnolineamine for the inadzole family. The authors also acknowledged the problem of 
maintaining a stable temperature.303 Kevin et al.304 by-passed the issue of fluctuating 
temperature by conducting a temperature controlled study on six carboxamide type SCA at 
200, 400, 600, and 800 °C using a pyro-probe coupled to a GC/MS, thus creating 
temperature-controlled pyrolysis conditions where the degradants were analysed at each 
temperature.304 In this chapter, a focus on the simulation of smoking is the aim rather than 
pyrolysis at high temperatures coupled to anaerobic conditions.  
The increased frequency of the discovery of fluorinated SCAs is exploited, and a 
confirmed 19F q-NMR spectroscopic method is implemented for the first time to quantify 
fluorinated SCAs, e.g. 5-F-ADB and AM-694 (Figure 107) in herbal blends recently seized in 
the South West of England. The technique was compared to 1H q-NMR and UHPLC for 
accuracy and was shown to be in good agreement. Moreover, quantitative differences 
between sample batches are discussed. Investigation of the acquisition parameters associated 
with 19F q-NMR will help drug analysts to run a fast and robust quantitative analysis for 
fluorinated (illicit) drugs with minimal background interference and signal overlap. 
Additionally, work on the combustion and degradation products is an area that 
requires further investigation due to the generation of potentially harmful products with 
possible alteration in the target receptor or the affinity for that receptor of the new 
compounds resulting from such exposure to high temperatures. In this study, a SCA smoking 
model was designed and constructed. It was then employed for the analysis of different SCAs 
and the detection of their combustion products. The resulting combustion products may help 






5.2.1 Chemicals and sample preparation 
All extraction solvents 99.9% anhydrous (chloroform, methanol, and acetonitrile), were 
purchased from Fisher Scientific (UK) and ACROS Organics (UK). Deuterated solvents 
(CDCl3, CD3OD, and CD3CN) were purchased from Cambridge Isotope Laboratories (Goss 
Scientific, UK). NMR internal standards (IS) 2-chloro-4-fluorotoluene, dimethyl sulfone 
(DMS), and maleic acid (MA) are TraceCERT certified reference materials purchased from 
Sigma-Aldrich (UK). [1-(5-Fluoropentyl)-1H-indol-3-yl](2-iodophenyl)-methanone (AM-
694) 10.0 mg, N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) (5F-AKB-
48) 1.0 mg/mL in a 1.0 mL vial, and (1-pentyl-1H-indol-3-yl)-1-naphthalenyl-methanone 
(JWH-018) 100 µg/mL in a 1.0 mL vial were purchased from LGC (Teddington, UK). N-
Methyltrifluoroacetamide (N-methyl-TFA) >98.0% was purchased from Tokyo Chemical 
Industry (TCI, Tokyo, Japan). Herbal-blend samples were provided by the DEAT, the Avon 
and Somerset Constabulary, from recent (2016-2018) seizures. The samples were in the form 
of herbal blends (1.0-3.0 g) as commercially packaged brands (Exodus, Loco Elite). Turnera 
diffusa (Damiana) dried herb (illicit-drug free) was purchased from Spiceworks (Hereford, 
UK). 
IS, reference standards, and samples were weighed using a SE2F Sartorius analytical 
balance, between 1.0-2.0 mg/mL of IS was used. Preliminary analysis of non-homogenized 
herbal blend samples yielded large variations in the contents of the plant materials between 
samples tested by NMR. Therefore, two approaches were employed for the homogenization 
of the samples. Either they were ground to a fine powder with 100 grit sandpaper,282 or they 
were frozen in liquid nitrogen, followed by grinding to a fine powder using a mortar and 
pestle. For sample preparation for UHPLC and NMR analysis, homogenized plant materials 
(100 mg) were extracted with methanol (2 x 4.0 mL) with sonication (30 min), centrifuged, 
and then the supernatant extract was decanted and the pellet (plant material) discarded. The 
extract was then evaporated to dryness under reduced pressure and reconstituted in deuterated 
solvent (1.0 mL) containing IS (DMS, MA or 2-chloro-4-fluorotoluene) for NMR 
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spectroscopic analysis. For UHPLC analysis, samples were diluted 100-fold to bring them 
within the calibration range and spiked with IS JWH-018 in the case of AM-694 quantitation, 
and 5F-AKB48 in the case of 5F-ADB quantitation (IS at 10.0 µg/mL). Data analysis was 
conducted using the Microsoft Excel data analysis tool pack. 
AM-694 was quantified using a 7-point calibration curve between 1.25-80 µg/mL 
with JWH-018 as IS, and 5F-ADB using a 6-point calibration curve between 1.25-40 µg/mL 
with 5F-AKB48 as IS, both were prepared in UHPLC solvent. The response was calculated 




NMR spectra were recorded on a Bruker AVANCE III 500 MHz spectrometer. 1H, 13C, and 
19F frequencies are 500.130, 125.758, and 470.592 MHz respectively. The probe was a 
variable temperature BBFO+ with three channels, temperature was 25˚C. Chemical shifts 
were referenced to 0.0 ppm for TMS or residual solvent peaks and are reported in ppm. 
Coupling constants (J, line-separations, absolute values) are rounded to the nearest 0.5 Hz. 
Structural elucidation was achieved with the use of 2D NMR spectroscopy. An Inversion 
recovery pulse sequence was performed to measure the longitudinal relaxation time T1 for the 
2-chloro-4-fluorotoluene IS and 5F-ADB. The T1 relaxation delay for the IS signal for 1H 
quantification for H5 (1H δ = 6.98 1H, td 8.5, 2.5 Hz) was 5.7s, and T1 for the indazole 5F-
ADB ranged from 2.9-3.5s. For quantitative 1H NMR analysis, the pulse sequence was 
composed of 64k data points, acquisition time of 3.18s, 16 scans, 50s delay, 90° pulse angle, 
phase and baseline corrections were done automatically while integration was performed 
manually. 19F q-NMR proton coupled and inverse gated pulse sequence used a sweep of 
241.51 ppm, O1P -168 ppm, 6k point counts, acquisition time 0.7s, 16 scans, delay 30s, 90° 
pulse angle, phase and baseline correction and integration were performed manually. NMR 




UHPLC quantitation, UHPLC/TOF-ESI-MS and GC/MS 
UHPLC calibration curve construction and sample quantitative analysis were performed on a 
Dionex Ultimate 3000 UHPLC (Thermo Fisher Scientific, California, USA) with a variable 
wavelength detector ( = 254, 280, 298 nm). Liquid chromatography separation was 
performed using an Acquity UPLC BEH C18, 1.7 µM, 2.1 x 50 mm RP-column (Waters, 
Milford, Massachusetts, USA) with a flow rate of 0.4 mL/min, and an injection volume of 10 
µL at a column temperature of 40°C.  
Mobile phase A consisted of LC/MS grade water 0.1% TFA v/v; mobile phase B 
consisted of acetonitrile 0.1% TFA v/v. For AM-694 and 5F-ADB calibration curves and 
quantitation the following gradient 1 was used, the solvent gradient started from 1% B for 2.0 
min followed by a linear increase from 2.1 min to 100% B at 5.0 min, held for 3 min, 
followed by a return to 1% B at 8.1 min, where it was held for 3.9 min for equilibration, 
giving a total run time of 12.0 min. For 5F-ADB purity determination, the flow rate was 0.4 
mL/min, column temperature 25.0 ˚C. Gradient 2 started with 10% B until 3.0 min, followed 
by a linear increase to 100% B at 20.0 min, held for 4.0 min, followed by a return to 10% B 
at 24.1 min where it was held for 10.9 min with a total run time of 35.0 min. Data analysis 
used Bruker data and quant analysis 4.3 package.  
For the combustion analysis using UHPLC/TOF-ESI-MS, the QTOF and MS 
parameters are reported in section 4.2.2, but with the following gradient 3 and mobile phases: 
mobile phase A consisted of LC/MS grade water 0.1% FA v/v; mobile phase B consisted of 
acetonitrile 0.1% FA v/v. Solvent gradient started from 1% B for 2 min followed by a linear 
increase from 2.1 min to 100% B at 9.0 min, held for 3 min, followed by a return to 1% B at 
12.1 min, where it was held for 2.9 min for equilibration, giving a total run time of 15.0 min.  
GC/MS analysis of SCA combustion was achieved on a Thermofisher ISQ series 
GC/MS. Full scan mode 50-650 m/z, injection volume splitless 1 µL, with He as the carrier 
gas, flow rate 12.0 mL/min. HP-1 column was used (30 m x 0.18 mm, 0.18 µm thickness) 
Temperature gradient started at 80°C, it was increased to 320°C at 20°C/min, then maintained 
for 3.0 min with a total run time of 15.0 min. Data analysis used Xcalibur software. 
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SCA smoking simulation apparatus  
The smoking model is a two-stage trap rig (Figure 108), constructed in-house using two 250 
mL gas washing bottles Lenz® (VWR, UK), filled to the midpoint with 8 mm glass beads 
(VWR, UK) to increase the surface area. The gas washing bottles heads were without filters, 
with traps placed in a dry ice/acetone slush-bath allowing the efficient trapping of the 
volatiles. A Quartz tube 8 mm OD x ID 6 mm was purchased from Almath crucibles 
(Suffolk, UK) where the SCA cigarettes were inserted. The traps were connected to a GAST 
G626X pump (General Electric, USA), the pump dial was used to control the flow rate which 
was measured using a Copley® DFM 2000 flow regulator (Nottingham, UK). The flow rate 
was set between 28-30 L/min and the temperature was monitored using a TENMA 
thermocouple. SCA doped herb (200 mg) was rolled into a cigarette and inserted into the 
Quartz tube followed by lighting it with a cigarette lighter. 
 A  
 




Figure 108. In-house constructed SCA smoking simulation model: (A) graphic, (B) cigarette 
inserted into the Quartz tube, (C) Copley flow rate meter in position. 
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5.3 Results and discussion 
5F-ADB reference material was extracted from a seized sample (1.3 g) with CHCl3 (2x 25.0 
ml) with sonication for 30 min each time. The combined extracts were passed through a 0.25 
µm syringe filter. The filtrate was evaporated to dryness under reduced pressure yielding ~90 
mg of residue which was purified by flash-column normal phase silica chromatography using 
gradient 1 (section 4.2.2), followed by semi-preparative RP HPLC, resulting in pure 5F-ADB 
(38.0 mg). Purity and confirmation of the structure were obtained by two analytical UHPLC 
methods (gradients 1 and 2 on a C18 column), NMR and also HRMS (Figure 109). 
1H NMR (500 MHz in CD3OD): δ 8.21 (4′) (1H, dd J = 8.0, 2.0 Hz), 7.83 (NH) (1H, 
br d J = 9.5 Hz), 7.64 (7′) (1H, dd J = 8.5, 1.5 Hz), 7.46 (6′) (1H, td J = 8.5, 1.5 Hz), 7.29 (5′) 
(1H, td J = 8.5, 2.0 Hz), 4.62 (2′′) (1H, d J = 9.5 Hz), 4.52 (1′′′) (2H, t J = 7.5 Hz), 4.40 (5′′′) 
(2H, dt J = 47.5, 6.0 Hz), 3.78 (5′′) (3H, s), 2.01 (2′′′) (2H, quintet J = 7.5 Hz), 1.73 (4′′′) (2H, 
d quintet J = 26.0, 6.0 Hz), 1.41-1.47 (3′′′) (2H, m), 1.10 (4′′) (9H, s). 
13C NMR (125.8 MHz in CD3OD): δ 173.1 (1′′), 164.2 (1), 142.5 (7′a), 137.3 (3′), 
126.8 (6′), 124.0 (5′), 123.9 (3′a), 123.0 (4′), 111.1 (7′), 84.7 (5′′′, d 1JCF = 164.0 Hz), 61.3 
(2′′), 52.5 (5′′), 50.2 (1′′′), 35.8 (3′′), 31.0 (4′′′, d 2JCF = 19.5 Hz), 30.4 (2′′′), 27.1 (4′′), 23.7 
(3′′′ d, 3JCF = 5.5 Hz); 19F observe δ -220.3 (5′′′F, tt 2JHF = 47.5, 3JHF = 26.0 Hz). HRMS found 
[M+H]+ 378.2193 for C20H29FN3O3 requiring 378.2187, found [M+Na]+ 400.2010 for 








Figure 109. Analytical purity of 5F-ADB as tested by (A) UHPLC RT = 22.0 min, (B) 1H-






5.3.1 19F and 1H quantitative NMR analyses of fluorinated SCA in seized herbal blends 
5F-ADB 
N-[[1-(5-Fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-L-valine methyl ester (5F-ADB) 
was identified in seized herbal blend samples named “Exodus”. Identification was achieved 
through 2D NMR and LC/MS/MS fragmentation pattern (Figure 101 A). Results are 
confirmed by comparison with the literature with only minor differences in the NMR, due to 
solvent effects.272,305 The target signal for fluorine q-NMR analysis is the fluorine on the N-
pentyl tail with its chemical shift of  = -220 ppm assigned as a triplet of triplets, 2JHF 47.5 Hz 
coupling to methylene protons on position 5′′′ and 3JHF 26.0 Hz coupling to methylene at 
position 4′′′. The extraction was evaluated in chloroform, methanol, and acetonitrile. 
The signals used for quantification in methanol were the indazole protons 4′ 8.22 
ppm, 7′ 7.64 ppm, 6′ 7.46 ppm, and 5′ 7.31 ppm. In acetonitrile, the same protons were used 
except 6′ due to an overlapping impurity. In chloroform, H-5′ was excluded due to overlap 
with the residual chloroform H-solvent signal, nevertheless chloroform gave a cleaner 
spectrum, with fewer impurities and no sugars from the matrix component (as found when 
methanol was the solvent of extraction) with additional signals available for integration such 
as the fluoropentyl methylenes 1′′′ and 5′′′. DMS singlet at  = 3.0 ppm integrating for six 
protons, was used as an IS in CDCl3. Additionally, N-methyltrifluoroacetamide was evaluated 
as an IS for 19F q-NMR, resulting in apparently significantly lower amounts of SCA, using 
Anova two factor analysis, in comparison to its contemporaneous analysis by 1H q-NMR and 
then by 1H q-NMR using maleic acid (IS) in methanol and acetonitrile, and DMS (IS) in 
chloroform (Table 23). The reason behind this apparently lower yield is the resonance 
(chemical shift) of the N-methyltrifluoroacetamide 19F signal at  = -75.9 compared to the 19F 
of 5F-ADB at  = -220.2 ppm, resulting in unequal excitation. Uniform excitation across the 
spectrum has to be achieved in order for all the signals to get the same magnetization in the 
pulse sequence, thus making the centre point of the spectra (O1P) a crucial parameter when 





Table 23. Quantitative analysis of a sample of 5F-ADB by 1H NMR in CD3OD, CD3CN, and 
CDCl3 compared to 19F q-NMR using N-methyltrifluoroacetamide (n = 4). 
Nucleus, Solvent 
(IS) 
1H in CD3OD 
(MA) 
1H in CD3CN 
(MA) 
1H in CDCl3 
(DMS) 
1H in CDCl3 
(N-Me-TFA) 
19F in CDCl3 
(N-Me-TFA) 
Amount (mg/g) 11.84 ± 0.28 11.06 ± 0.16 11.03 ± 0.14 11.48 ± 0.12 8.86 ± 0.19 
RSD (%) 2.34 1.45 1.30 1.01 2.18 
 
Therefore, 2-chloro-4-fluorotoluene was used as a 19F q-NMR IS with (protio) 
methanol as the extraction solvent and CD3OD as the NMR solvent, resulting in a good 
agreement with 1H q-NMR using maleic acid (MA) as the IS. The 19F NMR IS signal has 
chemical shift  = -117.8 ppm. As 5F-ADB 19F resonates at  = -220.2 ppm, the O1P was 
therefore set at  = -165 ppm approximately equally between both resonances resulting in 
equal excitation of both fluorines. Changing the O1P position significantly influenced the 
accuracy of the quantitative results. The 19F q-NMR results (Table 24) are in agreement with 
the 1H q-NMR using maleic acid (MA) (10.4 ± 0.2 mg/g, RSD 1.6%) as the IS. 
 
Table 24. Quantitative analysis of 5F-ADB by 1H and 19F NMR (proton coupled) in CD3OD 
with 2-chloro-4-fluorotoluene as IS at O1P = -160 ppm (n = 5). 
Nucleus 1H 19F 
Amount (mg/g) 9.8 ± 0.8 9.4 ± 0.7 
RSD (%) 7.9 7.3 
 
The effect of changing the O1P was tested using plant material (100.0 mg) containing 
5F-ADB with 2-chloro-4-fluorotoluene as the IS, setting the O1P approximately in the 
middle of the two signals (-165 ppm). This resulted in quantitative results in agreement with 
1H q-NMR results, while shifting the O1P to -220 and -117 ppm, resulted in significantly 
lower and higher integration values respectively and, consequently, significantly altered 






Figure 110. 19F-NMR (1H coupled) stacked spectra of 5F-ADB with its 19F signal at -220.2 
ppm and the IS 2-chloro-4-fluorotoluene (-117.8 ppm) with O1P set at: (A) -165 ppm, (B)       
-220 ppm, (C) -117 ppm, with (inset) expansion of the of 5F-ADB 19F signal. 
 
A seized sample (HN Exodus5) containing 5F-ADB was analysed using inverse-
gated decoupling 19F NMR in order to eliminate the Nuclear Overhauser Effect (NOE), and 
provide the added benefit of an enhanced signal to noise (S/N) ratio. The results were 
compared with proton-coupled 19F NMR; the results from the 19F proton coupled and 19F 
proton decoupled methods are in good agreement (Figure 111). 1H NMR q-NMR showed 7.1 
± 0.11 mg/g (RSD of 1.57%), 19F proton-coupled q-NMR showed 6.9 ± 0.02 mg/g (RSD of 





Figure 111. 5F-ADB quantified in a sample using 1H, 19F proton coupled, and 19F inverse-
gated decoupled spectroscopy. 
 
Two batches of seized “Exodus” brand, 8 seized in 2016, and 7 seized in 2017, were 
subjected to quantitative analysis using 19F proton coupled/decoupled and 1H NMR using the 
IS 2-chloro-4-fluorotoluene, and also by UHPLC. Confirmation of the quantitation by 19F q-
NMR was achieved with UHPLC using the purified 5F-ADB as the reference standard to 
construct a calibration curve (gradient 1), using  = 298 nm wavelength where the indazole 
absorbs strongly, resulting in RT = 6.8 min. Initially, 1-methylindazole-3-carboxylic acid was 
used as a UHPLC IS, but this was abandoned due to the overlap of the 1-methylindazole-3-
carboxylic acid peak with a plant matrix component at RT = 5.6 min (Figure 112). 5F-
AKB48 (RT = 7.2 min) was chosen instead as an IS in UHPLC analysis due to its similar 
chromophore to 5F-ADB (indazole), and the presence of an N-adamantanyl substituent 
provided sufficient hydrophobicity to be separated from the peak of 5F-ADB (Figure 112). 
5F-ADB UHPLC calibration curve using 5F-AKB48 as an IS was in the range 1.25-40.00 






















Figure 112. UHPLC chromatograms ( 298 nm) for an “Exodus” sample containing 5F-
ADB RT = 6.8 min (top) using 1-methylindazole-3-carboxylic acid as IS RT = 5.6 min 
showing overlap with a matrix component, (bottom) using 5F-AKB48 as IS RT = 7.2 min. 
 
 
Figure 113. (Top) stacked UHPLC chromatogram concentrations from 1.25-40.0 µg/mL ( = 
298 nm) of 5F-ADB (RT = 6.8 min) and 5F-AKB48 IS (RT = 7.2 min), 
(bottom) calibration curve of 5F-ADB against 5F-AKB48 (IS), R2 = 0.9999. 
208 
 
2016 seized “Exodus” samples analyses revealed a consistent dose of 5F-ADB across 
all 8 samples with an acceptable precision (RSD%) of less than 10% for the analysis of 
samples in the herbal form (Table 25).217 Furthermore, using ANOVA two-factor with 
replication analysis of the four groups (19F coupled, 19F decoupled, 1H NMR and UHPLC) 
revealed no statistically significant differences (p > 0.05). 
 
Table 25. Quantification (mg/g) of SCA in plant material of “Exodus” brand seized in 2016 
containing 5F-ADB. 
 NMR n = 3 UHPLC n = 4 
Sample 1H RSD 
% 
19F coupled RSD 
% 




Exodus9 7.39 ± 0.20 2.74 7.34 ± 0.27 3.73 7.12 ± 0.24 3.36 6.96 ± 0.12 1.67 
Exodus10 8.04 ± 0.43 5.35 7.87 ± 0.37 4.69 7.87 ± 0.47 5.94 7.92 ± 0.38 4.79 
Exodus11 8.24 ± 0.17 2.00 8.01 ± 0.12 1.48 8.05 ± 0.06 0.79 7.87 ± 0.11 1.46 
Exodus12 8.04 ± 0.12 1.49 7.89 ± 0.07 0.88 7.93 ± 0.14 1.81 7.97 ± 0.10 1.20 
Exodus13 7.78 ± 0.02 0.21 7.71± 0.04 0.54 7.72 ± 0.05 0.65 8.19 ± 0.07 0.79 
Exodus14 7.65 ± 0.08 1.00 7.61 ± 0.07 0.90 7.66 ± 0.11 1.45 7.91 ± 0.12 1.52 
Exodus15 7.57 ± 0.22 2.93 7.52± 0.24 3.14 7.50 ± 0.17 2.26 7.54 ± 0.09 1.17 
Exodus16 7.43 ± 0.18 2.46 7.45± 0.21 2.75 7.48 ± 0.24 3.18 7.94 ± 0.14 1.82 
 
Table 26. Quantification (mg/g) of SCA in plant material of “Exodus” brand seized in 2017 
containing 5F-ADB. 
 NMR n = 3 UHPLC n = 4 
Sample 1H RSD 
% 
19F coupled RSD 
% 




Exodus1 10.48 ± 0.29 2.78 10.65 ± 0.11 1.08 10.68 ± 0.12 1.11 12.44 ± 0.63 5.03 
Exodus2 7.81 ± 0.12 1.51 7.75 ± 0.07 0.92 7.77 ± 0.16 2.09 8.83 ± 0.03 0.34 
Exodus3 9.17 ± 0.13 1.41 9.07 ± 0.19 2.13 9.12 ± 0.23 2.55 11.10± 1.29 11.60 
Exodus4 8.69 ± 0.10 1.17 8.66 ± 0.13 1.49 8.60 ± 0.10 1.12 8.35 ± 0.15 1.80 
Exodus5 17.50 ± 0.09 0.53 17.48 ± 0.23 1.31 17.71 ± 0.05 0.26 20.22 ± 0.25 1.23 
Exodus6 8.70 ± 0.08 0.93 8.57 ± 0.09 1.01 8.59 ± 0.11 1.33 8.78 ± 0.07 0.83 
Exodus7 14.35 ± 0.10 0.69 13.88 ± 0.09 0.66 13.45 ± 0.53 3.92 16.08 ± 0.17 1.06 
 
However, 2017 “Exodus” samples containing 5F-ADB revealed different quantitative 
results (Table 26). 5 packs of the 7 contained a similar dose of 5F-ADB to the 2016 samples, 
but samples 5 and 7 contained from 1.5 to more than double the dose of 5F-ADB, with good 
precision in most of the samples. The presence of such a large quantitative variation in the 
2017 samples is alarming, especially as this recently identified SCA (5F-ADB) has no 
pharmacological data, so one can only compare it to similar analogues which have 
approximately 220-fold the potency of THC, e.g. 5F-ADBICA EC50 = 0.77 nM compared to 
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THC EC50 = 172 nM.78 This quantitative analysis is of importance to users/abusers, health 
professionals and law enforcement to get an idea of how much of the SCA is in the sample. It 
also clearly demonstrates how there is no quality control of the “Exodus” preparations. 
 
AM-694 
[1-(5-Fluoropentyl)-1H-indol-3-yl](2-iodophenyl)-methanone (AM-694) was identified (3.0 
g) in seized herbal blends branded as “LOCO elite”. Identification was achieved through 2D 
NMR spectroscopy and its LC/MS/MS fragmentation pattern (Figures 74 and 77). Results are 
confirmed by comparison with the published literature of the first analytical characterization 
of AM-694 in illicit seizures.262 Candidate signals for integration are:  3′′, 4′′, 5′′, and 6′′ of 
the iodophenyl substituent, 2′ and 7′ of the indole core, and 1′′′ and 5′′′ of the fluoropentyl 
chain. The impact of relaxation delay in 19F NMR was investigated, and it was found that 
using only a short relaxation delay (< 15s) significantly affected the quantitative results. 15s 
and 30s relaxation delays were sufficient to achieve reproducible quantitative results. 
Moreover, such relaxation delays still allowed fast overall sample run-times of 8 and 10 min 
respectively. 1H q-NMR and 19F q-NMR showed consistent results using 2-chloro-4-
fluorotoluene as the IS (Figure 114). Furthermore, cross-method confirmation was 
demonstrated using UHPLC with reference standard AM-694 RT = 6.9 min and JWH-018 
(IS) RT = 7.3 min, constructing a seven-point calibration curve between 1.25-80.0 µg with R2 
= 0.997 and IS RSD = 4.4% (Figure 115). 
Two samples were quantified, with significant differences (p < 0.05) in their AM-694 
content. Sample 1 analysis using (only) 1H NMR spectroscopy, with maleic acid as IS, 
showed 57.0 ± 2.9 mg/g of plant material, compared to the value for Sample 2 of 37.5 ± 1.1 
mg. That 1H NMR quantification of Sample 2 was shown to be consistent when analysed by 
1H NMR spectroscopy against both maleic acid and 2-chloro-4-fluorotoluene as IS, and by 
19F q-NMR, and also in agreement with UHPLC results, showing no significant differences 





Figure 114. (Top) expansion of 1H NMR aromatic region of AM-694 in CD3OD showing 
signals used for quantification where the integration of the 2-chloro-4-fluorotoluene IS H5 
signal (td) is normalized (1.00 H), (bottom) 19F NMR signals of AM-694 at -220 ppm and the 
same IS 19F signal at -117 ppm also normalized (1.00 F). 
 
Table 27. Quantitative analysis of AM-694 in Loco elite herbal blends by 1H and 19F NMR, 
using maleic acid (MA) or 2-chloro-4-fluorotoluene as IS, and UHPLC (against JWH-018). 






Sample 1 (mg/g)a 57.0 ± 2.9 n.d. n.d. n.d. 
RSD (%) 5.2 - - - 
Sample 2 (mg/g)a 37.5 ± 1.1 36.7 ± 2.0 35.4 ± 0.6 38.4 ± 2.6 
RSD (%) 3.0 5.4 1.7 6.6 







Figure 115. (Top) UHPLC chromatogram  = 254 nm) of AM-694 (RT = 6.9 min) and 
JWH-018 (RT = 7.3 min), (bottom) calibration curve of AM-694 against JWH-018 (IS), R2 = 
0.997. 
 
In the 1H NMR using 2-chloro-4-fluorotoluene as the IS, its H6 signal overlapped 
with 5′ of the indole and indazole SCA. Nevertheless, other SCA signals such as 4′′, 6′′, and 
7′ were resolved and used as candidate quantitative signals in CD3OD. 5-Fluoropentyl signals 
1′′′ and 5′′′ were resolved when CDCl3 or CD3CN was used as the NMR solvent. 
 
5.3.2 Combustion analysis of SCAs 
Combustion analysis resulted in the recovery of all six SCAs tested by UHPLC/TOF-ESI-MS 
(AB-CHMINACA, AM-694, 5F-ADB, MDMB-CHMICA, MMB-2201, 5F-PB-22) (Figure 
116). Three areas of the apparatus were tested for the presence of the SCA, trap 1, trap 2 and 
the combustion zone (CZ) in the quartz tube where the 200-300 mg cigarettes were fixed. 
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Most of the SCAs were detected in the first trap (80-90 %), interestingly no to very 
little SCAs were detected in the CZ, proving that the tested SCAs have a very good volatility. 
This is supporting evidence for reports of prisoners and prison guards being overcome by 
smoke inhalation in UK prisons.136  
 
Figure 116. SCAs tested by combustion analysis. 
 
Using gradient 3 for the UHPLC/TOF-ESI-MS/MS analysis resulted in the detection 
of the combustion samples of AB-CHMINACA, AM-694, 5F-ADB/MMB-2201 mixture, and 
5F-PB-22 (Figure 117), with their mass ions and fragmentation pattern assignments 
confirmed by comparison with our in-house built database. GC/MS analysis resulted in the 
detection of the SCA in trap 1 as well as some combustion products from some of the SCA 
tested. 5F-PB-22 GC/MS combustion analysis resulted in the detection of 5F-PB-22 at RT = 
8.20 min as well as the combustion products 1-(5-fluoropentyl)-indole (205 m/z) and 1-





Figure 117. Combustion analysis chromatogram of trap 1 for (A) AB-CHMINACA RT = 8.7 
min, (B) AM-694 RT = 9.1 min, (C) MMB-2201 RT = 8.6 min, 5F-ADB RT = 9.2 min, (D) 
5F-PB-22 RT = 8.9 min. 
 
MDMB-CHMICA combustion analysis resulted in the formation of a new, not 
previously reported, combustion product. Two peaks appear on the combustion sample TIC 
(Figure 119), MDMB-CHMICA RT = 11.74 min, and the novel combustion product 
(compound 7) RT = 10.80 min, which was absent in the crude sample of MDMB-CHMICA 











Figure 119. TIC of a combustion sample of MDMB-CHMICA showing the novel 
combustion product at RT = 10.80 min and MDMB-CHMICA at RT = 11.74 min. 
 
MDMB-CHMICA EI MS afforded a more extensive and slightly different 
fragmentation than the ESI/MS/MS seen in section 4.3.4 (Figure 101B). The first fragment 
resulted from the cleavage of the tert-butyl side chain (328) rather than the initial loss of 
methoxy observed in the ESI-MS/MS. In addition to the 240 base peak, also seen in the 
MS/MS analysis, 245 is concluded to be the result of the loss of the tert-butyl side-chain 
along with the cleavage of the cyclohexyl moiety with the formation of 1-methylidene-
indolinium ion (Figure 120). These results are in agreement with those of Langer et al.266 The 
proposed mechanism for the formation of compound 7 is rearrangement involving 
intramolecular electrophilic substitution of indole by the terminal methyl ester of MDMB-
CHMICA during the combustion process (Figures 120 and 121). 
Unlike in the MS fragmentation pattern of MDMB-CHMICA, the 296 m/z peak is 
more intense and is the result of the formation of an indole-1-cyclohexylmethyl-N-
propylidene ion, while the rest of the fragments are similar to MDMB-CHMICA with a base-
peak fragment of 240 m/z. LC chromatographic separation and HR-MS molecular ion 
identification of compound 7 were confirmed using UHPLC/TOF-ESI-MS showing a low 
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intensity peak and [M+H]+ for compound 7 at RT = 10.7 min, 353.2229 found for 
C22H29N2O2 requires 353.2223, and MDMB-CHMICA RT = 9.7 min, [M+H]+ 385.2493 




Figure 120. EI spectrum of (A) MDMB-CHMICA showing proposed fragmentation pattern 

























Figure 121. Proposed mechanism for the formation of combustion product compound 7. 
 
 
Figure 122. (A) UHPLC TIC of combustion sample of MDMB-CHMICA showing MDMB-
CHMICA peak at 9.7 min, (B) expansion of compound 7 peak at 10.7 min, (C) ESI-MS 




In this chapter, fluorine (19F) NMR spectroscopy has been applied for the first time to seized 
herbal blends containing fluorinated SCA to provide a fast (~8 min), accurate and robust 
quantitative analytical method with no background interference from the (plant material) 
matrix component. This analytical technique requires almost no method development 
(beyond the NMR acquisition parameters) compared to chromatographic methods. 2-Chloro-
4-fluorotoluene was used as an IS in 19F q-NMR, resulting in a method with close agreement 
to 1H q-NMR results using two different IS, and cross-method confirmation using UHPLC. 
Acquisition parameters such as the centre point of the spectra (O1P) and the 
relaxation delay have to be chosen carefully for accurate and precise outcomes. An inverse-
gated decoupling NMR experiment was employed to improve the S/N ratio and to remove 
any NOE enhancement. This technique has the potential to be applied for the fast analysis of 
herbal blends sprayed with fluorinated SCA, especially with the recent increase in the 
occurrence of such fluorinated 3rd generation SCA, and without the need to resort to any 
lengthy chromatographic analysis. Analysis of packs containing 5F-ADB revealed 
quantitative differences between 2016 and 2017 seizures in the dose of 5F-ADB, with some 
packs having double the dose compared to others.  
The in-house constructed SCA smoking simulator provided a good method for the 
recovery of combusted SCAs. SCAs showed good volatility with most of them being 
captured in the traps with little or no SCA left in the combustion zone (CZ) as tested by 
UHPLC/MS and GC/MS. GC/MS analysis revealed combustion products for 5F-PB-22. 
MDMB-CHMICA combustion sample GC/MS and UHPLC/ESI-MS analysis resulted in the 
detection of a novel combustion product, compound 7.  
This study of combustion products of SCAs provides markers which maybe useful 
for drug analysts and toxicologists in examining samples obtained from suspected SCA users. 
Thus, taken together, making reliable methods for the identification and quantification of 




General Conclusions  
In this research project, qualitative and quantitative analytical methods were developed for 
the chemical characterization and quantification of street-seized illicit drugs with a focus on 
NPS. All of the major classes of NPS were analysed, e.g. synthetic cannabinoids, cathinones, 
phenethylamines, arylcyclohexylamines, and phenidates. NPS represent a challenge to drug 
analysts and toxicologists worldwide, due to the frequent alteration in their chemical structure 
by the addition or removal of single or multiple substituents. This dynamic evolution makes 
them a moving target for which drug analysts need to develop new methods of analysis in 
order to stay ahead of the curve. Further complicating the analysis is the issue of purity. The 
presence of NPS in multiple components mixed together with benign cutting agents, which 
are added to make profit, makes for complex analytes. These sample therefore require more 
than one method for their characterization to obtain definite confirmation of their chemical 
structures. Drug analysis laboratories rely mainly on chromatographic methods coupled to 
MS for the daily analysis of seized samples. However, complex samples require the use of 
other techniques such as high-field NMR spectroscopy to provide assistance in resolving 
these mixtures and for the structural elucidation of novel compounds.  
Multiple analytical techniques were used in these investigations, with a main focus 
on NMR spectroscopy for the characterization and quantification of street samples. Detailed 
quantitative NMR (q-NMR) analysis was applied to numerous samples, including complex 
ones requiring the use of different IS. Fast, accurate, and precise results comparable to those 
obtained by chromatographic and MS techniques were achieved, without the use of a high 
purity reference standard of the drug being investigated. Such reference standards are mostly 
not available in the case of NPS especially for the more recent generations of SCA. 
The first part of this research project revolved around the analysis of night-club 
seizures from different parts of the South west of England especially concerning cathinones 
and phenethylamines. The analysis revealed a coexistence of MDMA, the most popular 
night-club drug, with other phenethylamines and cathinones, all of which have potent 
pharmacological profiles. 1D/2D NMR and q-NMR analysis allowed the structural 
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elucidation and quantification of complex MDMA/NPS/cutting agent samples. 1H q-NMR 
analysis of seized MDMA mixtures has not been reported before. Moreover, the use of a 
HILIC column, which is often used for the analysis of high polarity compounds (amino acids) 
coupled to MS, proved useful for the separation and identification of MDMA/cathinone 
mixtures. A 1H q-NMR-method was developed for the quantitative analysis of MDMA tablets 
with confirmation of the method using UHPLC/UV and UHPLC/MS. The developed q-NMR 
method resulted in good precision with advantages over chromatographic and MS techniques 
such as the ability of applying q-NMR to detect and quantify impurities that lack a 
chromophore (for UV/vis detection) or have poor ionization (for MS detection). This 
application is the first q-NMR cross-method confirmed analytical study on MDMA tablets. 
The quantitative analysis corroborated media accounts of high-dose MDMA tablets in 
circulation, where 35% of the tablets were shown to contain double to more than double the 
dose of MDMA for an adult, thus adding analytical evidence to media allegations. This 
contributes to drug analysis by q-NMR method development for MDMA analysis. It can also 
contribute to law enforcement and health officials being aware of the situation in night-club 
venues. Cathinone and phenethylamine carbamate derivatives were made and analysed via 
chromatographic and MS techniques, revealing an alteration in their polarity that allowed 
separation and the formation of distinctive isotopic clusters as the result of the incorporation 
of 3 chlorine atoms into their structure by making the trichloroethyl carbamate derivatives. 
This analytical study allowed the chromatographic separation and identification of cathinones 
and phenethylamines that usually have poor chromatography and non-distinctive MS 
fragments, two of which (ethylone a cathinone and 2C-B a phenethylamine) are reported for 
the first time.  
The second theme investigated in this research project is the arylcyclohexylamine 
and phenidate category of NPS. The analysis revealed much more complex samples with 4-6 
component mixtures, some of which were not detected by UHPLC/MS, e.g. dimethyl sulfone 
(DMS), which was detected and quantified by NMR. Components of less than 1% in the 
sample could not be easily detected by NMR. In these instances, UHPLC/TOF-ESI-MS/MS 
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proved invaluable for the confirmation of trace impurities that could arise from cross 
contamination. The presence of multiple samples containing the illicit drug ketamine along 
with its NPS analogues such as MXE and MXP are reported. Furthermore, NMR analysis of 
phenidate mixtures resulted in the detection of NPS from different families, MPA from 
phenethylamines and 5-MeO-DALT from tryptamines, along with compounds used as cutting 
agents, e.g. the excipient mannitol and the API benzocaine. Using maleic acid as an IS for q-
NMR allowed the quantification of a mixture that contains a high polarity component 
(mannitol) without resorting to chromatographic techniques that require derivatization and 
the construction of a calibration curve for each component in the mixture.  
In the following chapter, SCA characterization, structural elucidation and separation 
were achieved. SCAs are the number one class of NPS by frequency of seizures in Europe. 
They present many analytical challenges, mainly due to their structural complexity and the 
speed at which these NPS drugs are being altered, creating numerous analogues. The 
development of 3rd generation SCA that possess polar moieties makes their analysis different 
from the previous JWH and AM-series of low polarity. Therefore, an updated analytical 
protocol is urgently needed. 1D/2D NMR spectroscopy allowed the profiling of seized 
samples of SCA in attractively packaged brands. This is the first reported impurity profiling 
for SCA. Impurities such as propylene glycol, isopropyl alcohol and ethyl acetate were 
detected in SCA, either as additives or impurities arising from synthesis. The dispersive 
power of heteronuclear 2D NMR was employed for the characterization of SCA. 19F-HOESY 
and 19F-HMBC helped in the structural elucidation of fluorinated SCAs. HSQC-TOCSY 
allowed the separation of the cross-peak signals of each 1H-13C spin system, providing 
definitive confirmation in assigning the compound along with any impurities present. NMR 
ambiguities for AM-694 were clarified along with the first reported 15N NMR data for AB-
CHMINACA. These data are presented using nitromethane as an external reference standard. 
Derivatization of the impurities present such as propylene glycol using p-toluenesulfonyl 
isocyanate (PTSI) followed by UHPLC/ESI-MS analysis was achieved with 4 adducts 
formed, confirming the NMR results. Mislabelling was identified in all the packs of SCAs 
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analysed. This shows how misleading and how totally devoid of quality control is the illicit 
SCA market. Qualitative differences among packs seized in 2016 and 2017 were observed, 
the latter containing a more potent SCA. This could lead to drug user/abuser intoxication or 
even death due to the unintended intake of one or even 3 or 4 more powerful SCA. 
The analytical characterization of prison (HMP) samples is described using ESI-MS 
for fast detection and confirmation of samples. This revealed that SCAs are popular in this 
particular prison. There are mixtures of SCAs that have no published pharmacological data, 
but are presumed to be potent by comparison to known close structural analogues. Analytical 
characterization of AMB-FUBINACA using 1D/2D NMR is reported using different 
deuterated solvents. A combination of 1H-19F decoupled and pure shift NMR spectroscopy 
was used for the first time to study the effects of the fluorine of 4-fluorobenzyl on its 
neighbouring protons, thus aiding in the structural elucidation of the novel SCA. The 
separating power of 2D DOSY NMR spectroscopy was employed for the profiling of 
complex samples of SCAs, based on their self-diffusion coefficient (D) resulting in excellent 
separation. No study has been published on the use of DOSY NMR for the analysis of SCA. 
Six components of SCAs in “K2” packages of herbal blends were detected, separated 
and characterized using a protocol that was developed and is composed of UHPLC/TOF-ESI-
MS/MS, flash column chromatography and 1D/2D NMR spectroscopy. This analytical 
platform achieved base-line separation of all components in under 8 min on the UHPLC/ESI-
MS revealing an acid impurity (compound 2), a potential by-product or precursor from the 
synthesis of the amide (compound 1), reported for the first time, and the NMR 
characterization of compound 1 also reported for the first time. The developed flash column 
chromatography method allowed the separation of all detectable components in the mixture, 
providing drug analysts with a flash column chromatography method for the separation of 
recent 3rd generation SCAs with close structural similarities, with 1D/2D NMR spectroscopic 
characterization providing definitive confirmation of the compounds. This analysis also 
showed how the contents of the infamous “K2” packets evolved from 1st and 2nd generation 
SCA, to more recent SCAs, some of which have no published pharmacological data. 
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In the final chapter, the presence of terminally fluorinated SCA in the majority of the 
seized samples was exploited to develop the first reported quantitative 19F-NMR method 
using 2-chloro-4-fluorotoluene as an IS for their quantification. This method gave a fast (8-10 
min) and accurate analysis, achieving high precision results without any interference from the 
plant matrix components, Turnera diffusa (Damiana) or Althaea officinalis (marshmallow). q-
19F NMR spectroscopy was compared with the established analytical methods used in the 
pharmaceutical industry e.g. q-1H NMR and UHPLC and gave results in excellent agreement. 
Furthermore, packages of similar brands of herbal blends containing 5F-ADB from seizures 
in different years (2016 and 2017) were quantitatively assayed using q-19F NMR with cross-
method confirmation. Some 2017 packages were shown to contain double the dose of 5F-
ADB compared with the 2016 samples. The influence of the O1P (centre point of the spectra 
that defines the transmitter excitation) and of the NMR relaxation delays have been assessed 
and shown to have significant effects on the quantitative results. This will also provide aid to 
drug analysts working in NMR spectroscopic quantification of fluorinated compounds. 
A smoking simulation apparatus was designed and constructed in-house to simulate 
the SCA smoking process. This allowed the recovery of SCAs that had been burnt in 
cigarettes as analysed by UHPLC/TOF-ESI-MS. The capturing of some combustion 
degradation products was established using GC/MS analysis. Additionally, the structure of a 
novel combustion product (compound 7) is proposed, resulting from the combustion of 
MDMB-CHMICA. This proposed compound was detected by GC/MS and UHPLC/TOF-
ESI-MS. Furthermore, little-to-no SCA was detected in the combustion zone, proving its 
good volatility, and adding weight to media reports of prisoners and prison guards being 
overcome by SCA smoke inhalation. 
In conclusion, robust pharmaceutical analysis of illicit drugs and their cutting agents 
has been undertaken. This has resulted in new and potentially useful data for pharmaceutical 
analysts, forensic science, the Police and Prison Services, and for Accident and Emergency 
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Appendix 1. X-ray data of MXE 
 
Table 1. Crystal data and structure refinement for MXE. 
Identification code s16phar1 
Empirical formula C15 H22 Cl N O2 
Formula weight 283.78 
Temperature 150.01(10) K 
Wavelength 1.54184 Å 
Crystal system Monoclinic 
Space group P21 
Unit cell dimensions a = 8.51600(10) Å 
 
b = 9.88100(10) Å 
 
c = 8.7487(2) Å 
Volume 724.01(2) Å3 
Z 2 
Density (calculated) 1.302 Mg/m3 
Absorption coefficient 2.316 mm-1 
F(000) 304 
Crystal size 0.200 x 0.200 x 0.120 mm3 
Theta range for data collection 5.141 to 73.336°. 
Index ranges -10<=h<=10, -12<=k<=7, -10<=l<=10 
Reflections collected 6389 
Independent reflections 2121 [R(int) = 0.0207] 
Completeness to theta = 67.684° 99.90% 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.92993 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2121 / 1 / 182 
Goodness-of-fit on F2 1.054 
Final R indices [I>2sigma(I)] R1 = 0.0215, wR2 = 0.0577 
R indices (all data) R1 = 0.0216, wR2 = 0.0579 
Absolute structure parameter 0.014(10) 
Extinction coefficient n/a 







Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for MXE. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
Atom x y z U(eq) 
C(1) 2221(2) 4360(2) 7315(2) 30(1) 
C(2) 2983(2) 4992(2) 6063(2) 26(1) 
C(3) 2398(2) 5998(2) 3346(2) 17(1) 
C(4) 1071(2) 5961(2) 1892(2) 19(1) 
C(5) 1389(2) 6803(2) 554(2) 23(1) 
C(6) 1608(2) 8281(2) 1092(2) 26(1) 
C(7) 2968(2) 8396(2) 2488(2) 26(1) 
C(8) 2669(2) 7493(2) 3817(2) 20(1) 
C(9) 3883(2) 5259(2) 3012(2) 18(1) 
C(10) 5416(2) 5734(2) 3576(2) 21(1) 
C(11) 6732(2) 5000(2) 3296(2) 24(1) 
C(12) 6543(2) 3817(2) 2457(2) 23(1) 
C(13) 5003(2) 3337(2) 1883(2) 21(1) 
C(14) 3674(2) 4051(2) 2167(2) 20(1) 
C(15) 3375(2) 1593(2) 525(2) 30(1) 
N 1764(2) 5249(2) 4627(2) 18(1) 
O(1) -152(1) 5348(2) 1906(2) 26(1) 
O(2) 4923(1) 2150(2) 1076(2) 30(1) 


















































































































































Table 5. Anisotropic displacement parameters (Å2x 103) for MXE. The anisotropic 
displacement factor exponent takes the form: -22[ h2 a*2U11 +   + 2 h k a* b* U12 ] 
 
U11 U22 U33 U23 U13 U12 
C(1) 36(1) 32(1) 22(1) 5(1) 8(1) 1(1) 
C(2) 22(1) 31(1) 22(1) 5(1) 1(1) 2(1) 
C(3) 17(1) 18(1) 17(1) 2(1) 4(1) 1(1) 
C(4) 17(1) 19(1) 20(1) 3(1) 4(1) 2(1) 
C(5) 23(1) 29(1) 17(1) 2(1) 4(1) 1(1) 
C(6) 29(1) 25(1) 23(1) 5(1) 6(1) 3(1) 
C(7) 32(1) 19(1) 27(1) 2(1) 7(1) 5(1) 
C(8) 23(1) 16(1) 21(1) 2(1) 5(1) 1(1) 
C(9) 17(1) 19(1) 16(1) 2(1) 5(1) 0(1) 
C(10) 20(1) 24(1) 21(1) 0(1) 4(1) 5(1) 
C(11) 16(1) 34(1) 23(1) 5(1) 4(1) 4(1) 
C(12) 19(1) 31(1) 21(1) 6(1) 7(1) 5(1) 
C(13) 24(1) 20(1) 19(1) 2(1) 6(1) 2(1) 
C(14) 17(1) 22(1) 20(1) 2(1) 4(1) 1(1) 
C(15) 41(1) 19(1) 30(1) 4(1) 8(1) 4(1) 
N 18(1) 18(1) 18(1) 0(1) 4(1) 1(1) 
O(1) 19(1) 31(1) 27(1) 0(1) 2(1) 4(1) 
O(2) 30(1) 25(1) 35(1) 7(1) 8(1) 6(1) 
Cl 25(1) 21(1) 28(1) 2(1) 7(1) 4(1) 
 
Table 6. Hydrogen coordinates ( x 104) and isotropic  displacement parameters 
(Å2x 10 3) for MXE. 
 
x y z U(eq) 
     
H(1C) 3021 4263 8266 45 
H(1D) 1798 3467 6971 45 
H(1E) 1349 4939 7522 45 
H(2A) 3496 5857 6446 31 
H(2B) 3822 4382 5810 31 
H(5A) 482 6731 -327 27 
H(5B) 2364 6478 202 27 
H(6A) 1848 8848 231 31 
H(6B) 606 8617 1381 31 
H(7A) 3984 8130 2173 31 
H(7B) 3068 9348 2845 31 
H(8A) 1721 7831 4207 24 
H(8B) 3597 7556 4679 24 
H(10) 5565 6555 4149 26 
H(11) 7777 5323 3691 29 
H(12) 7450 3330 2267 28 
H(14) 2630 3719 1787 23 
263 
 
H(15A) 3485 724 15 45 
H(15B) 2757 2218 -222 45 
H(15C) 2822 1455 1402 45 
H(1A) 910(30) 5760(30) 4950(30) 35(7) 
H(1B) 1370(30) 4400(30) 4250(30) 27(6) 
 








































Appendix 2. X-ray data of AM-694 
 
Table 1. Crystal data and structure refinement for AM-694. 
Identification code s17phar10 
Empirical formula C20 H19 F I N O 
Formula weight 435.26 
Temperature 150.00(10) K 
Wavelength 1.54184 Å 
Crystal system Triclinic 
Space group P-1 
Unit cell dimensions a = 9.1798(3) Å     = 115.538(3)°. 
 
b = 10.4887(4) Å  = 97.804(3)°. 
 
c = 11.2304(4) Å   = 106.811(3)°. 
Volume 890.49(6) Å3 
Z 2 
Density (calculated) 1.623 Mg/m3 
Absorption coefficient 14.259 mm-1 
F(000) 432 
Crystal size 0.277 x 0.210 x 0.030 mm3 
Theta range for data collection 4.577 to 73.169°. 
Index ranges -10<=h<=11, -12<=k<=12, -13<=l<=13 
Reflections collected 18642 
Independent reflections 3540 [R(int) = 0.0630] 
Completeness to theta = 1.000° 100.00% 
Absorption correction Gaussian 
Max. and min. transmission 1.000 and 0.729 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3540 / 0 / 217 
Goodness-of-fit on F2 1.053 
Final R indices [I>2sigma(I)] R1 = 0.0355, wR2 = 0.0942 
R indices (all data) R1 = 0.0372, wR2 = 0.0971 
Extinction coefficient n/a 








Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 
103) for AM-694. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
C(1) 202(4) 1721(4) 1752(3) 35(1) 
C(2) 90(4) 3175(4) 2767(3) 33(1) 
C(3) 1023(4) 4572(4) 2683(3) 30(1) 
C(4) 840(4) 6012(4) 3677(4) 32(1) 
C(5) 1860(4) 7446(4) 3685(4) 33(1) 
C(6) 4202(4) 8800(3) 5843(3) 27(1) 
C(7) 3472(4) 9375(4) 6842(4) 34(1) 
C(8) 4409(5) 10202(4) 8205(4) 39(1) 
C(9) 6036(5) 10445(4) 8554(3) 38(1) 
C(10) 6752(4) 9857(4) 7548(3) 31(1) 
C(11) 5814(4) 8998(3) 6157(3) 25(1) 
C(12) 6109(4) 8220(3) 4855(3) 24(1) 
C(13) 4674(4) 7628(3) 3837(3) 26(1) 
C(14) 7549(4) 8025(3) 4599(3) 25(1) 
C(15) 7485(4) 7074(3) 3116(3) 24(1) 
C(16) 6678(4) 5483(4) 2334(3) 29(1) 
C(17) 6680(5) 4690(4) 981(4) 44(1) 
C(18) 7486(5) 5471(5) 396(4) 54(1) 
C(19) 8315(5) 7054(5) 1162(4) 44(1) 
C(20) 8326(4) 7836(4) 2510(3) 30(1) 
N 3549(3) 7969(3) 4406(3) 26(1) 
O 8820(3) 8624(3) 5518(2) 33(1) 
I 5614(1) 4188(1) 3206(1) 41(1) 
F -502(3) 1369(3) 408(2) 51(1) 
 



















































































































































Table 5. Anisotropic displacement parameters (Å2x 103) for AM-694. The 
anisotropic displacement factor exponent takes the form: -22[ h2 a*2U11 + ...  + 2 h k a* b* 
U12 ] 
 
U11 U22 U33 U23 U13 U12 
C(1) 39(2) 31(2) 32(2) 13(1) 10(1) 14(1) 
C(2) 36(2) 30(2) 34(2) 15(1) 13(1) 13(1) 
C(3) 28(2) 28(2) 33(1) 13(1) 14(1) 12(1) 
C(4) 26(2) 30(2) 40(2) 16(1) 14(1) 14(1) 
C(5) 26(2) 31(2) 45(2) 17(1) 10(1) 17(1) 
C(6) 31(2) 20(1) 33(1) 14(1) 14(1) 12(1) 
C(7) 39(2) 26(2) 42(2) 16(1) 21(2) 18(1) 
C(8) 50(2) 31(2) 41(2) 16(1) 25(2) 20(2) 
C(9) 50(2) 26(2) 32(2) 10(1) 12(2) 14(2) 
C(10) 35(2) 23(1) 32(2) 12(1) 8(1) 12(1) 
C(11) 28(2) 21(1) 29(1) 14(1) 12(1) 12(1) 
C(12) 24(2) 20(1) 29(1) 12(1) 9(1) 9(1) 
C(13) 27(2) 23(1) 29(1) 13(1) 9(1) 11(1) 
C(14) 27(2) 20(1) 30(1) 12(1) 10(1) 9(1) 
C(15) 22(1) 21(1) 29(1) 12(1) 8(1) 10(1) 
C(16) 23(2) 26(2) 35(2) 13(1) 9(1) 8(1) 
C(17) 39(2) 33(2) 39(2) 4(2) 12(2) 8(2) 
C(18) 53(2) 52(2) 32(2) 6(2) 19(2) 8(2) 
C(19) 38(2) 54(2) 42(2) 28(2) 18(2) 12(2) 
C(20) 26(2) 31(2) 38(2) 18(1) 10(1) 13(1) 
N 23(1) 23(1) 34(1) 14(1) 9(1) 11(1) 
O 25(1) 34(1) 31(1) 12(1) 5(1) 10(1) 
I 38(1) 29(1) 64(1) 27(1) 22(1) 13(1) 











Table 6. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) for 
AM-694. 
 
x y z U(eq) 
H(1A) 1336 1854 1883 42 
H(1B) -351 871 1908 42 
H(2A) 492 3362 3716 40 
H(2B) -1046 3037 2598 40 
H(3A) 2167 4740 2892 36 
H(3B) 651 4374 1727 36 
H(4A) 1133 6162 4624 38 
H(4B) -294 5868 3423 38 
H(5A) 1740 7229 2719 40 
H(5B) 1478 8273 4144 40 
H(7) 2374 9205 6597 40 
H(8) 3951 10613 8918 47 
H(9) 6658 11025 9501 46 
H(10) 7852 10032 7796 37 
H(13) 4513 7059 2871 31 
H(17) 6125 3608 456 53 
H(18) 7475 4926 -537 65 
H(19) 8871 7590 756 53 
H(20) 8916 8913 3040 36 
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Abstract - Identification and characterization of seized 
ethylone–ecstasy mixtures follows from 1D/2D nuclear 
magnetic resonance (NMR) spectroscopy, mass 
spectrometry, and thin layer chromatography analysis. 
Maleic acid was used as an NMR internal standard for 
quantification of the mixtures. Electrospray soft 
ionization mass spectrometry was used to determine the 
molecular ions. This is the first analytical report of 




 3,4-Methylendioxymethamphetamine (ecstasy, E) is a 
highly popular psychostimulatory, hallucinogenic 
empathogenic drug which belongs to the phenethylamine 
class, and exerts its physiological effects through actions on 
many neurotransmitters, primarily serotonin [1]. Ethylone is 
β-keto-methylenedioxy-ethylamphetamine. It is a new 
psychoactive substance (NPS), adding to the hundreds of 
recent NPS, synthesized as mainstream stimulants e.g. 
ecstasy, methamphetamine, and cocaine are class A and 
banned. Ethylone has a pharmacological profile similar to 
ecstasy and other stimulants [2]. Such mixtures, found in drug 
samples seized by the Bristol police, might lead to life 
threatening serotonin (5-HT) toxicity. 
 
MATERIALS AND METHODS 
 
 1) Seized samples (20 mg) were dissolved in D2O (1 mL) 
and analysed by high-field NMR spectroscopy. 1H, 13C, 
Distortionless Enhancement by Polarization Transfer 
(DEPT), and 2D NMR spectra were obtained on a Bruker 
AVANCE III 500 MHz spectrometer, with data processing 
using Bruker software (Topspin 2.1). 
 2) Stock solutions (1 mg/mL in HPLC grade methanol) 
of the seized samples were prepared. Mass spectra were 
obtained using electrospray ionization-mass spectrometry 
(ESI-MS) from Bruker daltonics with positive-ion mode 
samples (10 µg/mL in HPLC grade methanol). 
 3) Thin layer chromatography (TLC) was performed on 
seized samples using TLC silica gel 60 F254 plates and a 
mobile phase of ethyl acetate, methanol, and concentrated 
ammonia (85:10:5 v/v/v) visualized under UV light and with 
Dragendorff’s reagent. 
 
RESULTS AND DISCUSSION 
 
Complete assignment of the 1H and 13C signals in the 
mixtures was achieved with the aid of 2D NMR. The 1H NMR 
data revealed 18 non-coinciding signals for the ethylone–
ecstasy mixtures, with molar ratios of 3:1, 2:1, and 1:2. 
Additionally, the different chemical shifts of the 
methylenedioxy signals are diagnostic for both drugs in the 
mixture, 1H  6.03 ppm in ethylone and 5.87 ppm in ecstasy.
The splitting patterns of these signals are another distinction. 
The ethylone methylenedioxy signal appeared as a very fine 
doublet, while the comparable signal in ecstasy was a sharp 
singlet. We interpret this difference as an effect of the benzoyl 
carbonyl functional group in addition to the chiral centre.
Maleic acid (alkene 1H signal  6.31 ppm) was used as a 
quantitative internal standard. Initial confirmation of analytes 
in the mixtures was by TLC showing two resolved spots. The 
ESI-MS revealed both required molecular ions, m/z 194.1184




Fig. 1. 13C (above) and 1H (below) assignments of ecstasy (upper) and 




 NMR is a powerful tool for the identification of illicit 
drug mixtures including their quantification against an 
internal standard (e.g. maleic acid). The methylenedioxy 
NMR signals are diagnostic for the analysis of these 3:1, 2:1,
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Abstract - Derivatization studies using ethyl chloro-
formate (ECF) and 2,2,2-trichloroethyl chloroformate 
(TCF) showed that derivatization is essential for the 
chromatographic detection of MDMA (ecstasy) and 
ethylone, changing the polarity and making them more 
suitable for gas chromatography-flame ionization 
detection (GC-FID) analysis. However, mephedrone gave 
sufficiently clean chromatography without any sample 
derivatization. Both these carbamate derivatizing agents 
afford reproducible data from consecutive GC injections 
with enhanced chromatographic properties e.g. increased 




 The amphetamine analogue 3,4-methylenedioxy-
methamphetamine (MDMA, ecstasy, E) is an illicit 
psychedelic psychostimulant, producing euphoric effects, but 
with no current medical uses [1]. The term ecstasy began with 
reference to MDMA, but nowadays it also includes 
amphetamine derivatives such as 3,4-methylendioxyamphet-
amine (MDA) and 3,4-methylenedioxy-ethylamphetamine, 
due to the similar physiological effects induced by this class 
of illicit drugs. Mephedrone, also known as 4-methyl-
methcathinone, is another illicit drug but unlike MDMA and 
despite the structural similarity of these phenylethylamines, 
mephedrone is classified as a synthetic cathinone rather than 
an amphetamine derivative. Another emerging amphetamine 
derivative is ethylone, also known as MDEC or bk (β-ketone) 
MDEA. It is important to be able to separate these 
amphetamine derivatives in pharmaceutical and forensic 
analysis. To achieve enhanced chromatographic profiles, 
derivatization is often a routine, but essential step. To produce 
carbamate derivatives of these amphetamine-like 
phenylethylamines, two different but related chloroformates 
have been investigated:  ethyl chloroformate (ECF) and 2,2,2-
trichloroethyl chloroformate (TCF). 
 
MATERIALS AND METHODS 
 
 ECF or TCF (30 µL in ethyl acetate 70 µL) was gently 
shaken to dissolve the reagent [2]. Aliquots (50 µL) of the 
solutions were then added to methanolic solutions of the drug 
samples and heated for 15 min at 80 °C allowing them to 
concentrate. The residues were dried under a gentle stream of 
nitrogen followed by redissolving in ethyl acetate (50 µL). 
Solutions of the derivatized samples (1-1.5 µL of the ethyl 
acetate) were injected into the GC-FID (CP-9003 
Chrompack, Middelburg, Holland) equipped with a ZB-
WAX capillary column (polyethylene glycol, 9 m × 0.25 mm 
× 0.25 μm, Phenomenex), using He carrier gas at a flow rate 
of 23-27 mL/s. The injector was set at 250 ˚C; different 
isocratic (e.g. 180 ˚C or 230 ˚C) and gradient (e.g. 180-250 
˚C at 10 ˚C/min) oven temperature programmes were used. 
 
RESULTS AND DISCUSSION 
 
 The GC-FID analysis of non-derivatized MDMA yielded 
only poor chromatography with inconsistent, small broad 
peaks. Derivatization of MDMA with ECF resulted in better 
chromatography, with improved peak shape and signal 
intensity at an isocratic temperature of 230 °C with a typical
retention time of 5.08 min. 
 Ethylone is not detected without derivatization; its 
chromatography is therefore similar to that of MDMA. 
Chromatography of the TCF derivative, at an isocratic 
temperature of 250 °C, resulted in a consistent average 
retention time of 8.92 min. 
 The non-derivatized mephedrone gave good GC 
chromatograms isocratically at 180 ˚C with a retention time 
of 5.06 min. Derivatization with ECF resulted in a longer 
retention time of 9.73 min (at 180 ˚C). At a higher 
temperature, 230 ˚C, the average retention time was both 
stable and reproducible at 4.08 min. Indeed, these mild 
reagents, ECF and TCF allowed rapid and efficient switching 




 Derivatization is an essential step in the identification of 
illicit drugs samples. ECF and TCF are reliable derivatizing
agents for pharmaceutical analysis that are used for 
production of more volatile carbamate derivatives with
enhanced chromatographic properties. The optimum 
operating GC-FID oven temperature range for these 
derivatized samples is between 200-250 °C. Ethylone is 
similar to ecstasy in the fact that it requires derivatization in 
order to be detected by GC-FID, while mephedrone was 
detected without derivatization. Nevertheless, derivatization
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Pharmaceutical analysis of seized ethylone–ecstasy mixtures 
using quantitative NMR spectroscopy and ESI-MS 
 
Husain A. Naqi, Timothy J. Woodman, Stephen M. Husbands, and Ian S. Blagbrough 
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK 
 
   Ethylone-ecstasy (MDMA) mixtures were obtained from different Bristol night clubs 
following Police seizures. NMR spectroscopic analysis allowed identification, structural 
elucidation, and quantification of these mixtures. Additional confirmation of the structures 
came from Electrospray Ionization Mass Spectrometry (ESI-MS). Quantitative NMR 
analysis, using maleic acid as the internal standard, revealed different ratios of the mixtures, 
e.g. 2:1, 1:2, and 1:3 ethylone:ecstasy. 
   The different chemical shifts of the methylenedioxy signals are diagnostic for both drugs in 
the mixture, 1H  6.03 ppm in ethylone and 5.87 ppm in ecstasy. The fine splitting patterns of 
these methylenedioxy signals are another distinction. The ethylone methylenedioxy signal 
appeared as a very fine doublet, while the comparable signal in ecstasy was a sharp singlet. 
Maleic acid was used as a quantitative internal standard due to its high solubility and the non-
overlapping peak at  6.30 ppm. In these mixtures, the majority of the NMR signals of 
ethylone and ecstasy are suitable candidates for quantification due to the absence of any peak 
overlap. The ESI-MS revealed both required molecular ions, m/z 194.1184 found for ecstasy 
and 222.1122 found for ethylone. Fragmentation of both [M+H]+ provided further 
corroboration of the components in the mixture. 
   Such combinations of illicit drugs, e.g ecstasy with a Novel Psychoactive Substance (NPS), 
e.g. ethylone, might be aimed at altering the experience for the user. However, the presence 
of another pharmacologically active substance might result in serious harm, even lethality, 
especially as the biological activities of NPS are not well understood. 
   We gratefully acknowledge the Government of Kuwait for a studentship (to H.A.N.) and the 
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Purpose 
3,4-Methylendioxymethamphetamine (ecstasy, E) is a highly popular psychostimulatory, hallucinogenic 
empathogenic drug which belongs to the phenethylamine class, and exerts its physiological effects 
through actions on many neurotransmitters, primarily serotonin (5-HT). Ethylone is β-keto-
methylenedioxy-ethylamphetamine with a pharmacological profile similar to ecstasy and other 
stimulants [1]. Ethylone is a new psychoactive substance (NPS), adding to the hundreds of recent NPS, 
synthesized as mainstream stimulants. Mixtures of such NPS are found in drug samples seized by the 
Bristol police; they may well lead to life threatening serotonin toxicity. We aim to identify and 
characterize seized ethylone–ecstasy mixtures by 1D/2D nuclear magnetic resonance (NMR) 
spectroscopy and mass spectrometry, using maleic acid as an NMR internal standard for quantification 
of the mixtures. 
 
Method 
Seized samples (20 mg) were dissolved in D2O (1 mL) and analysed by high-field NMR spectroscopy. 
1H, 13C, Distortionless Enhancement by Polarization Transfer (DEPT), and 2D NMR spectra were 
obtained on a Bruker AVANCE III 500 MHz spectrometer, with data processing using Bruker software 
(Topspin 2.1). Mass spectra were obtained using electrospray ionization-mass spectrometry (ESI-MS) 
from Bruker daltonics with positive-ion mode samples (10 µg/mL in HPLC grade methanol). Maleic 
acid (alkene 1H signal  6.31 ppm) was used as a quantitative internal standard. 
 
Results 
Complete assignment of the 1H and 13C NMR signals in the mixtures was achieved with the aid of 2D 
NMR. From three independent samples, the 1H NMR data revealed 18 non-coinciding signals for the 
ethylone–ecstasy mixtures, with molar ratios of 3:1, 2:1, and 1:2 respectively, following the 1H NMR 
integration. Additionally, the different chemical shifts of the methylenedioxy signals are diagnostic for 
both the drugs in the mixture, 1H  6.03 ppm in ethylone and 5.87 ppm in ecstasy. The splitting patterns 
of these signals are another distinction. The ethylone methylenedioxy signal appeared as a very fine 
doublet, while the comparable signal in ecstasy is a sharp singlet. We interpret this difference as an 
effect of the benzoyl carbonyl functional group in addition to the chiral centre. ESI-MS revealed both 
molecular ions, found m/z 194.1184 for ecstasy, requires 194.1175 for C11H16NO2 [M+H]+, and m/z
222.1122 for ethylone, requires 222.1123 for C12H16NO3 [M+H]+ both within 5 ppm mass accuracy limits.
 
Conclusion 
NMR is a powerful tool for the identification of illicit drug mixtures including their quantification against 
an internal standard, e.g. maleic acid. The methylenedioxy NMR signals, inter alia, are diagnostic for 
the pharmaceutical analysis of these three 3:1, 2:1, and 1:2 (molar ratio) mixtures. 
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Purpose: The amphetamine analogue 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy, E) is 
an illicit psychedelic psychostimulant, producing euphoric effects, but with no current medical uses [1]. 
The term ecstasy began with reference to MDMA, but nowadays it also includes amphetamine 
derivatives such as 3,4-methylendioxyamphet-amine (MDA) and 3,4-methylenedioxy-
ethylamphetamine, due to the similar physiological effects induced by this class of illicit drugs. 
Mephedrone, also known as 4-methyl-methcathinone, is another illicit drug but unlike MDMA and 
despite the structural similarity of these phenylethylamines, mephedrone is classified as a synthetic 
cathinone rather than an amphetamine derivative. Another emerging amphetamine derivative is 
ethylone, also known as MDEC or bk (β-ketone) MDEA. It is important to be able to separate these 
amphetamine derivatives in pharmaceutical and forensic analysis. To achieve enhanced 
chromatographic profiles, derivatization is often a routine, but essential step. To produce carbamate 
derivatives of these amphetamine-like phenylethylamines, two different but related chloroformates have 
been investigated:  ethyl chloroformate (ECF) and 2,2,2-trichloroethyl chloroformate (TCF).
Derivatization studies using ethyl chloro-formate (ECF) and 2,2,2-trichloroethyl chloroformate (TCF) 
showed that derivatization is essential for the chromatographic detection of MDMA (ecstasy) and 
ethylone, changing the polarity and making them more suitable for gas chromatography-flame ionization 
detection (GC-FID) analysis. However, mephedrone gave sufficiently clean chromatography without 
any sample derivatization. Both these carbamate derivatizing agents afford reproducible data from 
consecutive GC injections with enhanced chromatographic properties e.g. increased peak intensity, 
and non-tailing, sharp peaks. 
 
Method: ECF or TCF (30 µL in ethyl acetate 70 µL) was gently shaken to dissolve the reagent [2]. 
Aliquots (50 µL) of the solutions were then added to methanolic solutions of the drug samples and 
heated for 15 min at 80 °C allowing them to concentrate. The residues were dried under a gentle 
stream of nitrogen followed by re-dissolving in ethyl acetate (50 µL). Solutions of the derivatized 
samples (1-1.5 µL of the ethyl acetate) were injected into the GC-FID (CP-9003 Chrompack, 
Middelburg, Holland) equipped with a ZB-WAX capillary column (polyethylene glycol, 9 m × 0.25 mm 
× 0.25 μm, Phenomenex), using He carrier gas at a flow rate of 23-27 mL/s. The injector was set at 
250 ˚C; different isocratic (e.g. 180 ˚C or 230 ˚C) and gradient (e.g. 180-250 ˚C at 10 ˚C/min) oven 
temperature programmes were used. 
 
Results: The GC-FID analysis of non-derivatized MDMA yielded only poor chromatography with 
inconsistent, small broad peaks. Derivatization of MDMA with ECF resulted in better chromatography, 
with improved peak shape and signal intensity at an isocratic temperature of 230 °C with a typical 
retention time of 5.08 min. Ethylone is not detected without derivatization; its chromatography is 
therefore similar to that of MDMA. Chromatography of the TCF derivative, at an isocratic temperature 
of 250 °C, resulted in a consistent average retention time of 8.92 min. The non-derivatized mephedrone 
gave good GC chromatograms isocratically at 180 ˚C with a retention time of 5.06 min. Derivatization 
with ECF resulted in a longer retention time of 9.73 min (at 180 ˚C). At a higher temperature, 230 ˚C, 
the average retention time was both stable and reproducible at 4.08 min. Indeed, these mild reagents, 
ECF and TCF allowed rapid and efficient switching between the different analytical conditions [3]. 
 
Conclusion: Derivatization is an essential step in the identification of illicit drugs samples. ECF and 
TCF are reliable derivatizing agents for pharmaceutical analysis that are used for production of more 
volatile carbamate derivatives with enhanced chromatographic properties. The optimum operating GC-
FID oven temperature range for these derivatized samples is between 200-250 °C. Ethylone is similar 
to ecstasy in the fact that it requires derivatization in order to be detected by GC-FID, while mephedrone 
was detected without derivatization. Nevertheless, derivatization of mephedrone with TCF produced 
better chromatography. 
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